{"cells":[{"cell_type":"markdown","source":["## Overview\n\nThis notebook will show you how to create and query a table or DataFrame that you uploaded to DBFS. [DBFS](https://docs.databricks.com/user-guide/dbfs-databricks-file-system.html) is a Databricks File System that allows you to store data for querying inside of Databricks. This notebook assumes that you have a file already inside of DBFS that you would like to read from.\n\nThis notebook is written in **Python** so the default cell type is Python. However, you can use different languages by using the `%LANGUAGE` syntax. Python, Scala, SQL, and R are all supported."],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"96816ed7-b08a-4ca3-abb9-f99880c3535d"}}},{"cell_type":"markdown","source":["DataFrames vs RDD:\n# https://databricks.com/glossary/tungsten\nDataFrame Advantages over RDD\n1.  Custom Memory management Project Tungsten Data is stored in off-heap memory in binary format. \n    This saves a lot of memory space.\n    Also there is no Garbage Collection overhead involved. \n    By knowing the schema of data in advance and storing efficiently in binary format, \n    expensive java Serialization is also avoided.\n\n\n2. Optimized Execution Plans (aka Catalyst Optimizer)\n    # https://databricks.com/glossary/catalyst-optimizer\n    Query plans are created for execution using Spark catalyst optimiser. \n    After an optimised execution plan is prepared going through some steps, \n    the final execution happens internally on RDDs only \n    but thats completely hidden from the users.\n\n3. ever use RDD's unless you want to handle the low-level optimizations/serializations yourself."],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"310b22d3-d5c1-490e-a560-efeaac93eb72"}}},{"cell_type":"code","source":["print('Apache Spark Version :'+spark.version)\n"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"a9e19ef5-6c9d-4505-8862-6732e9e3adc4"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Apache Spark Version :3.1.2\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Apache Spark Version :3.1.2\n"]}}],"execution_count":0},{"cell_type":"code","source":["import sys\nprint(\"Python version\")\nprint (sys.version)\nprint(\"Version info.\")\nprint (sys.version_info)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"360373f1-f64c-4dd7-9fbe-aa55e15bf464"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Python version\n3.8.10 (default, Mar 15 2022, 12:22:08) \n[GCC 9.4.0]\nVersion info.\nsys.version_info(major=3, minor=8, micro=10, releaselevel='final', serial=0)\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Python version\n3.8.10 (default, Mar 15 2022, 12:22:08) \n[GCC 9.4.0]\nVersion info.\nsys.version_info(major=3, minor=8, micro=10, releaselevel='final', serial=0)\n"]}}],"execution_count":0},{"cell_type":"code","source":["# Defining schema for the data loaded to be in RDD and Dataframe\nfrom pyspark.sql.types import StructType,StructField, StringType, IntegerType \n \nschema = StructType() \\\n      .add(\"Id\",StringType(),True) \\\n      .add(\"Sponsor\",StringType(),True) \\\n      .add(\"Status\",StringType(),True) \\\n      .add(\"Start\",StringType(),True) \\\n      .add(\"Completion\",StringType(),True) \\\n      .add(\"Type\",StringType(),True) \\\n      .add(\"Submission\",StringType(),True) \\\n      .add(\"Conditions\",StringType(),True) \nprint(schema)\n"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"SCHEMA FOR CLINICAL DATA","showTitle":true,"inputWidgets":{},"nuid":"11cc0101-f894-4b52-9172-529e8a6c3c33"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"StructType(List(StructField(Id,StringType,true),StructField(Sponsor,StringType,true),StructField(Status,StringType,true),StructField(Start,StringType,true),StructField(Completion,StringType,true),StructField(Type,StringType,true),StructField(Submission,StringType,true),StructField(Conditions,StringType,true)))\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["StructType(List(StructField(Id,StringType,true),StructField(Sponsor,StringType,true),StructField(Status,StringType,true),StructField(Start,StringType,true),StructField(Completion,StringType,true),StructField(Type,StringType,true),StructField(Submission,StringType,true),StructField(Conditions,StringType,true)))\n"]}}],"execution_count":0},{"cell_type":"code","source":["# PRE PROCESSING \n# DEFINING GLOBAL VARIBALES AND CONFIG\n#files_2019 = [\"/FileStore/tables/clinicaltrial_2019_csv.gz\"]\n#files_2020 = [\"/FileStore/tables/clinicaltrial_2020_csv.gz\"]\n#files_2021 = [\"/FileStore/tables/clinicaltrial_2021_csv.gz\"]\n\nfile_type = \"csv\"\ninfer_schema = \"true\"\nfirst_row_is_header = \"True\"\ndelimiter = \"|\"\n\n"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"DEFIING DATA FILES AND GLOBAL VARIABLES","showTitle":true,"inputWidgets":{},"nuid":"06b3a2f8-5712-4f04-b238-65eb9afbd75f"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["# Multiple ways to Read  Data files from dbfs file system\n# /FileStore/tables/clinicaltrial_2019.csv\n# df_2019 = spark.read.format(file_type) \\\n # .option(\"inferSchema\", infer_schema) \\\n # .option(\"header\", first_row_is_header) \\\n # .option(\"sep\", delimiter) \\\n # .load(files_2019)\n\nfiles_2019 = [\"/FileStore/tables/clinicaltrial_2019_csv.gz\"]\nfiles_2020 = [\"/FileStore/tables/clinicaltrial_2020_csv.gz\"]\nfiles_2021 = [\"/FileStore/tables/clinicaltrial_2021_csv.gz\"]\n\n# /FileStore/tables/clinicaltrial_2019.csv\ndf_2019 = spark.read.options(header='True', inferSchema='True', delimiter='|').csv(files_2019)\n\n# /FileStore/tables/clinicaltrial_2020.csv\ndf_2020 = spark.read.options(header='True', inferSchema='True', delimiter='|').csv(files_2020)\n\n# Reading csv file from gz file  /FileStore/tables/clinicaltrial_2021.csv.gz\ndf_2021 = spark.read.options(header='True', inferSchema='True', delimiter='|').csv(files_2021)\n\n\n# Reading csv throuhg com.databricks.spark.csv\n# df = spark.read.format('com.databricks.spark.csv').\\\n#                               options(header='true', \\\n#                               inferschema='true').\\\n#                load(\"/FileStore/tables/clinicaltrial_2019.csv\",header=True)\n\n\n"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"LOADING THE DATA TO SPARK DATA FRAME","showTitle":true,"inputWidgets":{},"nuid":"321f3254-9493-45fa-8130-f837d568810b"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["# Data and Schema validation\nprint(\"Year 2019\")\ndf_2019.show(5)\nprint(\"Year 2020\")\ndf_2020.show(5)\nprint(\"Year 2021\")\ndf_2021.show(5)\ndf.printSchema()\n\ndf_2019.printSchema()\ndf_2020.printSchema()\ndf_2021.printSchema()\ndf.printSchema()\n"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"PYSPARK - DATAFRAMES Data and Schema validation","showTitle":true,"inputWidgets":{},"nuid":"aac3cc0e-d651-41a0-b650-ca4297866aea"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Year 2019\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+-------------+\n|         Id|             Sponsor|              Status|   Start|Completion|                Type|Submission|          Conditions|Interventions|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+-------------+\n|NCT02758028|The University of...|          Recruiting|Aug 2005|  Nov 2021|      Interventional|  Apr 2016|                null|         null|\n|NCT02751957|     Duke University|           Completed|Jul 2016|  Jul 2020|      Interventional|  Apr 2016|Autistic Disorder...|         null|\n|NCT02758483|Universidade Fede...|           Completed|Mar 2017|  Jan 2018|      Interventional|  Apr 2016|   Diabetes Mellitus|         null|\n|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|Tuberculosis,Lung...|         null|\n|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|Diverticular Dise...|         null|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+-------------+\nonly showing top 5 rows\n\nYear 2020\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+-------------+\n|         Id|             Sponsor|              Status|   Start|Completion|                Type|Submission|          Conditions|Interventions|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+-------------+\n|NCT02758028|The University of...|          Recruiting|Aug 2005|  Nov 2021|      Interventional|  Apr 2016|                null|         null|\n|NCT02751957|     Duke University|           Completed|Jul 2016|  Jul 2020|      Interventional|  Apr 2016|Autistic Disorder...|         null|\n|NCT02758483|Universidade Fede...|           Completed|Mar 2017|  Jan 2018|      Interventional|  Apr 2016|   Diabetes Mellitus|         null|\n|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|Tuberculosis,Lung...|         null|\n|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|Diverticular Dise...|         null|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+-------------+\nonly showing top 5 rows\n\nYear 2021\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+-------------+\n|         Id|             Sponsor|              Status|   Start|Completion|                Type|Submission|          Conditions|Interventions|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+-------------+\n|NCT02758028|The University of...|          Recruiting|Aug 2005|  Nov 2021|      Interventional|  Apr 2016|                null|         null|\n|NCT02751957|     Duke University|           Completed|Jul 2016|  Jul 2020|      Interventional|  Apr 2016|Autistic Disorder...|         null|\n|NCT02758483|Universidade Fede...|           Completed|Mar 2017|  Jan 2018|      Interventional|  Apr 2016|   Diabetes Mellitus|         null|\n|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|Tuberculosis,Lung...|         null|\n|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|Diverticular Dise...|         null|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+-------------+\nonly showing top 5 rows\n\nroot\n |-- Company: string (nullable = true)\n |-- Parent_Company: string (nullable = true)\n |-- Penalty_Amount: string (nullable = true)\n |-- Subtraction_From_Penalty: string (nullable = true)\n |-- Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting: string (nullable = true)\n |-- Penalty_Year: string (nullable = true)\n |-- Penalty_Date: string (nullable = true)\n |-- Offense_Group: string (nullable = true)\n |-- Primary_Offense: string (nullable = true)\n |-- Secondary_Offense: string (nullable = true)\n |-- Description: string (nullable = true)\n |-- Level_of_Government: string (nullable = true)\n |-- Action_Type: string (nullable = true)\n |-- Agency: string (nullable = true)\n |-- Civil/Criminal: string (nullable = true)\n |-- Prosecution_Agreement: string (nullable = true)\n |-- Court: string (nullable = true)\n |-- Case_ID: string (nullable = true)\n |-- Private_Litigation_Case_Title: string (nullable = true)\n |-- Lawsuit_Resolution: string (nullable = true)\n |-- Facility_State: string (nullable = true)\n |-- City: string (nullable = true)\n |-- Address: string (nullable = true)\n |-- Zip: string (nullable = true)\n |-- NAICS_Code: string (nullable = true)\n |-- NAICS_Translation: string (nullable = true)\n |-- HQ_Country_of_Parent: string (nullable = true)\n |-- HQ_State_of_Parent: string (nullable = true)\n |-- Ownership_Structure: string (nullable = true)\n |-- Parent_Company_Stock_Ticker: string (nullable = true)\n |-- Major_Industry_of_Parent: string (nullable = true)\n |-- Specific_Industry_of_Parent: string (nullable = true)\n |-- Info_Source: string (nullable = true)\n |-- Notes: string (nullable = true)\n\nroot\n |-- Id: string (nullable = true)\n |-- Sponsor: string (nullable = true)\n |-- Status: string (nullable = true)\n |-- Start: string (nullable = true)\n |-- Completion: string (nullable = true)\n |-- Type: string (nullable = true)\n |-- Submission: string (nullable = true)\n |-- Conditions: string (nullable = true)\n |-- Interventions: string (nullable = true)\n\nroot\n |-- Id: string (nullable = true)\n |-- Sponsor: string (nullable = true)\n |-- Status: string (nullable = true)\n |-- Start: string (nullable = true)\n |-- Completion: string (nullable = true)\n |-- Type: string (nullable = true)\n |-- Submission: string (nullable = true)\n |-- Conditions: string (nullable = true)\n |-- Interventions: string (nullable = true)\n\nroot\n |-- Id: string (nullable = true)\n |-- Sponsor: string (nullable = true)\n |-- Status: string (nullable = true)\n |-- Start: string (nullable = true)\n |-- Completion: string (nullable = true)\n |-- Type: string (nullable = true)\n |-- Submission: string (nullable = true)\n |-- Conditions: string (nullable = true)\n |-- Interventions: string (nullable = true)\n\nroot\n |-- Company: string (nullable = true)\n |-- Parent_Company: string (nullable = true)\n |-- Penalty_Amount: string (nullable = true)\n |-- Subtraction_From_Penalty: string (nullable = true)\n |-- Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting: string (nullable = true)\n |-- Penalty_Year: string (nullable = true)\n |-- Penalty_Date: string (nullable = true)\n |-- Offense_Group: string (nullable = true)\n |-- Primary_Offense: string (nullable = true)\n |-- Secondary_Offense: string (nullable = true)\n |-- Description: string (nullable = true)\n |-- Level_of_Government: string (nullable = true)\n |-- Action_Type: string (nullable = true)\n |-- Agency: string (nullable = true)\n |-- Civil/Criminal: string (nullable = true)\n |-- Prosecution_Agreement: string (nullable = true)\n |-- Court: string (nullable = true)\n |-- Case_ID: string (nullable = true)\n |-- Private_Litigation_Case_Title: string (nullable = true)\n |-- Lawsuit_Resolution: string (nullable = true)\n |-- Facility_State: string (nullable = true)\n |-- City: string (nullable = true)\n |-- Address: string (nullable = true)\n |-- Zip: string (nullable = true)\n |-- NAICS_Code: string (nullable = true)\n |-- NAICS_Translation: string (nullable = true)\n |-- HQ_Country_of_Parent: string (nullable = true)\n |-- HQ_State_of_Parent: string (nullable = true)\n |-- Ownership_Structure: string (nullable = true)\n |-- Parent_Company_Stock_Ticker: string (nullable = true)\n |-- Major_Industry_of_Parent: string (nullable = true)\n |-- Specific_Industry_of_Parent: string (nullable = true)\n |-- Info_Source: string (nullable = true)\n |-- Notes: string (nullable = true)\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Year 2019\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+-------------+\n|         Id|             Sponsor|              Status|   Start|Completion|                Type|Submission|          Conditions|Interventions|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+-------------+\n|NCT02758028|The University of...|          Recruiting|Aug 2005|  Nov 2021|      Interventional|  Apr 2016|                null|         null|\n|NCT02751957|     Duke University|           Completed|Jul 2016|  Jul 2020|      Interventional|  Apr 2016|Autistic Disorder...|         null|\n|NCT02758483|Universidade Fede...|           Completed|Mar 2017|  Jan 2018|      Interventional|  Apr 2016|   Diabetes Mellitus|         null|\n|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|Tuberculosis,Lung...|         null|\n|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|Diverticular Dise...|         null|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+-------------+\nonly showing top 5 rows\n\nYear 2020\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+-------------+\n|         Id|             Sponsor|              Status|   Start|Completion|                Type|Submission|          Conditions|Interventions|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+-------------+\n|NCT02758028|The University of...|          Recruiting|Aug 2005|  Nov 2021|      Interventional|  Apr 2016|                null|         null|\n|NCT02751957|     Duke University|           Completed|Jul 2016|  Jul 2020|      Interventional|  Apr 2016|Autistic Disorder...|         null|\n|NCT02758483|Universidade Fede...|           Completed|Mar 2017|  Jan 2018|      Interventional|  Apr 2016|   Diabetes Mellitus|         null|\n|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|Tuberculosis,Lung...|         null|\n|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|Diverticular Dise...|         null|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+-------------+\nonly showing top 5 rows\n\nYear 2021\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+-------------+\n|         Id|             Sponsor|              Status|   Start|Completion|                Type|Submission|          Conditions|Interventions|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+-------------+\n|NCT02758028|The University of...|          Recruiting|Aug 2005|  Nov 2021|      Interventional|  Apr 2016|                null|         null|\n|NCT02751957|     Duke University|           Completed|Jul 2016|  Jul 2020|      Interventional|  Apr 2016|Autistic Disorder...|         null|\n|NCT02758483|Universidade Fede...|           Completed|Mar 2017|  Jan 2018|      Interventional|  Apr 2016|   Diabetes Mellitus|         null|\n|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|Tuberculosis,Lung...|         null|\n|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|Diverticular Dise...|         null|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+-------------+\nonly showing top 5 rows\n\nroot\n |-- Company: string (nullable = true)\n |-- Parent_Company: string (nullable = true)\n |-- Penalty_Amount: string (nullable = true)\n |-- Subtraction_From_Penalty: string (nullable = true)\n |-- Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting: string (nullable = true)\n |-- Penalty_Year: string (nullable = true)\n |-- Penalty_Date: string (nullable = true)\n |-- Offense_Group: string (nullable = true)\n |-- Primary_Offense: string (nullable = true)\n |-- Secondary_Offense: string (nullable = true)\n |-- Description: string (nullable = true)\n |-- Level_of_Government: string (nullable = true)\n |-- Action_Type: string (nullable = true)\n |-- Agency: string (nullable = true)\n |-- Civil/Criminal: string (nullable = true)\n |-- Prosecution_Agreement: string (nullable = true)\n |-- Court: string (nullable = true)\n |-- Case_ID: string (nullable = true)\n |-- Private_Litigation_Case_Title: string (nullable = true)\n |-- Lawsuit_Resolution: string (nullable = true)\n |-- Facility_State: string (nullable = true)\n |-- City: string (nullable = true)\n |-- Address: string (nullable = true)\n |-- Zip: string (nullable = true)\n |-- NAICS_Code: string (nullable = true)\n |-- NAICS_Translation: string (nullable = true)\n |-- HQ_Country_of_Parent: string (nullable = true)\n |-- HQ_State_of_Parent: string (nullable = true)\n |-- Ownership_Structure: string (nullable = true)\n |-- Parent_Company_Stock_Ticker: string (nullable = true)\n |-- Major_Industry_of_Parent: string (nullable = true)\n |-- Specific_Industry_of_Parent: string (nullable = true)\n |-- Info_Source: string (nullable = true)\n |-- Notes: string (nullable = true)\n\nroot\n |-- Id: string (nullable = true)\n |-- Sponsor: string (nullable = true)\n |-- Status: string (nullable = true)\n |-- Start: string (nullable = true)\n |-- Completion: string (nullable = true)\n |-- Type: string (nullable = true)\n |-- Submission: string (nullable = true)\n |-- Conditions: string (nullable = true)\n |-- Interventions: string (nullable = true)\n\nroot\n |-- Id: string (nullable = true)\n |-- Sponsor: string (nullable = true)\n |-- Status: string (nullable = true)\n |-- Start: string (nullable = true)\n |-- Completion: string (nullable = true)\n |-- Type: string (nullable = true)\n |-- Submission: string (nullable = true)\n |-- Conditions: string (nullable = true)\n |-- Interventions: string (nullable = true)\n\nroot\n |-- Id: string (nullable = true)\n |-- Sponsor: string (nullable = true)\n |-- Status: string (nullable = true)\n |-- Start: string (nullable = true)\n |-- Completion: string (nullable = true)\n |-- Type: string (nullable = true)\n |-- Submission: string (nullable = true)\n |-- Conditions: string (nullable = true)\n |-- Interventions: string (nullable = true)\n\nroot\n |-- Company: string (nullable = true)\n |-- Parent_Company: string (nullable = true)\n |-- Penalty_Amount: string (nullable = true)\n |-- Subtraction_From_Penalty: string (nullable = true)\n |-- Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting: string (nullable = true)\n |-- Penalty_Year: string (nullable = true)\n |-- Penalty_Date: string (nullable = true)\n |-- Offense_Group: string (nullable = true)\n |-- Primary_Offense: string (nullable = true)\n |-- Secondary_Offense: string (nullable = true)\n |-- Description: string (nullable = true)\n |-- Level_of_Government: string (nullable = true)\n |-- Action_Type: string (nullable = true)\n |-- Agency: string (nullable = true)\n |-- Civil/Criminal: string (nullable = true)\n |-- Prosecution_Agreement: string (nullable = true)\n |-- Court: string (nullable = true)\n |-- Case_ID: string (nullable = true)\n |-- Private_Litigation_Case_Title: string (nullable = true)\n |-- Lawsuit_Resolution: string (nullable = true)\n |-- Facility_State: string (nullable = true)\n |-- City: string (nullable = true)\n |-- Address: string (nullable = true)\n |-- Zip: string (nullable = true)\n |-- NAICS_Code: string (nullable = true)\n |-- NAICS_Translation: string (nullable = true)\n |-- HQ_Country_of_Parent: string (nullable = true)\n |-- HQ_State_of_Parent: string (nullable = true)\n |-- Ownership_Structure: string (nullable = true)\n |-- Parent_Company_Stock_Ticker: string (nullable = true)\n |-- Major_Industry_of_Parent: string (nullable = true)\n |-- Specific_Industry_of_Parent: string (nullable = true)\n |-- Info_Source: string (nullable = true)\n |-- Notes: string (nullable = true)\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["# QUESTION -1 The number of studies in the dataset\n# PRE PROCESSING \n# DEFINING GLOBAL VARIBALES AND CONFIG\nfile_type = \"csv\"\ninfer_schema = \"true\"\nfirst_row_is_header = \"True\"\ndelimiter = \"|\"\n\nfiles_2019 = [\"/FileStore/tables/clinicaltrial_2019_csv.gz\"]\ndf_2019 = spark.read.options(header='True', inferSchema='True', delimiter='|').csv(files_2019)\n\nfiles_2020 = [\"/FileStore/tables/clinicaltrial_2020_csv.gz\"]\ndf_2020 = spark.read.options(header='True', inferSchema='True', delimiter='|').csv(files_2020)\n\nfiles_2021 = [\"/FileStore/tables/clinicaltrial_2021_csv.gz\"]\ndf_2021 = spark.read.options(header='True', inferSchema='True', delimiter='|').csv(files_2021)\n"],"metadata":{"application/vnd.databricks.v1+cell":{"title":" LOADING THE DATA TO SPARK DATA FRAME","showTitle":true,"inputWidgets":{},"nuid":"300f4515-93d8-489f-bb9b-80c689b2ec41"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["count_in_2019 = df_2019.select(\"Id\").count()\ncount_in_2020 = df_2020.select(\"Id\").count()\ncount_in_2021 = df_2021.select(\"Id\").count()\n\nprint(\"count is \", count_in_2019)\nprint(\"count is \", count_in_2020)\nprint(\"count is \", count_in_2021)\n\ndf_count = spark.createDataFrame([(2019, count_in_2019),(2020, count_in_2020),(2021, count_in_2021),],[\"Year\", \"count\"])\ndf_count.show()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"QUESTION -1 PYSPARK 2019 2020 2021","showTitle":true,"inputWidgets":{},"nuid":"0513ff42-54d1-44f2-9e81-03e4ea7a2339"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"count is  326348\ncount is  356466\ncount is  387261\n+----+------+\n|Year| count|\n+----+------+\n|2019|326348|\n|2020|356466|\n|2021|387261|\n+----+------+\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["count is  326348\ncount is  356466\ncount is  387261\n+----+------+\n|Year| count|\n+----+------+\n|2019|326348|\n|2020|356466|\n|2021|387261|\n+----+------+\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["# QUESTION -2 \n# list all the types (as contained in the Type column) of studies in the dataset along with\n# the frequencies of each type. These should be ordered from most frequent to least frequent\nprint(\"2019 types of Studies along with Frequncies\")\ntypewise_2019 = df_2019.groupBy('Type').count().sort('Type', ascending=True).show()\n\nprint(\"2020 types of Studies along with Frequncies\")\ntypewise_2020 = df_2020.groupBy('Type').count().sort('Type', ascending=True).show()\n\nprint(\"2021 types of Studies along with Frequncies\")\ntypewise_2021 = df_2021.groupBy('Type').count().sort('Type', ascending=True).show()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"QUESTION -2 PYSPARK","showTitle":true,"inputWidgets":{},"nuid":"747d6fe3-be44-4899-aa29-ebd77ec88d53"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"2019 types of Studies along with Frequncies\n+--------------------+------+\n|                Type| count|\n+--------------------+------+\n|     Expanded Access|    69|\n|      Interventional|255945|\n|       Observational| 64163|\n|Observational [Pa...|  6171|\n+--------------------+------+\n\n2020 types of Studies along with Frequncies\n+--------------------+------+\n|                Type| count|\n+--------------------+------+\n|     Expanded Access|    69|\n|      Interventional|277631|\n|       Observational| 71434|\n|Observational [Pa...|  7332|\n+--------------------+------+\n\n2021 types of Studies along with Frequncies\n+--------------------+------+\n|                Type| count|\n+--------------------+------+\n|     Expanded Access|    69|\n|      Interventional|301472|\n|       Observational| 77540|\n|Observational [Pa...|  8180|\n+--------------------+------+\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["2019 types of Studies along with Frequncies\n+--------------------+------+\n|                Type| count|\n+--------------------+------+\n|     Expanded Access|    69|\n|      Interventional|255945|\n|       Observational| 64163|\n|Observational [Pa...|  6171|\n+--------------------+------+\n\n2020 types of Studies along with Frequncies\n+--------------------+------+\n|                Type| count|\n+--------------------+------+\n|     Expanded Access|    69|\n|      Interventional|277631|\n|       Observational| 71434|\n|Observational [Pa...|  7332|\n+--------------------+------+\n\n2021 types of Studies along with Frequncies\n+--------------------+------+\n|                Type| count|\n+--------------------+------+\n|     Expanded Access|    69|\n|      Interventional|301472|\n|       Observational| 77540|\n|Observational [Pa...|  8180|\n+--------------------+------+\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["# QUESTION -3 \nfrom pyspark.sql.functions import split\nfrom pyspark.sql.functions import col\nimport pyspark.sql.functions as F\n\ndf_2021 = spark.read.options(header='True', inferSchema='True', delimiter='|') .csv(files_2021)\ndf_2021_with_cond = df_2021.withColumn(\"Conditions\",split(col(\"Conditions\"), \"\\\\,\"))\ndf = df_2021_with_cond.withColumn('Conditions',F.explode(\"Conditions\")).groupBy('Conditions').count().orderBy(F.desc(\"count\"))\ndf.show(5)\n\n"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"QUESTION -3 PYSPARK 2019 2020 2021","showTitle":true,"inputWidgets":{},"nuid":"bd82bb99-1479-4d5c-be10-8c36df0f1d44"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+-----------------+-----+\n|       Conditions|count|\n+-----------------+-----+\n|        Carcinoma|13389|\n|Diabetes Mellitus|11080|\n|        Neoplasms| 9371|\n| Breast Neoplasms| 8640|\n|         Syndrome| 8032|\n+-----------------+-----+\nonly showing top 5 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+-----------------+-----+\n|       Conditions|count|\n+-----------------+-----+\n|        Carcinoma|13389|\n|Diabetes Mellitus|11080|\n|        Neoplasms| 9371|\n| Breast Neoplasms| 8640|\n|         Syndrome| 8032|\n+-----------------+-----+\nonly showing top 5 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["#QUESTION - 4\nfile_name = \"/FileStore/tables/mesh.csv\"\ndelimiter = \",\"\n\n\nmeshdf = spark.read.format(file_type) \\\n  .option(\"inferSchema\", infer_schema) \\\n  .option(\"header\", first_row_is_header) \\\n  .option(\"sep\", delimiter) \\\n  .load(file_name)\n\n\nmeshdf.printSchema()\nmeshdf.select('tree').show(5)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"QUESTION - 4 PYSPARK MESH DATA","showTitle":true,"inputWidgets":{},"nuid":"e7f0e7f7-5637-4b66-ba0d-e0222d2aa2b7"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"root\n |-- term: string (nullable = true)\n |-- tree: string (nullable = true)\n\n+-------------------+\n|               tree|\n+-------------------+\n|D03.633.100.221.173|\n|D03.633.100.221.173|\n|D02.705.400.625.800|\n|D02.705.539.345.800|\n|D02.886.300.692.800|\n+-------------------+\nonly showing top 5 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["root\n |-- term: string (nullable = true)\n |-- tree: string (nullable = true)\n\n+-------------------+\n|               tree|\n+-------------------+\n|D03.633.100.221.173|\n|D03.633.100.221.173|\n|D02.705.400.625.800|\n|D02.705.539.345.800|\n|D02.886.300.692.800|\n+-------------------+\nonly showing top 5 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["# YEAR - 2019\nfrom pyspark.sql.functions import col,substring\nfrom pyspark.sql.functions import split\nfrom pyspark.sql.functions import col\nimport pyspark.sql.functions as F\n\ndf_2019 = spark.read.options(header='True', inferSchema='True', delimiter='|').csv(files_2019)\ndf_2019_cond_formatted = df_2019.withColumn(\"Conditions\",split(col(\"Conditions\"),\"\\\\,\"))\ndf_2019_conditions = df_2019_cond_formatted.withColumn(\"Conditions\",F.explode(\"Conditions\"))\n\n\nmeshdata_df = meshdf.select('term','tree',substring('tree',1,3).alias('root')).drop('tree')#.show(15)\n\n#meshdata_df.show(4)\njoin_with_clinical =  df_2019_conditions.join(meshdata_df,(df_2019_conditions.Conditions==meshdata_df.term),'left')\njoin_with_clinical_with_mesh = join_with_clinical.select(meshdata_df.root,df_2019_conditions.Conditions)\n#join_with_clinical.show(5)\nroot_wise_count_in_2019 = join_with_clinical_with_mesh.groupBy('root').count().sort('count', ascending=False).filter(\"root IS NOT null\")\nroot_wise_count_in_2019.show(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"Question -4 2019 PYSPARK","showTitle":true,"inputWidgets":{},"nuid":"f042b9a4-f55d-4ed9-9d5f-668e31db3f39"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+----+------+\n|root| count|\n+----+------+\n| C04|123221|\n| C23|113997|\n| C14| 82043|\n| C10| 76665|\n| C01| 73477|\n| C06| 73272|\n| C08| 45180|\n| C13| 36293|\n| C18| 36051|\n| C12| 34699|\n+----+------+\nonly showing top 10 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+----+------+\n|root| count|\n+----+------+\n| C04|123221|\n| C23|113997|\n| C14| 82043|\n| C10| 76665|\n| C01| 73477|\n| C06| 73272|\n| C08| 45180|\n| C13| 36293|\n| C18| 36051|\n| C12| 34699|\n+----+------+\nonly showing top 10 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["# YEAR - 2020\nfrom pyspark.sql.functions import col,substring\nfrom pyspark.sql.functions import split\nfrom pyspark.sql.functions import col\nimport pyspark.sql.functions as F\n\ndf_2020 = spark.read.options(header='True', inferSchema='True', delimiter='|').csv(files_2020)\ndf_2020_cond_formatted = df_2020.withColumn(\"Conditions\",split(col(\"Conditions\"),\"\\\\,\"))\ndf_2020_conditions = df_2020_cond_formatted.withColumn(\"Conditions\",F.explode(\"Conditions\"))\n\nmeshdata_df = meshdf.select('term','tree',substring('tree',1,3).alias('root')).drop('tree')#.show(15)\n\n#meshdata_df.show(4)\njoin_with_clinical =  df_2020_conditions.join(meshdata_df,(df_2020_conditions.Conditions==meshdata_df.term),'left')\njoin_with_clinical_with_mesh = join_with_clinical.select(meshdata_df.root,df_2020_conditions.Conditions)\n#join_with_clinical.show(5)\nroot_wise_count_in_2020 = join_with_clinical_with_mesh.groupBy('root').count().sort('count', ascending=False).filter(\"root IS NOT null\")\nroot_wise_count_in_2020.show(10)\n"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"question -4 2020 PYSPARK","showTitle":true,"inputWidgets":{},"nuid":"ce48b78e-a8f7-4f87-8eab-a09463d4dc05"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+----+------+\n|root| count|\n+----+------+\n| C04|133091|\n| C23|124589|\n| C01| 94293|\n| C14| 88065|\n| C10| 83894|\n| C06| 79382|\n| C08| 61138|\n| C13| 39316|\n| C18| 38439|\n| C12| 37294|\n+----+------+\nonly showing top 10 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+----+------+\n|root| count|\n+----+------+\n| C04|133091|\n| C23|124589|\n| C01| 94293|\n| C14| 88065|\n| C10| 83894|\n| C06| 79382|\n| C08| 61138|\n| C13| 39316|\n| C18| 38439|\n| C12| 37294|\n+----+------+\nonly showing top 10 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["# YEAR - 2021\nfrom pyspark.sql.functions import col,substring\nfrom pyspark.sql.functions import split\nfrom pyspark.sql.functions import col\nimport pyspark.sql.functions as F\n\ndf_2021 = spark.read.options(header='True', inferSchema='True', delimiter='|').csv(files_2021)\ndf_2021_cond_formatted = df_2021.withColumn(\"Conditions\",split(col(\"Conditions\"),\"\\\\,\"))\ndf_2021_conditions = df_2021_cond_formatted.withColumn(\"Conditions\",F.explode(\"Conditions\"))\nmeshdata_df = meshdf.select('term','tree',substring('tree',1,3).alias('root')).drop('tree')#.show(15)\n\n#meshdata_df.show(4)\njoin_with_clinical =  df_2021_conditions.join(meshdata_df,(df_2021_conditions.Conditions==meshdata_df.term),'left')\njoin_with_clinical_with_mesh = join_with_clinical.select(meshdata_df.root,df_2021_conditions.Conditions)\n#join_with_clinical.show(5)\nroot_wise_count_in_2021 = join_with_clinical_with_mesh.groupBy('root').count().sort('count', ascending=False).filter(\"root IS NOT null\")\nroot_wise_count_in_2021.show(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"Question -4 2021 PYSPARK","showTitle":true,"inputWidgets":{},"nuid":"3036473a-e78e-4a99-ba4d-c02e4024a5b6"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+----+------+\n|root| count|\n+----+------+\n| C04|143994|\n| C23|136079|\n| C01|106674|\n| C14| 94523|\n| C10| 92310|\n| C06| 85646|\n| C08| 70720|\n| C13| 42599|\n| C18| 41276|\n| C12| 40161|\n+----+------+\nonly showing top 10 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+----+------+\n|root| count|\n+----+------+\n| C04|143994|\n| C23|136079|\n| C01|106674|\n| C14| 94523|\n| C10| 92310|\n| C06| 85646|\n| C08| 70720|\n| C13| 42599|\n| C18| 41276|\n| C12| 40161|\n+----+------+\nonly showing top 10 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["\nnewdf_2019pandasDF = root_wise_count_in_2019.toPandas()\nnewdf_2020pandasDF = root_wise_count_in_2020.toPandas()\nnewdf_2021pandasDF = root_wise_count_in_2021.toPandas()\n#print(pandasDF)\n\nmerged = newdf_2019pandasDF.merge(newdf_2020pandasDF, on='root').merge(newdf_2021pandasDF, on='root')\nmerged = merged.set_index('root')\nnewmerge = merged.rename(columns={'count_x': '2019', 'count_y': '2020','count':'2021'})\nnewmerge.head(10)\n\n\n\n"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"Question -4 OUTPUT DATAFRAME FOR ALL THE THREE YEARS","showTitle":true,"inputWidgets":{},"nuid":"a6aeee7e-4095-4d8a-8e5e-c1cba678f94e"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>2019</th>\n      <th>2020</th>\n      <th>2021</th>\n    </tr>\n    <tr>\n      <th>root</th>\n      <th></th>\n      <th></th>\n      <th></th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>C04</th>\n      <td>123221</td>\n      <td>133091</td>\n      <td>143994</td>\n    </tr>\n    <tr>\n      <th>C23</th>\n      <td>113997</td>\n      <td>124589</td>\n      <td>136079</td>\n    </tr>\n    <tr>\n      <th>C14</th>\n      <td>82043</td>\n      <td>88065</td>\n      <td>94523</td>\n    </tr>\n    <tr>\n      <th>C10</th>\n      <td>76665</td>\n      <td>83894</td>\n      <td>92310</td>\n    </tr>\n    <tr>\n      <th>C01</th>\n      <td>73477</td>\n      <td>94293</td>\n      <td>106674</td>\n    </tr>\n    <tr>\n      <th>C06</th>\n      <td>73272</td>\n      <td>79382</td>\n      <td>85646</td>\n    </tr>\n    <tr>\n      <th>C08</th>\n      <td>45180</td>\n      <td>61138</td>\n      <td>70720</td>\n    </tr>\n    <tr>\n      <th>C13</th>\n      <td>36293</td>\n      <td>39316</td>\n      <td>42599</td>\n    </tr>\n    <tr>\n      <th>C18</th>\n      <td>36051</td>\n      <td>38439</td>\n      <td>41276</td>\n    </tr>\n    <tr>\n      <th>C12</th>\n      <td>34699</td>\n      <td>37294</td>\n      <td>40161</td>\n    </tr>\n  </tbody>\n</table>\n</div>","textData":null,"removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"htmlSandbox","arguments":{}}},"output_type":"display_data","data":{"text/html":["<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>2019</th>\n      <th>2020</th>\n      <th>2021</th>\n    </tr>\n    <tr>\n      <th>root</th>\n      <th></th>\n      <th></th>\n      <th></th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>C04</th>\n      <td>123221</td>\n      <td>133091</td>\n      <td>143994</td>\n    </tr>\n    <tr>\n      <th>C23</th>\n      <td>113997</td>\n      <td>124589</td>\n      <td>136079</td>\n    </tr>\n    <tr>\n      <th>C14</th>\n      <td>82043</td>\n      <td>88065</td>\n      <td>94523</td>\n    </tr>\n    <tr>\n      <th>C10</th>\n      <td>76665</td>\n      <td>83894</td>\n      <td>92310</td>\n    </tr>\n    <tr>\n      <th>C01</th>\n      <td>73477</td>\n      <td>94293</td>\n      <td>106674</td>\n    </tr>\n    <tr>\n      <th>C06</th>\n      <td>73272</td>\n      <td>79382</td>\n      <td>85646</td>\n    </tr>\n    <tr>\n      <th>C08</th>\n      <td>45180</td>\n      <td>61138</td>\n      <td>70720</td>\n    </tr>\n    <tr>\n      <th>C13</th>\n      <td>36293</td>\n      <td>39316</td>\n      <td>42599</td>\n    </tr>\n    <tr>\n      <th>C18</th>\n      <td>36051</td>\n      <td>38439</td>\n      <td>41276</td>\n    </tr>\n    <tr>\n      <th>C12</th>\n      <td>34699</td>\n      <td>37294</td>\n      <td>40161</td>\n    </tr>\n  </tbody>\n</table>\n</div>"]}}],"execution_count":0},{"cell_type":"code","source":["# QUESTION - 5 \nfile_name = \"/FileStore/tables/pharma.csv\"\nfile_type = \"csv\"\ninfer_schema = \"false\"\nfirst_row_is_header = \"True\"\ndelimiter = \",\"\n\n\ndf = spark.read.format(file_type) \\\n  .option(\"inferSchema\", infer_schema) \\\n  .option(\"header\", first_row_is_header) \\\n  .option(\"sep\", delimiter) \\\n  .load(file_name)\n\ndf.printSchema()\n#display(df)\n"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"QUESTION -5 PHARMA DATASET TO PYSPARK DATAFRAME","showTitle":true,"inputWidgets":{},"nuid":"5ecf5f19-e2f5-4e49-95a5-3f7904cf6ad5"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"root\n |-- Company: string (nullable = true)\n |-- Parent_Company: string (nullable = true)\n |-- Penalty_Amount: string (nullable = true)\n |-- Subtraction_From_Penalty: string (nullable = true)\n |-- Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting: string (nullable = true)\n |-- Penalty_Year: string (nullable = true)\n |-- Penalty_Date: string (nullable = true)\n |-- Offense_Group: string (nullable = true)\n |-- Primary_Offense: string (nullable = true)\n |-- Secondary_Offense: string (nullable = true)\n |-- Description: string (nullable = true)\n |-- Level_of_Government: string (nullable = true)\n |-- Action_Type: string (nullable = true)\n |-- Agency: string (nullable = true)\n |-- Civil/Criminal: string (nullable = true)\n |-- Prosecution_Agreement: string (nullable = true)\n |-- Court: string (nullable = true)\n |-- Case_ID: string (nullable = true)\n |-- Private_Litigation_Case_Title: string (nullable = true)\n |-- Lawsuit_Resolution: string (nullable = true)\n |-- Facility_State: string (nullable = true)\n |-- City: string (nullable = true)\n |-- Address: string (nullable = true)\n |-- Zip: string (nullable = true)\n |-- NAICS_Code: string (nullable = true)\n |-- NAICS_Translation: string (nullable = true)\n |-- HQ_Country_of_Parent: string (nullable = true)\n |-- HQ_State_of_Parent: string (nullable = true)\n |-- Ownership_Structure: string (nullable = true)\n |-- Parent_Company_Stock_Ticker: string (nullable = true)\n |-- Major_Industry_of_Parent: string (nullable = true)\n |-- Specific_Industry_of_Parent: string (nullable = true)\n |-- Info_Source: string (nullable = true)\n |-- Notes: string (nullable = true)\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["root\n |-- Company: string (nullable = true)\n |-- Parent_Company: string (nullable = true)\n |-- Penalty_Amount: string (nullable = true)\n |-- Subtraction_From_Penalty: string (nullable = true)\n |-- Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting: string (nullable = true)\n |-- Penalty_Year: string (nullable = true)\n |-- Penalty_Date: string (nullable = true)\n |-- Offense_Group: string (nullable = true)\n |-- Primary_Offense: string (nullable = true)\n |-- Secondary_Offense: string (nullable = true)\n |-- Description: string (nullable = true)\n |-- Level_of_Government: string (nullable = true)\n |-- Action_Type: string (nullable = true)\n |-- Agency: string (nullable = true)\n |-- Civil/Criminal: string (nullable = true)\n |-- Prosecution_Agreement: string (nullable = true)\n |-- Court: string (nullable = true)\n |-- Case_ID: string (nullable = true)\n |-- Private_Litigation_Case_Title: string (nullable = true)\n |-- Lawsuit_Resolution: string (nullable = true)\n |-- Facility_State: string (nullable = true)\n |-- City: string (nullable = true)\n |-- Address: string (nullable = true)\n |-- Zip: string (nullable = true)\n |-- NAICS_Code: string (nullable = true)\n |-- NAICS_Translation: string (nullable = true)\n |-- HQ_Country_of_Parent: string (nullable = true)\n |-- HQ_State_of_Parent: string (nullable = true)\n |-- Ownership_Structure: string (nullable = true)\n |-- Parent_Company_Stock_Ticker: string (nullable = true)\n |-- Major_Industry_of_Parent: string (nullable = true)\n |-- Specific_Industry_of_Parent: string (nullable = true)\n |-- Info_Source: string (nullable = true)\n |-- Notes: string (nullable = true)\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["OrderSchema = df.schema \ndisplay(OrderSchema)\ndf.show(1)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"QUESTION -5 PYSPARK DATA VALIDATION","showTitle":true,"inputWidgets":{},"nuid":"da978581-e2aa-4413-95b3-03519b21a1eb"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"StructType(List(StructField(Company,StringType,true),StructField(Parent_Company,StringType,true),StructField(Penalty_Amount,StringType,true),StructField(Subtraction_From_Penalty,StringType,true),StructField(Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting,StringType,true),StructField(Penalty_Year,StringType,true),StructField(Penalty_Date,StringType,true),StructField(Offense_Group,StringType,true),StructField(Primary_Offense,StringType,true),StructField(Secondary_Offense,StringType,true),StructField(Description,StringType,true),StructField(Level_of_Government,StringType,true),StructField(Action_Type,StringType,true),StructField(Agency,StringType,true),StructField(Civil/Criminal,StringType,true),StructField(Prosecution_Agreement,StringType,true),StructField(Court,StringType,true),StructField(Case_ID,StringType,true),StructField(Private_Litigation_Case_Title,StringType,true),StructField(Lawsuit_Resolution,StringType,true),StructField(Facility_State,StringType,true),StructField(City,StringType,true),StructField(Address,StringType,true),StructField(Zip,StringType,true),StructField(NAICS_Code,StringType,true),StructField(NAICS_Translation,StringType,true),StructField(HQ_Country_of_Parent,StringType,true),StructField(HQ_State_of_Parent,StringType,true),StructField(Ownership_Structure,StringType,true),StructField(Parent_Company_Stock_Ticker,StringType,true),StructField(Major_Industry_of_Parent,StringType,true),StructField(Specific_Industry_of_Parent,StringType,true),StructField(Info_Source,StringType,true),StructField(Notes,StringType,true)))+-------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+--------------------+--------------------+--------------------+--------------------+-------------------+-------------+--------------------+--------------+---------------------+-----+-------+-----------------------------+------------------+--------------+----+-------+----+----------+-----------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+--------------------+-----+\n|            Company|     Parent_Company|Penalty_Amount|Subtraction_From_Penalty|Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting|Penalty_Year|Penalty_Date|       Offense_Group|     Primary_Offense|   Secondary_Offense|         Description|Level_of_Government|  Action_Type|              Agency|Civil/Criminal|Prosecution_Agreement|Court|Case_ID|Private_Litigation_Case_Title|Lawsuit_Resolution|Facility_State|City|Address| Zip|NAICS_Code|NAICS_Translation|HQ_Country_of_Parent|HQ_State_of_Parent|Ownership_Structure|Parent_Company_Stock_Ticker|Major_Industry_of_Parent|Specific_Industry_of_Parent|         Info_Source|Notes|\n+-------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+--------------------+--------------------+--------------------+--------------------+-------------------+-------------+--------------------+--------------+---------------------+-----+-------+-----------------------------+------------------+--------------+----+-------+----+----------+-----------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+--------------------+-----+\n|Abbott Laboratories|Abbott Laboratories|    $5,475,000|                      $0|                                               $5,475,000|        2013|    20131227|government-contra...|False Claims Act ...|kickbacks and bri...|Abbott Laboratori...|            federal|agency action|Justice Departmen...|         civil|                 null| null|   null|                         null|              null|          null|null|   null|null|      null|             null|                 USA|          Illinois|    publicly traded|                        ABT|         pharmaceuticals|            pharmaceuticals|https://www.justi...| null|\n+-------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+--------------------+--------------------+--------------------+--------------------+-------------------+-------------+--------------------+--------------+---------------------+-----+-------+-----------------------------+------------------+--------------+----+-------+----+----------+-----------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+--------------------+-----+\nonly showing top 1 row\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["StructType(List(StructField(Company,StringType,true),StructField(Parent_Company,StringType,true),StructField(Penalty_Amount,StringType,true),StructField(Subtraction_From_Penalty,StringType,true),StructField(Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting,StringType,true),StructField(Penalty_Year,StringType,true),StructField(Penalty_Date,StringType,true),StructField(Offense_Group,StringType,true),StructField(Primary_Offense,StringType,true),StructField(Secondary_Offense,StringType,true),StructField(Description,StringType,true),StructField(Level_of_Government,StringType,true),StructField(Action_Type,StringType,true),StructField(Agency,StringType,true),StructField(Civil/Criminal,StringType,true),StructField(Prosecution_Agreement,StringType,true),StructField(Court,StringType,true),StructField(Case_ID,StringType,true),StructField(Private_Litigation_Case_Title,StringType,true),StructField(Lawsuit_Resolution,StringType,true),StructField(Facility_State,StringType,true),StructField(City,StringType,true),StructField(Address,StringType,true),StructField(Zip,StringType,true),StructField(NAICS_Code,StringType,true),StructField(NAICS_Translation,StringType,true),StructField(HQ_Country_of_Parent,StringType,true),StructField(HQ_State_of_Parent,StringType,true),StructField(Ownership_Structure,StringType,true),StructField(Parent_Company_Stock_Ticker,StringType,true),StructField(Major_Industry_of_Parent,StringType,true),StructField(Specific_Industry_of_Parent,StringType,true),StructField(Info_Source,StringType,true),StructField(Notes,StringType,true)))+-------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+--------------------+--------------------+--------------------+--------------------+-------------------+-------------+--------------------+--------------+---------------------+-----+-------+-----------------------------+------------------+--------------+----+-------+----+----------+-----------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+--------------------+-----+\n|            Company|     Parent_Company|Penalty_Amount|Subtraction_From_Penalty|Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting|Penalty_Year|Penalty_Date|       Offense_Group|     Primary_Offense|   Secondary_Offense|         Description|Level_of_Government|  Action_Type|              Agency|Civil/Criminal|Prosecution_Agreement|Court|Case_ID|Private_Litigation_Case_Title|Lawsuit_Resolution|Facility_State|City|Address| Zip|NAICS_Code|NAICS_Translation|HQ_Country_of_Parent|HQ_State_of_Parent|Ownership_Structure|Parent_Company_Stock_Ticker|Major_Industry_of_Parent|Specific_Industry_of_Parent|         Info_Source|Notes|\n+-------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+--------------------+--------------------+--------------------+--------------------+-------------------+-------------+--------------------+--------------+---------------------+-----+-------+-----------------------------+------------------+--------------+----+-------+----+----------+-----------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+--------------------+-----+\n|Abbott Laboratories|Abbott Laboratories|    $5,475,000|                      $0|                                               $5,475,000|        2013|    20131227|government-contra...|False Claims Act ...|kickbacks and bri...|Abbott Laboratori...|            federal|agency action|Justice Departmen...|         civil|                 null| null|   null|                         null|              null|          null|null|   null|null|      null|             null|                 USA|          Illinois|    publicly traded|                        ABT|         pharmaceuticals|            pharmaceuticals|https://www.justi...| null|\n+-------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+--------------------+--------------------+--------------------+--------------------+-------------------+-------------+--------------------+--------------+---------------------+-----+-------+-----------------------------+------------------+--------------+----+-------+----+----------+-----------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+--------------------+-----+\nonly showing top 1 row\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["from pyspark.sql.functions import col, coalesce, lit\n\nclinical_data_2019 = spark.read.options(header='True', inferSchema='True', delimiter='|') .csv(files_2019)\n\njoin_clinical_with_pharma = clinical_data_2019.join(df,clinical_data_2019.Sponsor==df.Parent_Company,\"leftouter\")\n# newdf_2020.show(10)\nsponsor_from_join = join_clinical_with_pharma.where(coalesce(col(\"Major_Industry_of_Parent\") != 'pharmaceuticals', lit(True)))#.show()\n\nsponsor_count_2019 = sponsor_from_join.groupBy('Sponsor').count() .orderBy('count', ascending=False)\nsponsor_count_2019.show(10)\n"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"QUESTION -5 PYSPARK 2019","showTitle":true,"inputWidgets":{},"nuid":"db066d2b-3269-4167-928f-ee8e5809108b"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+--------------------+-----+\n|             Sponsor|count|\n+--------------------+-----+\n|National Cancer I...| 3003|\n|Merck Sharp & Doh...| 2124|\n|M.D. Anderson Can...| 2097|\n|         Mayo Clinic| 1930|\n|Novartis Pharmace...| 1881|\n|Assistance Publiq...| 1764|\n|Massachusetts Gen...| 1715|\n|   Hoffmann-La Roche| 1694|\n|National Taiwan U...| 1608|\n|Eli Lilly and Com...| 1500|\n+--------------------+-----+\nonly showing top 10 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+--------------------+-----+\n|             Sponsor|count|\n+--------------------+-----+\n|National Cancer I...| 3003|\n|Merck Sharp & Doh...| 2124|\n|M.D. Anderson Can...| 2097|\n|         Mayo Clinic| 1930|\n|Novartis Pharmace...| 1881|\n|Assistance Publiq...| 1764|\n|Massachusetts Gen...| 1715|\n|   Hoffmann-La Roche| 1694|\n|National Taiwan U...| 1608|\n|Eli Lilly and Com...| 1500|\n+--------------------+-----+\nonly showing top 10 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["# question 5\nfrom pyspark.sql.functions import col, coalesce, lit\n\nclinical_data_2020 = spark.read.options(header='True', inferSchema='True', delimiter='|') .csv(files_2020)\n\njoin_clinical_with_pharma = clinical_data_2020.join(df,clinical_data_2020.Sponsor==df.Parent_Company,\"leftouter\")\n# newdf_2020.show(10)\nsponsor_from_join = join_clinical_with_pharma.where(coalesce(col(\"Major_Industry_of_Parent\") != 'pharmaceuticals', lit(True)))#.show()\n\nsponsor_count_2020 = sponsor_from_join.groupBy('Sponsor').count() .orderBy('count', ascending=False)\nsponsor_count_2020.show(10)\n "],"metadata":{"application/vnd.databricks.v1+cell":{"title":"QUESTION -5 2020","showTitle":true,"inputWidgets":{},"nuid":"dedad6aa-245c-486b-aad5-56c16e73af0f"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+--------------------+-----+\n|             Sponsor|count|\n+--------------------+-----+\n|National Cancer I...| 3100|\n|M.D. Anderson Can...| 2238|\n|Merck Sharp & Doh...| 2184|\n|         Mayo Clinic| 2097|\n|Assistance Publiq...| 2043|\n|Novartis Pharmace...| 1962|\n|Massachusetts Gen...| 1823|\n|   Assiut University| 1806|\n|   Hoffmann-La Roche| 1761|\n|National Taiwan U...| 1720|\n+--------------------+-----+\nonly showing top 10 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+--------------------+-----+\n|             Sponsor|count|\n+--------------------+-----+\n|National Cancer I...| 3100|\n|M.D. Anderson Can...| 2238|\n|Merck Sharp & Doh...| 2184|\n|         Mayo Clinic| 2097|\n|Assistance Publiq...| 2043|\n|Novartis Pharmace...| 1962|\n|Massachusetts Gen...| 1823|\n|   Assiut University| 1806|\n|   Hoffmann-La Roche| 1761|\n|National Taiwan U...| 1720|\n+--------------------+-----+\nonly showing top 10 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["from pyspark.sql.functions import col, coalesce, lit\n\nclinical_data_2021 = spark.read.options(header='True', inferSchema='True', delimiter='|') .csv(files_2021)\n\njoin_clinical_with_pharma = clinical_data_2021.join(df,clinical_data_2021.Sponsor==df.Parent_Company,\"leftouter\")\n# newdf_2020.show(10)\nsponsor_from_join = join_clinical_with_pharma.where(coalesce(col(\"Major_Industry_of_Parent\") != 'pharmaceuticals', lit(True)))#.show()\n\nsponsor_count_2021 = sponsor_from_join.groupBy('Sponsor').count() .orderBy('count', ascending=False)\nsponsor_count_2021.show(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"QUESTION -5 PYSPARK 2021","showTitle":true,"inputWidgets":{},"nuid":"0d712691-f45d-4fd0-8c69-890d535aa07a"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+--------------------+-----+\n|             Sponsor|count|\n+--------------------+-----+\n|National Cancer I...| 3218|\n|M.D. Anderson Can...| 2414|\n|Assistance Publiq...| 2369|\n|         Mayo Clinic| 2300|\n|Merck Sharp & Doh...| 2243|\n|   Assiut University| 2154|\n|Novartis Pharmace...| 2088|\n|Massachusetts Gen...| 1971|\n|    Cairo University| 1928|\n|   Hoffmann-La Roche| 1828|\n+--------------------+-----+\nonly showing top 10 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+--------------------+-----+\n|             Sponsor|count|\n+--------------------+-----+\n|National Cancer I...| 3218|\n|M.D. Anderson Can...| 2414|\n|Assistance Publiq...| 2369|\n|         Mayo Clinic| 2300|\n|Merck Sharp & Doh...| 2243|\n|   Assiut University| 2154|\n|Novartis Pharmace...| 2088|\n|Massachusetts Gen...| 1971|\n|    Cairo University| 1928|\n|   Hoffmann-La Roche| 1828|\n+--------------------+-----+\nonly showing top 10 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["df1 = sponsor_count_2019.toPandas()\ndf2 = sponsor_count_2020.toPandas()\ndf3 = sponsor_count_2021.toPandas()\n#print(pandasDF)\n\nmerged = df1.merge(df2, on='Sponsor').merge(df3, on='Sponsor')\nmerged = merged.set_index('Sponsor')\nnewmerge = merged.rename(columns={'count_x': '2019', 'count_y': '2020','count':'2021'})\nnewmerge.head(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"dae7590a-a1dc-4e7a-bfbc-1c333c5c65be"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>2019</th>\n      <th>2020</th>\n      <th>2021</th>\n    </tr>\n    <tr>\n      <th>Sponsor</th>\n      <th></th>\n      <th></th>\n      <th></th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>National Cancer Institute (NCI)</th>\n      <td>3003</td>\n      <td>3100</td>\n      <td>3218</td>\n    </tr>\n    <tr>\n      <th>Merck Sharp &amp; Dohme Corp.</th>\n      <td>2124</td>\n      <td>2184</td>\n      <td>2243</td>\n    </tr>\n    <tr>\n      <th>M.D. Anderson Cancer Center</th>\n      <td>2097</td>\n      <td>2238</td>\n      <td>2414</td>\n    </tr>\n    <tr>\n      <th>Mayo Clinic</th>\n      <td>1930</td>\n      <td>2097</td>\n      <td>2300</td>\n    </tr>\n    <tr>\n      <th>Novartis Pharmaceuticals</th>\n      <td>1881</td>\n      <td>1962</td>\n      <td>2088</td>\n    </tr>\n    <tr>\n      <th>Assistance Publique - Hpitaux de Paris</th>\n      <td>1764</td>\n      <td>2043</td>\n      <td>2369</td>\n    </tr>\n    <tr>\n      <th>Massachusetts General Hospital</th>\n      <td>1715</td>\n      <td>1823</td>\n      <td>1971</td>\n    </tr>\n    <tr>\n      <th>Hoffmann-La Roche</th>\n      <td>1694</td>\n      <td>1761</td>\n      <td>1828</td>\n    </tr>\n    <tr>\n      <th>National Taiwan University Hospital</th>\n      <td>1608</td>\n      <td>1720</td>\n      <td>1814</td>\n    </tr>\n    <tr>\n      <th>Eli Lilly and Company</th>\n      <td>1500</td>\n      <td>1578</td>\n      <td>1641</td>\n    </tr>\n  </tbody>\n</table>\n</div>","textData":null,"removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"htmlSandbox","arguments":{}}},"output_type":"display_data","data":{"text/html":["<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>2019</th>\n      <th>2020</th>\n      <th>2021</th>\n    </tr>\n    <tr>\n      <th>Sponsor</th>\n      <th></th>\n      <th></th>\n      <th></th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>National Cancer Institute (NCI)</th>\n      <td>3003</td>\n      <td>3100</td>\n      <td>3218</td>\n    </tr>\n    <tr>\n      <th>Merck Sharp &amp; Dohme Corp.</th>\n      <td>2124</td>\n      <td>2184</td>\n      <td>2243</td>\n    </tr>\n    <tr>\n      <th>M.D. Anderson Cancer Center</th>\n      <td>2097</td>\n      <td>2238</td>\n      <td>2414</td>\n    </tr>\n    <tr>\n      <th>Mayo Clinic</th>\n      <td>1930</td>\n      <td>2097</td>\n      <td>2300</td>\n    </tr>\n    <tr>\n      <th>Novartis Pharmaceuticals</th>\n      <td>1881</td>\n      <td>1962</td>\n      <td>2088</td>\n    </tr>\n    <tr>\n      <th>Assistance Publique - Hpitaux de Paris</th>\n      <td>1764</td>\n      <td>2043</td>\n      <td>2369</td>\n    </tr>\n    <tr>\n      <th>Massachusetts General Hospital</th>\n      <td>1715</td>\n      <td>1823</td>\n      <td>1971</td>\n    </tr>\n    <tr>\n      <th>Hoffmann-La Roche</th>\n      <td>1694</td>\n      <td>1761</td>\n      <td>1828</td>\n    </tr>\n    <tr>\n      <th>National Taiwan University Hospital</th>\n      <td>1608</td>\n      <td>1720</td>\n      <td>1814</td>\n    </tr>\n    <tr>\n      <th>Eli Lilly and Company</th>\n      <td>1500</td>\n      <td>1578</td>\n      <td>1641</td>\n    </tr>\n  </tbody>\n</table>\n</div>"]}}],"execution_count":0},{"cell_type":"code","source":["import numpy as np\nimport pandas as pd\nimport matplotlib.pyplot as plt\n%matplotlib inline\n#pd_df_sub = newmerge[['2019', '2020','2021']]\ndf1 = sponsor_count_2019.toPandas()\ndf1.plot.scatter(x='Sponsor', y='count')"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"c854d058-a94f-4377-bc14-2937eeaafedc"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"data":"","errorSummary":"Command skipped","metadata":{},"errorTraceType":"ansi","type":"ipynbError","arguments":{}}},"output_type":"display_data","data":{"text/plain":[""]}}],"execution_count":0},{"cell_type":"code","source":["# QUESTION - 6 2019\n#Visualizing the no of complted studies each month in a given year\nfrom pyspark.sql. functions import substring\nfrom pyspark.sql. functions import date_format, to_date\n\nclinical_df_2019 = spark.read.options(header='True', inferSchema='False', delimiter='|').csv(files_2019)\n\nclinical_status_in_date_format = clinical_df_2019.select(\"Completion\",\"Status\",date_format(to_date(\"Completion\",\"MMM yyyy\"),\"MM-dd-yyyy\").alias (\"col\"))\n#clinical_status_in_date_format.show(5)\n\nstats_completed = clinical_status_in_date_format.where(clinical_status_in_date_format.Status == \"Completed\")\n\nstats_completed_in_2019 = stats_completed.where(substring(\"Completion\",5,8)== \"2019\")\n\nmonthwise_stats_completed_in_2019 = stats_completed_in_2019.select(substring(\"Completion\", 1,3).alias(\"month\"),\"Status\",\"col\")\n\n#monthwise_stats_completed_in_2019.show(3)\nmonth_wise = monthwise_stats_completed_in_2019.select(\"month\", \"col\").where(monthwise_stats_completed_in_2019.month.isNotNull()).groupBy(\"month\", \"col\").count().orderBy(\"col\",ascending = True)\n\ntotal_completed_status_month_wise = month_wise.select(\"month\", \"count\")\n\ntotal_completed_status_month_wise.show()\n"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"QUESTION - 6 PYSPARK - 2019","showTitle":true,"inputWidgets":{},"nuid":"042e2405-b60b-47c6-94a8-fc4893ceec44"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+-----+-----+\n|month|count|\n+-----+-----+\n|  Jan| 1368|\n|  Feb| 1149|\n|  Mar| 1470|\n|  Apr| 1368|\n|  May| 1342|\n|  Jun| 1647|\n|  Jul| 1547|\n|  Aug| 1406|\n|  Sep| 1421|\n|  Oct| 1310|\n|  Nov| 1223|\n|  Dec| 2690|\n+-----+-----+\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+-----+-----+\n|month|count|\n+-----+-----+\n|  Jan| 1368|\n|  Feb| 1149|\n|  Mar| 1470|\n|  Apr| 1368|\n|  May| 1342|\n|  Jun| 1647|\n|  Jul| 1547|\n|  Aug| 1406|\n|  Sep| 1421|\n|  Oct| 1310|\n|  Nov| 1223|\n|  Dec| 2690|\n+-----+-----+\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["# QUESTION - 6 2020\n#Visualizing the no of complted studies each month in a given year\nfrom pyspark.sql. functions import substring\nfrom pyspark.sql. functions import date_format, to_date\n\nclinical_df_2020 = spark.read.options(header='True', inferSchema='False', delimiter='|').csv(files_2020)\n\nclinical_status_in_date_format = clinical_df_2020.select(\"Completion\",\"Status\",date_format(to_date(\"Completion\",\"MMM yyyy\"),\"MM-dd-yyyy\").alias (\"col\"))\n#clinical_status_in_date_format.show(5)\n\nstats_completed = clinical_status_in_date_format.where(clinical_df_2020.Status == \"Completed\")\n\nstats_completed_in_2020 = stats_completed.where(substring(\"Completion\",5,8)== \"2020\")\n\nmonthwise_stats_completed_in_2020 = stats_completed_in_2020.select(substring(\"Completion\", 1,3).alias(\"month\"),\"Status\",\"col\")\n\n#monthwise_stats_completed_in_2020.show(3)\nmonth_wise =monthwise_stats_completed_in_2020.select(\"month\", \"col\").where(monthwise_stats_completed_in_2020.month.isNotNull()).groupBy(\"month\", \"col\").count().orderBy(\"col\",ascending = True)\ntotal_completed_status_month_wise = month_wise.select(\"month\", \"count\")\ntotal_completed_status_month_wise.show()\n\n"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"QUESTION - 6 PYSPARK - 2020","showTitle":true,"inputWidgets":{},"nuid":"3cfdfa06-2c21-4e47-9163-153c0dd3357d"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+-----+-----+\n|month|count|\n+-----+-----+\n|  Jan| 1544|\n|  Feb| 1286|\n|  Mar| 1740|\n|  Apr| 1080|\n|  May| 1176|\n|  Jun| 1424|\n|  Jul| 1237|\n|  Aug| 1126|\n|  Sep| 1167|\n|  Oct| 1176|\n|  Nov| 1078|\n|  Dec| 2084|\n+-----+-----+\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+-----+-----+\n|month|count|\n+-----+-----+\n|  Jan| 1544|\n|  Feb| 1286|\n|  Mar| 1740|\n|  Apr| 1080|\n|  May| 1176|\n|  Jun| 1424|\n|  Jul| 1237|\n|  Aug| 1126|\n|  Sep| 1167|\n|  Oct| 1176|\n|  Nov| 1078|\n|  Dec| 2084|\n+-----+-----+\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["from pyspark.sql. functions import substring\nfrom pyspark.sql. functions import date_format, to_date\n#\nclinical_df_2021 = spark.read.options(header='True', inferSchema='False', delimiter='|').csv(files_2021)\n\nclinical_status_in_date_format = clinical_df_2021.select(\"Completion\",\"Status\",date_format(to_date(\"Completion\",\"MMM yyyy\"),\"MM-dd-yyyy\").alias (\"col\"))\nstats_completed = clinical_status_in_date_format.where(clinical_df_2021.Status == \"Completed\")\n\nstats_completed_in_2021 = stats_completed.where(substring(\"Completion\",5,8)== \"2021\")\n\nmonthwise_stats_completed_in_2021 = stats_completed_in_2021.select(substring(\"Completion\", 1,3).alias(\"month\"),\"Status\",\"col\")\nmonth_wise =monthwise_stats_completed_in_2021.select(\"month\", \"col\").where(monthwise_stats_completed_in_2021.month.isNotNull()).groupBy(\"month\", \"col\").count().orderBy(\"col\",ascending = True)\ntotal_completed_status_month_wise = month_wise.select(\"month\", \"count\")\ntotal_completed_status_month_wise.show()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"QUESTION - 6 PYSPARK - 2021","showTitle":true,"inputWidgets":{},"nuid":"af385efc-32d6-4ac4-9747-524b9cda10c1"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+-----+-----+\n|month|count|\n+-----+-----+\n|  Jan| 1131|\n|  Feb|  934|\n|  Mar| 1227|\n|  Apr|  967|\n|  May|  984|\n|  Jun| 1094|\n|  Jul|  819|\n|  Aug|  700|\n|  Sep|  528|\n|  Oct|  187|\n+-----+-----+\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+-----+-----+\n|month|count|\n+-----+-----+\n|  Jan| 1131|\n|  Feb|  934|\n|  Mar| 1227|\n|  Apr|  967|\n|  May|  984|\n|  Jun| 1094|\n|  Jul|  819|\n|  Aug|  700|\n|  Sep|  528|\n|  Oct|  187|\n+-----+-----+\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["import numpy as np\nimport pandas as pd\nimport matplotlib.pyplot as plt\n%matplotlib inline\ndf1 = total_completed_status_month_wise.toPandas()\ndf1.plot.scatter(x='month', y='count')"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"2c65a89c-804a-46a2-af96-bf8821d21a03"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[33]: <AxesSubplot:xlabel='month', ylabel='count'>","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[33]: <AxesSubplot:xlabel='month', ylabel='count'>"]}},{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"data:image/png;base64,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\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"image","arguments":{}}},"output_type":"display_data","data":{"image/png":"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\n"}}],"execution_count":0},{"cell_type":"code","source":["\ndf1.plot.line()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"a1351245-8b84-435c-adcd-3526691449ed"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[34]: <AxesSubplot:>","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[34]: <AxesSubplot:>"]}},{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"data:image/png;base64,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\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"image","arguments":{}}},"output_type":"display_data","data":{"image/png":"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\n"}}],"execution_count":0},{"cell_type":"code","source":["display(dbutils.fs.head(\"/FileStore/tables/mesh.csv\"))\n"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"b96181ab-6a9b-41c8-9bb0-2f75c164d8f4"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"[Truncated to first 65536 bytes]\n'term,tree\\r\\nCalcimycin,D03.633.100.221.173\\r\\nA-23187,D03.633.100.221.173\\r\\nTemefos,D02.705.400.625.800\\r\\nTemefos,D02.705.539.345.800\\r\\nTemefos,D02.886.300.692.800\\r\\nAbate,D02.705.400.625.800\\r\\nAbate,D02.705.539.345.800\\r\\nAbate,D02.886.300.692.800\\r\\nDifos,D02.705.400.625.800\\r\\nDifos,D02.705.539.345.800\\r\\nDifos,D02.886.300.692.800\\r\\nAbattoirs,J01.576.423.200.700.100\\r\\nAbattoirs,J03.540.020\\r\\nAbbreviations as Topic,L01.559.598.400.556.131\\r\\nAcronyms as Topic,L01.559.598.400.556.131\\r\\nAbdomen,A01.923.047\\r\\n\"Abdomen, Acute\",C23.888.592.612.054.200\\r\\n\"Abdomen, Acute\",C23.888.821.030.249\\r\\nAbdominal Injuries,C26.017\\r\\nAbdominal Neoplasms,C04.588.033\\r\\nAbdominal Muscles,A02.633.567.050\\r\\nCremaster Muscle,A02.633.567.050\\r\\nPyramidalis Muscle,A02.633.567.050\\r\\nQuadratus Abdominis,A02.633.567.050\\r\\nTransversus Abdominis,A02.633.567.050\\r\\nAbducens Nerve,A08.800.800.120.030\\r\\nAbelson murine leukemia virus,B04.613.807.375.525.020\\r\\nAbelson murine leukemia virus,B04.820.650.375.525.020\\r\\nAbetalipoproteinemia,C16.320.565.398.500.440.500\\r\\nAbetalipoproteinemia,C18.452.584.500.875.440.500\\r\\nAbetalipoproteinemia,C18.452.648.398.500.440.500\\r\\nCongenital Abnormalities,C16.131\\r\\nFetal Malformations,C16.131\\r\\nFetal Anomalies,C16.131\\r\\n\"Abnormalities, Drug-Induced\",C16.131.042\\r\\n\"Abnormalities, Multiple\",C16.131.077\\r\\n\"Abnormalities, Radiation-Induced\",C16.131.080\\r\\n\"Abnormalities, Radiation-Induced\",C26.733.031\\r\\n\"Abnormalities, Radiation-Induced\",G01.750.748.500.031\\r\\n\"Abnormalities, Radiation-Induced\",N06.850.460.350.850.500.031\\r\\n\"Abnormalities, Radiation-Induced\",N06.850.810.300.360.031\\r\\nABO Blood-Group System,D23.050.301.290.031\\r\\nABO Blood-Group System,D23.050.705.230.031\\r\\nBlood Group H Type 1 Antigen,D23.050.301.290.031\\r\\nBlood Group H Type 1 Antigen,D23.050.705.230.031\\r\\nABO Factors,D23.050.301.290.031\\r\\nABO Factors,D23.050.705.230.031\\r\\nAbomasum,A13.869.106\\r\\nAbortifacient Agents,D27.505.696.875.131\\r\\nAbortifacient Agents,D27.505.954.705.131\\r\\nAbortifacient Effect,D27.505.696.875.131\\r\\nAbortifacient Effect,D27.505.954.705.131\\r\\n\"Abortifacient Agents, Nonsteroidal\",D27.505.696.875.131.100\\r\\n\"Abortifacient Agents, Nonsteroidal\",D27.505.954.705.131.100\\r\\n\"Abortifacient Agents, Steroidal\",D27.505.696.875.131.200\\r\\n\"Abortifacient Agents, Steroidal\",D27.505.954.705.131.200\\r\\n\"Abortion, Spontaneous\",C13.703.039\\r\\n\"Abortion, Spontaneous\",G08.686.784.769.496.125\\r\\nEarly Pregnancy Loss,C13.703.039\\r\\nEarly Pregnancy Loss,G08.686.784.769.496.125\\r\\nMiscarriage,C13.703.039\\r\\nMiscarriage,G08.686.784.769.496.125\\r\\n\"Abortion, Tubal\",C13.703.039\\r\\n\"Abortion, Tubal\",G08.686.784.769.496.125\\r\\nAbortion Applicants,M01.050\\r\\n\"Abortion Seekers, Repeated\",M01.050\\r\\n\"Abortion Seekers, Refused\",M01.050\\r\\n\"Abortion, Criminal\",I01.198.240.089\\r\\n\"Abortion, Eugenic\",E04.520.050.050\\r\\n\"Abortion, Selective\",E04.520.050.050\\r\\n\"Abortion, Habitual\",C13.703.039.089\\r\\n\"Abortion, Incomplete\",C13.703.039.093\\r\\n\"Abortion, Induced\",E04.520.050\\r\\nAbortion Rate,E04.520.050\\r\\nAbortion Techniques,E04.520.050\\r\\n\"Abortion, Drug-Induced\",E04.520.050\\r\\nPrevious Abortion,E04.520.050\\r\\n\"Abortion, Saline-Solution\",E04.520.050\\r\\n\"Abortion, Soap-Solution\",E04.520.050\\r\\nAnti-Abortion Groups,E04.520.050\\r\\nEmbryotomy,E04.520.050\\r\\n\"Fertility Control, Postconception\",E04.520.050\\r\\nAbortion Failure,E04.520.050\\r\\n\"Abortion, Rivanol\",E04.520.050\\r\\n\"Abortion, Legal\",E04.520.050.055\\r\\nAbortion on Demand,E04.520.050.055\\r\\n\"Abortion, Missed\",C13.703.039.173\\r\\n\"Abortion, Septic\",C01.674.173\\r\\n\"Abortion, Septic\",C13.703.039.256\\r\\n\"Abortion, Septic\",C13.703.700.173\\r\\n\"Abortion, Therapeutic\",E04.520.050.060\\r\\n\"Abortion, Threatened\",C13.703.090\\r\\n\"Abortion, Veterinary\",C13.703.039.422\\r\\n\"Abortion, Veterinary\",C22.021\\r\\nAbreaction,F04.754.720.107\\r\\nAbrin,D08.811.277.450.430.700.750.111\\r\\nAbrin,D12.776.503.499.249\\r\\nAbrin,D12.776.765.678.906.111\\r\\nAbrin C,D08.811.277.450.430.700.750.111\\r\\nAbrin C,D12.776.503.499.249\\r\\nAbrin C,D12.776.765.678.906.111\\r\\nAbrin A,D08.811.277.450.430.700.750.111\\r\\nAbrin A,D12.776.503.499.249\\r\\nAbrin A,D12.776.765.678.906.111\\r\\nAbruptio Placentae,C13.703.420.078\\r\\nAbruptio Placentae,C13.703.590.132\\r\\nAbscess,C01.830.025\\r\\nAbscess,C23.550.470.756.100\\r\\nPeritonsillar Abscess,C01.748.561.750.500\\r\\nPeritonsillar Abscess,C01.830.025.675\\r\\nPeritonsillar Abscess,C07.550.781.750.500\\r\\nPeritonsillar Abscess,C08.730.561.750.500\\r\\nPeritonsillar Abscess,C09.775.649.750.500\\r\\nAbscisic Acid,D02.241.223.268.034\\r\\nAbscisic Acid,D02.455.326.271.665.202.061\\r\\nAbscisic Acid,D02.455.426.392.368.367.379.249.024\\r\\nAbscisic Acid,D02.455.849.131.061\\r\\nAbscisic Acid,D02.455.849.765.521.500\\r\\n\"Abscisic Acid, (+,-)-Isomer\",D02.241.223.268.034\\r\\n\"Abscisic Acid, (+,-)-Isomer\",D02.455.326.271.665.202.061\\r\\n\"Abscisic Acid, (+,-)-Isomer\",D02.455.426.392.368.367.379.249.024\\r\\n\"Abscisic Acid, (+,-)-Isomer\",D02.455.849.131.061\\r\\n\"Abscisic Acid, (+,-)-Isomer\",D02.455.849.765.521.500\\r\\n\"Abscisic Acid, (Z,E)-Isomer\",D02.241.223.268.034\\r\\n\"Abscisic Acid, (Z,E)-Isomer\",D02.455.326.271.665.202.061\\r\\n\"Abscisic Acid, (Z,E)-Isomer\",D02.455.426.392.368.367.379.249.024\\r\\n\"Abscisic Acid, (Z,E)-Isomer\",D02.455.849.131.061\\r\\n\"Abscisic Acid, (Z,E)-Isomer\",D02.455.849.765.521.500\\r\\n\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.241.223.268.034\\r\\n\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.326.271.665.202.061\\r\\n\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.426.392.368.367.379.249.024\\r\\n\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.849.131.061\\r\\n\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.849.765.521.500\\r\\n\"Abscisic Acid, (R)-Isomer\",D02.241.223.268.034\\r\\n\"Abscisic Acid, (R)-Isomer\",D02.455.326.271.665.202.061\\r\\n\"Abscisic Acid, (R)-Isomer\",D02.455.426.392.368.367.379.249.024\\r\\n\"Abscisic Acid, (R)-Isomer\",D02.455.849.131.061\\r\\n\"Abscisic Acid, (R)-Isomer\",D02.455.849.765.521.500\\r\\n\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.241.223.268.034\\r\\n\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.326.271.665.202.061\\r\\n\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.426.392.368.367.379.249.024\\r\\n\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.849.131.061\\r\\n\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.849.765.521.500\\r\\n\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.241.223.268.034\\r\\n\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.326.271.665.202.061\\r\\n\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.426.392.368.367.379.249.024\\r\\n\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.849.131.061\\r\\n\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.849.765.521.500\\r\\nAbsenteeism,F02.784.692.107\\r\\nAbsorption,G01.015\\r\\nAbsorption,G02.010\\r\\nAbsorption,G03.015\\r\\nAbsorption,G03.787.024\\r\\nAbsorption,G07.690.725.015\\r\\nAbstracting and Indexing,L01.453.245.100\\r\\nIndexing,L01.453.245.100\\r\\nIndexes as Topic,L01.453.245.100\\r\\nAbstracting,L01.453.245.100\\r\\nDental Abutments,E06.780.346.500\\r\\nDental Abutments,E07.695.190.175\\r\\nAcacia,B01.650.940.800.575.912.250.401.025\\r\\nAcacia catechu,B01.650.940.800.575.912.250.401.025\\r\\nAcademic Medical Centers,N02.278.020\\r\\nAcademies and Institutes,N03.540.052\\r\\nInstitutes,N03.540.052\\r\\nResearch Institutes,N03.540.052\\r\\nAcademies,N03.540.052\\r\\nAcanthamoeba,B01.046.500.100.075.080\\r\\nAcanthocephala,B01.050.500.500.132\\r\\nAcanthocytes,A11.118.290.330.100\\r\\nAcanthocytes,A11.443.240.330.100\\r\\nAcanthocytes,A15.145.229.334.330.100\\r\\nAcantholysis,C17.800.865.070\\r\\nAcantholysis,C23.550.035\\r\\nAcanthosis Nigricans,C17.800.621.430.530.100\\r\\nAcari,B01.050.500.131.166.132\\r\\nAcceleration,G01.482.107\\r\\nAccessory Nerve,A08.800.800.120.060\\r\\nAccident Prevention,N06.850.135.060\\r\\nAccident Proneness,F01.145.015\\r\\nAccidental Falls,N06.850.135.122\\r\\nSlip and Fall,N06.850.135.122\\r\\nAccidents,N06.850.135\\r\\n\"Accidents, Aviation\",N06.850.135.185\\r\\n\"Accidents, Home\",N06.850.135.217\\r\\n\"Accidents, Occupational\",N06.850.135.240\\r\\n\"Accidents, Industrial\",N06.850.135.240\\r\\n\"Accidents, Traffic\",N06.850.135.392\\r\\nTraffic Collisions,N06.850.135.392\\r\\nTraffic Crashes,N06.850.135.392\\r\\nAcclimatization,G07.025.133\\r\\nAcclimatization,G16.012.500.133\\r\\n\"Accommodation, Ocular\",G14.010\\r\\n\"Accommodation, Lens\",G14.010\\r\\nAccounting,N03.219.463.030\\r\\nOil and Gas Industry,J01.576.655.875.750\\r\\nPetroleum Industry,J01.576.655.875.750\\r\\nOil Refinery,J01.576.655.875.750\\r\\nNatural Gas Industry,J01.576.655.875.750\\r\\nCoal Industry,J01.576.655.875.200\\r\\nDriving Under the Influence,F01.145.250.250\\r\\nDriving Under the Influence,F01.145.263.500\\r\\nDriving Under the Influence,I01.880.735.223.250\\r\\nDriving Under the Influence,I03.125.649\\r\\nDrinking and Driving,F01.145.250.250\\r\\nDrinking and Driving,F01.145.263.500\\r\\nDrinking and Driving,I01.880.735.223.250\\r\\nDrinking and Driving,I03.125.649\\r\\nHuman Embryonic Stem Cells,A11.872.700.250.750\\r\\nMouse Embryonic Stem Cells,A11.872.700.250.875\\r\\nEmbryonic Germ Cells,A11.497.124\\r\\nEmbryonic Germ Cells,A11.872.700.250.625\\r\\nWork Performance,I03.946.675\\r\\nJob Performance,I03.946.675\\r\\nCriminal Behavior,F01.145.250\\r\\nClinical Decision-Making,E01.055\\r\\nCognitive Aging,G07.345.124.260\\r\\nCognitive Neuroscience,F04.096.628.255.500\\r\\nCognitive Neuroscience,H01.158.610.030\\r\\nSocial Neuroscience,F04.096.628.255.500\\r\\nSocial Neuroscience,H01.158.610.030\\r\\nEmotional Adjustment,F01.058.144\\r\\nEmotional Adjustment,F01.752.543.500.250\\r\\nFacial Recognition,F02.463.593.524.250.500\\r\\nFacial Recognition,F02.463.593.524.500.500\\r\\nFacial Recognition,F02.463.593.932.622.500\\r\\nFacial Emotion Recognition,F02.463.593.524.250.500\\r\\nFacial Emotion Recognition,F02.463.593.524.500.500\\r\\nFacial Emotion Recognition,F02.463.593.932.622.500\\r\\nGrandparents,F01.829.263.403\\r\\nGrandparents,I01.880.853.150.452\\r\\nGrandparents,M01.264\\r\\nGrandmother,F01.829.263.403\\r\\nGrandmother,I01.880.853.150.452\\r\\nGrandmother,M01.264\\r\\nGrandfather,F01.829.263.403\\r\\nGrandfather,I01.880.853.150.452\\r\\nGrandfather,M01.264\\r\\nHelp-Seeking Behavior,F01.145.813.217\\r\\nHeuristics,F02.463.425.725.500\\r\\nHeuristics,F02.463.785.810.500\\r\\nIntimate Partner Violence,I01.198.240.856.575\\r\\nIntimate Partner Violence,I01.880.735.900.688\\r\\nDating Violence,I01.198.240.856.575\\r\\nDating Violence,I01.880.735.900.688\\r\\nNeurological Rehabilitation,E02.760.169.063.500.477\\r\\nNeurological Rehabilitation,E02.831.477\\r\\nNeurological Rehabilitation,H02.403.680.600.750\\r\\nNeurological Rehabilitation,N02.421.784.511\\r\\nPhysical Abuse,I01.198.240.856.688\\r\\nPhysical Abuse,I01.880.735.900.744\\r\\nProblem Behavior,F01.145.126.972\\r\\nProblem Behavior,F01.145.179.750\\r\\n\"Dysfunctional Behavior, Psychology\",F01.145.126.972\\r\\n\"Dysfunctional Behavior, Psychology\",F01.145.179.750\\r\\nDisruptive Behavior,F01.145.126.972\\r\\nDisruptive Behavior,F01.145.179.750\\r\\nUnderage Drinking,F01.145.022.750\\r\\nUnderage Drinking,F01.145.317.269.875\\r\\nUnderage Drinking,I01.880.735.878\\r\\nLegal Drinking Age,F01.145.022.750\\r\\nLegal Drinking Age,F01.145.317.269.875\\r\\nLegal Drinking Age,I01.880.735.878\\r\\nEctopic Gene Expression,G05.308.202\\r\\nCell Plasticity,G04.356.250\\r\\nCell Self Renewal,G04.144.220.235\\r\\nCell Self Renewal,G04.161.750.500.375\\r\\nCell Self Renewal,G05.113.415\\r\\nCell Self Renewal,G07.345.249.410.750.500.625\\r\\nStem Cell Self-Renewal,G04.144.220.235\\r\\nStem Cell Self-Renewal,G04.161.750.500.375\\r\\nStem Cell Self-Renewal,G05.113.415\\r\\nStem Cell Self-Renewal,G07.345.249.410.750.500.625\\r\\nRehabilitation Research,H01.770.644.145.472\\r\\nOrthodontists,M01.526.485.330.655\\r\\nOrthodontists,N02.360.330.655\\r\\nDentofacial Orthopedists,M01.526.485.330.655\\r\\nDentofacial Orthopedists,N02.360.330.655\\r\\nOral and Maxillofacial Surgeons,M01.526.485.330.483\\r\\nOral and Maxillofacial Surgeons,N02.360.330.483\\r\\nExodontists,M01.526.485.330.483\\r\\nExodontists,N02.360.330.483\\r\\nNeuroprotection,G11.561.645\\r\\n\"Diet, Food, and Nutrition\",G07.203\\r\\nTriticale,B01.650.940.800.575.912.250.822.906\\r\\nCritical Care Outcomes,N04.761.559.590.399.250\\r\\nCritical Care Outcomes,N05.715.360.575.575.399.250\\r\\nSimulation Training,I02.903.847\\r\\nInteractive Learning,I02.903.847\\r\\nMillets,B01.650.940.800.575.912.250.822.587\\r\\nBiobehavioral Sciences,H01.770.644.108.687\\r\\nProtein Corona,D12.776.642\\r\\nVegetarians,M01.928\\r\\nLacto-Ovo Vegetarians,M01.928\\r\\nVegans,M01.928.500\\r\\nAccounts Payable and Receivable,N03.219.463.030.080\\r\\nAccounts Payable,N03.219.463.030.080\\r\\nYouth Sports,I03.450.642.845.987\\r\\nOrganized Youth Sports,I03.450.642.845.987\\r\\nLiteracy,F01.145.209.429\\r\\nLiteracy,N01.824.196.500\\r\\nIlliteracy,F01.145.209.429\\r\\nIlliteracy,N01.824.196.500\\r\\nSevere Acute Malnutrition,C18.654.521.719\\r\\n\"Banking, Personal\",N03.219.463.030.100\\r\\nSavings Accounts,N03.219.463.030.100\\r\\nChecking Accounts,N03.219.463.030.100\\r\\nEvidence-Based Facility Design,N02.278.200.252\\r\\n\"Physical Appearance, Body\",E01.370.600.115.450\\r\\n\"Physical Appearance, Body\",G07.100.175\\r\\nFruit and Vegetable Juices,G07.203.100.606\\r\\nFruit and Vegetable Juices,J02.200.606\\r\\nVegetable Juices,G07.203.100.606\\r\\nVegetable Juices,J02.200.606\\r\\nFruit Juices,G07.203.100.606\\r\\nFruit Juices,J02.200.606\\r\\nGhee,D10.212.302.199.500\\r\\nGhee,G07.203.300.350.100.500\\r\\nGhee,G07.203.300.375.200.500\\r\\nGhee,J02.500.350.100.500\\r\\nGhee,J02.500.375.200.500\\r\\nHydraulic Fracking,J01.576.655.875.750.500\\r\\nPsychological Trauma,F03.950.750.375\\r\\nPeer Influence,F01.829.316.483.750\\r\\nPeer Pressure,F01.829.316.483.750\\r\\nVegetable Products,G07.203.300.850.450\\r\\nVegetable Products,J02.500.850.800\\r\\nDirect-to-Consumer Advertising,J01.219.687.274.500\\r\\nDirect-To-Consumer Screening and Testing,E01.370.398\\r\\nDirect-To-Consumer Screening and Testing,N02.421.726.233.166\\r\\nExtracellular Vesicles,A11.284.295.588\\r\\nExovesicles,A11.284.295.588\\r\\nApoptotic Bodies,A11.284.295.588\\r\\nFungal Viruses,B04.352\\r\\nTelocytes,A11.329.830.750\\r\\nExoskeleton Device,E07.341\\r\\nRobotic Exoskeleton,E07.341\\r\\nShellfish Hypersensitivity,C20.543.480.370.763\\r\\n\"Failure to Rescue, Health Care\",E01.789.800.760.500\\r\\n\"Failure to Rescue, Health Care\",H01.770.644.145.431.500\\r\\n\"Failure to Rescue, Health Care\",N04.761.559.590.800.760.500\\r\\n\"Failure to Rescue, Health Care\",N05.715.360.575.575.800.760.500\\r\\nPsychiatric Rehabilitation,H02.403.680.600.875\\r\\nPsychiatric Rehabilitation,N02.421.784.578\\r\\nPsychosocial Care,H02.403.680.600.875\\r\\nPsychosocial Care,N02.421.784.578\\r\\nSymptom Flare Up,C23.550.291.937.500\\r\\nSymptom Exacerbation,C23.550.291.937.500\\r\\nIsolated Heart Preparation,E05.519\\r\\nIsolated Heart Preparation,E05.598.750\\r\\nLangendorff Perfused Heart,E05.519\\r\\nLangendorff Perfused Heart,E05.598.750\\r\\nWorking Heart Preparation Technique,E05.519\\r\\nWorking Heart Preparation Technique,E05.598.750\\r\\nWorking Heart Preparation,E05.519\\r\\nWorking Heart Preparation,E05.598.750\\r\\nIsolated Heart Preparation Technique,E05.519\\r\\nIsolated Heart Preparation Technique,E05.598.750\\r\\n\"Diet, Vegan\",E02.642.249.300.750\\r\\n\"Diet, Vegan\",G07.203.650.240.300.750\\r\\nVeganism,E02.642.249.300.750\\r\\nVeganism,G07.203.650.240.300.750\\r\\nBehavior Observation Techniques,E05.796.112\\r\\nBehavior Observation Techniques,F04.669.112\\r\\nBehavior Rating Scale,F04.711.271\\r\\nBehavior Test,F04.711.271\\r\\nAlcohol Drinking in College,F01.145.317.269.625\\r\\n\"Obesity, Metabolically Benign\",C18.654.726.500.650\\r\\n\"Obesity, Metabolically Benign\",C23.888.144.699.500.250\\r\\n\"Obesity, Metabolically Benign\",E01.370.600.115.100.160.120.699.500.375\\r\\n\"Obesity, Metabolically Benign\",G07.100.100.160.120.699.500.375\\r\\nWhole Grains,G07.203.300.300.550.500\\r\\nWhole Grains,G07.203.300.775.500.500\\r\\nWhole Grains,J02.500.300.550.500\\r\\nWhole Grains,J02.500.775.500.500\\r\\nWhole Grain Cereals,G07.203.300.300.550.500\\r\\nWhole Grain Cereals,G07.203.300.775.500.500\\r\\nWhole Grain Cereals,J02.500.300.550.500\\r\\nWhole Grain Cereals,J02.500.775.500.500\\r\\nTransanal Endoscopic Surgery,E01.370.388.250.630.500\\r\\nTransanal Endoscopic Surgery,E04.210.240.250.680.500\\r\\nTransanal Endoscopic Surgery,E04.502.250.250.250.680.500\\r\\nTransanal Endoscopic Surgery,E04.502.250.630.500\\r\\nTransanal Minimally Invasive Surgery,E01.370.388.250.630.500\\r\\nTransanal Minimally Invasive Surgery,E04.210.240.250.680.500\\r\\nTransanal Minimally Invasive Surgery,E04.502.250.250.250.680.500\\r\\nTransanal Minimally Invasive Surgery,E04.502.250.630.500\\r\\nTransanal Endoscopic Microsurgery,E01.370.388.250.630.500.500\\r\\nTransanal Endoscopic Microsurgery,E04.210.240.250.680.500.500\\r\\nTransanal Endoscopic Microsurgery,E04.494.787\\r\\nTransanal Endoscopic Microsurgery,E04.502.250.250.250.680.500.500\\r\\nTransanal Endoscopic Microsurgery,E04.502.250.630.500.500\\r\\nCold Injury,C26.212\\r\\nPersonal Protective Equipment,E07.700.560\\r\\nPersonal Protective Equipment,J01.637.708.560\\r\\nNerve Agents,D27.720.599\\r\\nNerve Agents,D27.720.777.300.500\\r\\nNerve Gas,D27.720.599\\r\\nNerve Gas,D27.720.777.300.500\\r\\nWar-Related Injuries,C26.946\\r\\nWar-Related Injuries,I01.880.735.950.500.951.500\\r\\nWar-Related Injuries,N06.850.460.350.600.903.500\\r\\nWar-Related Trauma,C26.946\\r\\nWar-Related Trauma,I01.880.735.950.500.951.500\\r\\nWar-Related Trauma,N06.850.460.350.600.903.500\\r\\nAbnormal Involuntary Movement Scale,E01.370.600.550.162\\r\\nBlood Alcohol Content,D02.033.375.135\\r\\nSocial Communication Disorder,F03.625.374.250\\r\\nLegal Services,I01.880.604.583.482\\r\\nDefamation,I01.198.240.240\\r\\nDefamation,I01.880.735.191.051\\r\\nSlander,I01.198.240.240\\r\\nSlander,I01.880.735.191.051\\r\\nLibel,I01.198.240.240\\r\\nLibel,I01.880.735.191.051\\r\\nAnger Management Therapy,F04.754.137.087\\r\\n\"Psychology, Sports\",F04.096.628.914\\r\\nWar Exposure,I01.880.735.950.500.951\\r\\nWar Exposure,N06.850.460.350.600.903\\r\\nChildhood-Onset Fluency Disorder,F03.625.374.125\\r\\nNo-Show Patients,F01.100.150.750.500.600.750\\r\\nNo-Show Patients,F01.145.488.887.500.600.750\\r\\nNo-Show Patients,M01.643.550\\r\\nNo-Show Patients,N04.452.758.635.500\\r\\nNo-Show Patients,N05.300.150.800.500.600.750\\r\\nCellular Reprogramming Techniques,E05.200.500.380\\r\\nCellular Reprogramming Techniques,E05.242.378\\r\\nCellular Reprogramming Techniques,E05.393.085\\r\\nDirected Differentiation Techniques,E05.200.500.380\\r\\nDirected Differentiation Techniques,E05.242.378\\r\\nDirected Differentiation Techniques,E05.393.085\\r\\nDirect Cell Reprogramming Techniques,E05.200.500.380\\r\\nDirect Cell Reprogramming Techniques,E05.242.378\\r\\nDirect Cell Reprogramming Techniques,E05.393.085\\r\\nMetacognition,F02.463.188.756\\r\\nMetacognitive Awareness,F02.463.188.756\\r\\nMetacognitive Monitoring,F02.463.188.756\\r\\nMetacognitive Control,F02.463.188.756\\r\\nMetaemotion,F02.463.188.756\\r\\nMetamemory,F02.463.188.756\\r\\nPrescription Drug Overuse,E02.319.306.500.750\\r\\n\"Near Miss, Healthcare\",E02.319.529.750\\r\\n\"Near Miss, Healthcare\",N02.421.450.500.750\\r\\n\"Near Miss, Healthcare\",N02.421.450.550\\r\\n\"Near Miss, Healthcare\",N04.761.700.594\\r\\n\"Near Miss, Healthcare\",N05.700.513\\r\\nRNAi Therapeutics,E02.095.301.250\\r\\nDynamic Light Scattering,E05.196.822.325\\r\\nQuasi-Elastic Light Scattering (QELS),E05.196.822.325\\r\\n\"Time Out, Healthcare\",N04.761.700.635\\r\\n\"Time Out, Healthcare\",N05.700.739\\r\\nSurgical Time Out,N04.761.700.635\\r\\nSurgical Time Out,N05.700.739\\r\\nHealthcare Failure Mode and Effect Analysis,E05.318.740.600.800.715.500\\r\\nHealthcare Failure Mode and Effect Analysis,N04.452.871.715.400\\r\\nHealthcare Failure Mode and Effect Analysis,N05.715.360.750.625.700.690.400\\r\\nHealthcare Failure Mode and Effect Analysis,N06.850.505.715.500\\r\\nHealthcare Failure Mode and Effect Analysis,N06.850.520.830.600.800.715.500\\r\\nFailure Mode and Effect Analysis,E05.318.740.600.800.715.500\\r\\nFailure Mode and Effect Analysis,N04.452.871.715.400\\r\\nFailure Mode and Effect Analysis,N05.715.360.750.625.700.690.400\\r\\nFailure Mode and Effect Analysis,N06.850.505.715.500\\r\\nFailure Mode and Effect Analysis,N06.850.520.830.600.800.715.500\\r\\nSpirit Possession,K01.844.619.500\\r\\n\"Crew Resource Management, Healthcare\",N04.590.254\\r\\nComputer Heuristics,L01.224.050.375.095\\r\\nAtaxins,D12.776.631.069\\r\\nAtaxins,D12.776.660.075\\r\\nAlarmins,D23.035\\r\\nDermal Fillers,D27.720.102.461\\r\\nAction Spectrum,E05.196.867.826.150\\r\\nDiplomacy,F01.829.316.171\\r\\nDiplomacy,F02.463.785.373.520.500\\r\\nDiplomacy,I01.738.305\\r\\nMutation Accumulation,G05.365.590.594\\r\\nSpontaneous Mutation Accumulation,G05.365.590.594\\r\\nInternal Ribosome Entry Sites,D13.444.735.790.878.942.250\\r\\nInternal Ribosome Entry Sites,G02.111.570.080.689.687.093\\r\\nInternal Ribosome Entry Sites,G05.360.080.689.687.093\\r\\nBiological Mimicry,G16.012.750\\r\\nBiological Camouflage,G16.012.750\\r\\nSpecific Learning Disorder,F03.625.562.700\\r\\nPotentially Inappropriate Medication List,N04.761.700.615\\r\\nPotentially Inappropriate Medication List,N05.700.594\\r\\nBeers Criteria,N04.761.700.615\\r\\nBeers Criteria,N05.700.594\\r\\nSTOPP (Screening Tool of Older Persons Potentially Inappropriate Prescriptions),N04.761.700.615\\r\\nSTOPP (Screening Tool of Older Persons Potentially Inappropriate Prescriptions),N05.700.594\\r\\nMedication Appropriateness Index,N04.761.700.615\\r\\nMedication Appropriateness Index,N05.700.594\\r\\nLate Onset Disorders,C23.550.291.883\\r\\nPhakopsora pachyrhizi,B01.300.179.113\\r\\nFarmers,M01.526.390\\r\\nRanchers,M01.526.390\\r\\nCulturally Appropriate Technology,J01.897.052\\r\\nIntermediate Technology,J01.897.052\\r\\nSoft Technology,J01.897.052\\r\\nSocial Learning,F02.784.629.529.663\\r\\nFinancial Statements,N03.219.463.030.140\\r\\n\"Assets, Financial\",N03.219.463.030.140\\r\\nCash Flow Statement,N03.219.463.030.140\\r\\nBalance Sheet,N03.219.463.030.140\\r\\nExpense Statement,N03.219.463.030.140\\r\\nIncome Statement,N03.219.463.030.140\\r\\n\"Equity, Financial\",N03.219.463.030.140\\r\\n\"Liabilities, Financial\",N03.219.463.030.140\\r\\nMiners,M01.526.693\\r\\nChronopharmacokinetics,G07.690.725.249\\r\\n\"Administrative Claims, Healthcare\",N04.452.859.564.137\\r\\nChild Health,N01.400.225\\r\\nChild Well Being,N01.400.225\\r\\nInterleukin-33,D12.644.276.374.465.850\\r\\nInterleukin-33,D12.776.467.374.465.850\\r\\nInterleukin-33,D23.529.374.465.850\\r\\nS100A12 Protein,D12.776.157.125.750.875\\r\\nTelopodes,A11.284.180.900\\r\\nTelopodes,A11.329.830.750.500\\r\\nPodomers,A11.284.180.900\\r\\nPodomers,A11.329.830.750.500\\r\\nPodoms,A11.284.180.900\\r\\nPodoms,A11.329.830.750.500\\r\\nDrosophila simulans,B01.050.500.131.617.720.500.500.750.310.250.750\\r\\nOptimism,F01.100.787\\r\\nPositive Attitude,F01.100.787\\r\\nPositive Thinking,F01.100.787\\r\\nPessimism,F01.100.893\\r\\nAtaxin-1,D12.776.631.069.500\\r\\nAtaxin-1,D12.776.660.075.500\\r\\nAdolescent Health,N01.400.075\\r\\nAdolescent Well Being,N01.400.075\\r\\nAtaxin-2,D12.776.157.725.452.125\\r\\nAtaxin-2,D12.776.631.069.750\\r\\nAtaxin-2,D12.776.660.075.750\\r\\nAtaxin-2,D12.776.664.962.452.125\\r\\nAtaxin-3,D08.811.037.250\\r\\nAtaxin-3,D12.776.631.069.875\\r\\nAtaxin-3,D12.776.660.075.875\\r\\nPoint-of-Care Testing,N04.590.874.500\\r\\nBedside Testing,N04.590.874.500\\r\\nAtaxin-7,D12.776.631.069.901\\r\\nAtaxin-7,D12.776.660.075.900\\r\\nAtaxin-10,D12.776.631.069.950\\r\\nGlucagon-Like Peptide Receptors,D12.776.543.750.695.021\\r\\nGlucagon-Like Peptide Receptors,D12.776.543.750.750.360.100\\r\\nGlucagon-Like Peptide-1 Receptor,D12.776.543.750.695.021.500\\r\\nGlucagon-Like Peptide-1 Receptor,D12.776.543.750.750.360.100.500\\r\\nGlucagon-Like Peptide-2 Receptor,D12.776.543.750.695.021.600\\r\\nGlucagon-Like Peptide-2 Receptor,D12.776.543.750.750.360.100.600\\r\\nReceptor for Advanced Glycation End Products,D12.776.543.750.615\\r\\nRNA Recognition Motif Proteins,D12.776.157.725.813\\r\\nRNA Recognition Motif Proteins,D12.776.664.962.813\\r\\nELAV-Like Protein 2,D12.776.157.725.813.500.500\\r\\nELAV-Like Protein 2,D12.776.631.520.500\\r\\nELAV-Like Protein 2,D12.776.664.962.813.500.500\\r\\nELAV-Like Protein 3,D12.776.157.725.813.500.750\\r\\nELAV-Like Protein 3,D12.776.631.520.750\\r\\nELAV-Like Protein 3,D12.776.664.962.813.500.750\\r\\nELAV-Like Protein 4,D12.776.157.725.813.500.875\\r\\nELAV-Like Protein 4,D12.776.631.520.875\\r\\nELAV-Like Protein 4,D12.776.664.962.813.500.875\\r\\nELAV-Like Protein 1,D12.776.157.725.813.500.250\\r\\nELAV-Like Protein 1,D12.776.664.962.813.500.250\\r\\nWhey,A12.790.760\\r\\nWhey,G07.203.100.700.750\\r\\nWhey,G07.203.300.350.525.760\\r\\nWhey,J02.200.700.750\\r\\nWhey,J02.500.350.525.760\\r\\nWhey Proteins,A12.790.520.500\\r\\nWhey Proteins,A12.790.760.500\\r\\nWhey Proteins,D12.776.256.159.750.816\\r\\nWhey Proteins,G07.203.300.350.525.760.500\\r\\nWhey Proteins,G07.203.300.428.159.812.500\\r\\nWhey Proteins,J02.500.350.525.520.500\\r\\nWhey Proteins,J02.500.350.525.760.500\\r\\nWhey Proteins,J02.500.428.159.750.500\\r\\nHoarding Disorder,F03.080.600.250\\r\\nObsessive Hoarding,F03.080.600.250\\r\\nPoly(ADP-ribose) Polymerase Inhibitors,D27.505.519.389.739\\r\\nPoly(ADP-ribose) Polymerase Inhibitors,D27.505.954.248.692\\r\\nAutism Spectrum Disorder,F03.625.164.113\\r\\nCELF Proteins,D12.776.157.725.813.250\\r\\nCELF Proteins,D12.776.664.962.813.250\\r\\nCELF1 Protein,D12.776.157.725.813.250.500\\r\\nCELF1 Protein,D12.776.664.962.813.250.500\\r\\nIndustrial Development,I01.261.262.500\\r\\nIndustrial Development,J01.576.519\\r\\nTechnology Development,I01.261.262.500\\r\\nTechnology Development,J01.576.519\\r\\nIndustrialization,I01.261.262.500\\r\\nIndustrialization,J01.576.519\\r\\nCloud Computing,L01.224.097\\r\\nNatural Resources,G16.500.275.553\\r\\nNatural Resources,J01.728\\r\\nNatural Resources,N06.230.350\\r\\nLand Supply,G16.500.275.553\\r\\nLand Supply,J01.728\\r\\nLand Supply,N06.230.350\\r\\nGlycemic Load,G07.203.650.660.750\\r\\nGlycemic Load,J01.576.423.850.730.750.750\\r\\nGlycemic Load,N06.850.601.750.750\\r\\nAdenylyl Cyclase Inhibitors,D27.505.519.389.108\\r\\nRAW 264.7 Cells,A11.251.210.172.875\\r\\nRAW 264.7 Cells,A11.733.397.815\\r\\nAccreditation,N03.706.110.070\\r\\nAccreditation,N05.700.200.100\\r\\nClostridiales,B03.353.625\\r\\nGraphic Novel,V02.700.415\\r\\nComic Book,V02.700.415\\r\\nSouth Sudan,Z01.058.290.120.745\\r\\nMotor Disorders,F03.608\\r\\nMaternal Health,N01.400.900.500\\r\\nSeed Bank,N02.278.065.650\\r\\nGermplasm Bank,N02.278.065.650\\r\\nTrauma and Stressor Related Disorders,F03.950\\r\\nMaternal-Child Health Services,N02.421.143.130.660\\r\\nMaternal-Child Health Services,N02.421.143.620.275\\r\\nSerine-Arginine Splicing Factors,D12.776.157.725.829.500\\r\\nSerine-Arginine Splicing Factors,D12.776.664.962.829.500\\r\\nInfant Health,N01.400.388\\r\\nNewborn Health,N01.400.388\\r\\nBipolar and Related Disorders,F03.084\\r\\nGender Dysphoria,F03.835.550\\r\\nFormative Feedback,F02.784.629.529.223\\r\\nAripiprazole,D03.383.606.170\\r\\nAripiprazole,D03.633.100.810.835.122\\r\\nAbilify,D03.383.606.170\\r\\nAbilify,D03.633.100.810.835.122\\r\\nOPC 14597,D03.383.606.170\\r\\nOPC 14597,D03.633.100.810.835.122\\r\\nPrunus dulcis,B01.650.940.800.575.912.250.859.937.500.625.500\\r\\nAlmonds,B01.650.940.800.575.912.250.859.937.500.625.500\\r\\nAlbumin-Bound Paclitaxel,D02.455.426.392.368.242.888.777.500\\r\\nAlbumin-Bound Paclitaxel,D02.455.849.291.850.777.500\\r\\nAlbumin-Bound Paclitaxel,D12.776.034.073\\r\\nAbraxane,D02.455.426.392.368.242.888.777.500\\r\\nAbraxane,D02.455.849.291.850.777.500\\r\\nAbraxane,D12.776.034.073\\r\\nABI007,D02.455.426.392.368.242.888.777.500\\r\\nABI007,D02.455.849.291.850.777.500\\r\\nABI007,D12.776.034.073\\r\\nChild Protective Services,I01.409.418.500\\r\\nChild Protective Services,N03.540.400.500\\r\\nSocial Workers,M01.526.919\\r\\nPrunus africana,B01.650.940.800.575.912.250.859.937.500.625.250\\r\\nPrunus armeniaca,B01.650.940.800.575.912.250.859.937.500.625.375\\r\\nApricot,B01.650.940.800.575.912.250.859.937.500.625.375\\r\\nPrunus avium,B01.650.940.800.575.912.250.859.937.500.625.400\\r\\nPrunus serotina,B01.650.940.800.575.912.250.859.937.500.625.400\\r\\nSweet Cherries,B01.650.940.800.575.912.250.859.937.500.625.400\\r\\nPrunus cerasus,B01.650.940.800.575.912.250.859.937.500.625.400\\r\\nRefugium,G16.500.275.683\\r\\nRefugium,G16.500.819\\r\\nDistance Counseling,F02.784.176.350\\r\\nDistance Counseling,F04.408.413.437\\r\\nDistance Counseling,N02.421.143.303.175\\r\\nDistance Counseling,N02.421.461.363.437\\r\\nDistance Counseling,N04.452.758.849.550.500\\r\\nLubiprostone,D10.251.355.325.050.500\\r\\nRU 0211,D10.251.355.325.050.500\\r\\nAmitiza,D10.251.355.325.050.500\\r\\nSPI 0211,D10.251.355.325.050.500\\r\\nPrunus persica,B01.650.940.800.575.912.250.859.937.500.625.750\\r\\nPeach,B01.650.940.800.575.912.250.859.937.500.625.750\\r\\nData Anonymization,H01.770.644.205\\r\\nData Anonymization,L01.224.134.500\\r\\nData Anonymization,N03.706.437.650.124.160\\r\\nData Anonymization,N04.452.910.200.500\\r\\nDe-Identification,H01.770.644.205\\r\\nDe-Identification,L01.224.134.500\\r\\nDe-Identification,N03.706.437.650.124.160\\r\\nDe-Identification,N04.452.910.200.500\\r\\nData Masking,H01.770.644.205\\r\\nData Masking,L01.224.134.500\\r\\nData Masking,N03.706.437.650.124.160\\r\\nData Masking,N04.452.910.200.500\\r\\nPersonally Identifiable Information,I01.880.604.583.080.660\\r\\nPrunus domestica,B01.650.940.800.575.912.250.859.937.500.625.450\\r\\nPlum,B01.650.940.800.575.912.250.859.937.500.625.450\\r\\nPrunus cerasifera,B01.650.940.800.575.912.250.859.937.500.625.450\\r\\nPrunus salicina,B01.650.940.800.575.912.250.859.937.500.625.450\\r\\nDarbepoetin alfa,D12.776.395.240.150.500\\r\\nAranesp,D12.776.395.240.150.500\\r\\nKRN 321,D12.776.395.240.150.500\\r\\n\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D02.705.429.906.125\\r\\n\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D03.383.533.375\\r\\n\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D03.383.742.680.245.500.600.125\\r\\n\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D03.633.100.759.138.881.125\\r\\n\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D26.310.375\\r\\nAtripla,D02.705.429.906.125\\r\\nAtripla,D03.383.533.375\\r\\nAtripla,D03.383.742.680.245.500.600.125\\r\\nAtripla,D03.633.100.759.138.881.125\\r\\nAtripla,D26.310.375\\r\\nBevacizumab,D12.776.124.486.485.114.224.060.375\\r\\nBevacizumab,D12.776.124.790.651.114.224.060.438\\r\\nBevacizumab,D12.776.377.715.548.114.224.200.438\\r\\nMvasi,D12.776.124.486.485.114.224.060.375\\r\\nMvasi,D12.776.124.790.651.114.224.060.438\\r\\nMvasi,D12.776.377.715.548.114.224.200.438\\r\\nBevacizumab-awwb,D12.776.124.486.485.114.224.060.375\\r\\nBevacizumab-awwb,D12.776.124.790.651.114.224.060.438\\r\\nBevacizumab-awwb,D12.776.377.715.548.114.224.200.438\\r\\nAvastin,D12.776.124.486.485.114.224.060.375\\r\\nAvastin,D12.776.124.790.651.114.224.060.438\\r\\nAvastin,D12.776.377.715.548.114.224.200.438\\r\\nGiraffes,B01.050.150.900.649.313.500.380.443\\r\\nOkapis,B01.050.150.900.649.313.500.380.443\\r\\nRisedronic Acid,D02.705.429.500.872\\r\\nRisedronic Acid,D03.383.725.836\\r\\n1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate,D02.705.429.500.872\\r\\n1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate,D03.383.725.836\\r\\nAtelvia,D02.705.429.500.872\\r\\nAtelvia,D03.383.725.836\\r\\nRisedronate Sodium,D02.705.429.500.872\\r\\nRisedronate Sodium,D03.383.725.836\\r\\n2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonate,D02.705.429.500.872\\r\\n2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonate,D03.383.725.836\\r\\n\"Risedronic Acid, Monosodium Salt\",D02.705.429.500.872\\r\\n\"Risedronic Acid, Monosodium Salt\",D03.383.725.836\\r\\nActonel,D02.705.429.500.872\\r\\nActonel,D03.383.725.836\\r\\nRisedronate,D02.705.429.500.872\\r\\nRisedronate,D03.383.725.836\\r\\nBisphosphonate Risedronate Sodium,D02.705.429.500.872\\r\\nBisphosphonate Risedronate Sodium,D03.383.725.836\\r\\nFluticasone-Salmeterol Drug Combination,D02.033.100.291.057.750.500\\r\\nFluticasone-Salmeterol Drug Combination,D02.092.063.291.057.750.500\\r\\nFluticasone-Salmeterol Drug Combination,D02.092.471.683.061.750.500\\r\\nFluticasone-Salmeterol Drug Combination,D04.210.500.054.079.129.114.500\\r\\nFluticasone-Salmeterol Drug Combination,D26.310.438\\r\\n\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D02.033.100.291.057.750.500\\r\\n\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D02.092.063.291.057.750.500\\r\\n\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D02.092.471.683.061.750.500\\r\\n\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D04.210.500.054.079.129.114.500\\r\\n\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D26.310.438\\r\\nAdvair Diskus,D02.033.100.291.057.750.500\\r\\nAdvair Diskus,D02.092.063.291.057.750.500\\r\\nAdvair Diskus,D02.092.471.683.061.750.500\\r\\nAdvair Diskus,D04.210.500.054.079.129.114.500\\r\\nAdvair Diskus,D26.310.438\\r\\nSeretide,D02.033.100.291.057.750.500\\r\\nSeretide,D02.092.063.291.057.750.500\\r\\nSeretide,D02.092.471.683.061.750.500\\r\\nSeretide,D04.210.500.054.079.129.114.500\\r\\nSeretide,D26.310.438\\r\\nAdvair HFA,D02.033.100.291.057.750.500\\r\\nAdvair HFA,D02.092.063.291.057.750.500\\r\\nAdvair HFA,D02.092.471.683.061.750.500\\r\\nAdvair HFA,D04.210.500.054.079.129.114.500\\r\\nAdvair HFA,D26.310.438\\r\\nAdvair,D02.033.100.291.057.750.500\\r\\nAdvair,D02.092.063.291.057.750.500\\r\\nAdvair,D02.092.471.683.061.750.500\\r\\nAdvair,D04.210.500.054.079.129.114.500\\r\\nAdvair,D26.310.438\\r\\nFluticasone,D04.210.500.054.079.129.114\\r\\nFlonase,D04.210.500.054.079.129.114\\r\\nFlovent HFA,D04.210.500.054.079.129.114\\r\\nCutivate,D04.210.500.054.079.129.114\\r\\nFluticasone Propionate,D04.210.500.054.079.129.114\\r\\nFlixonase,D04.210.500.054.079.129.114\\r\\nFlixotide,D04.210.500.054.079.129.114\\r\\nFlovent,D04.210.500.054.079.129.114\\r\\nSalmeterol Xinafoate,D02.033.100.291.057.750\\r\\nSalmeterol Xinafoate,D02.092.063.291.057.750\\r\\nSalmeterol Xinafoate,D02.092.471.683.061.750\\r\\nSalmeterol,D02.033.100.291.057.750\\r\\nSalmeterol,D02.092.063.291.057.750\\r\\nSalmeterol,D02.092.471.683.061.750\\r\\nSerevent,D02.033.100.291.057.750\\r\\nSerevent,D02.092.063.291.057.750\\r\\nSerevent,D02.092.471.683.061.750\\r\\n\"Parks, Recreational\",J03.925.680\\r\\nNational Parks,J03.925.680\\r\\nCommunity Parks,J03.925.680\\r\\nGreen Space,J03.925.680\\r\\nUrban Parks,J03.925.680\\r\\nWarfare and Armed Conflicts,I01.880.735.950\\r\\nArmed Conflicts,I01.880.735.950.250\\r\\nWars,I01.880.735.950.250\\r\\nEverolimus,D02.540.505.760.500\\r\\nRAD 001,D02.540.505.760.500\\r\\nAfinitor,D02.540.505.760.500\\r\\nCertican,D02.540.505.760.500\\r\\n\"Aspirin, Dipyridamole Drug Combination\",D02.455.426.559.389.657.410.595.176.500\\r\\n\"Aspirin, Dipyridamole Drug Combination\",D03.383.742.175.500\\r\\n\"Aspirin, Dipyridamole Drug Combination\",D26.310.125\\r\\nTX 3301,D02.455.426.559.389.657.410.595.176.500\\r\\nTX 3301,D03.383.742.175.500\\r\\nTX 3301,D26.310.125\\r\\nExtended-Release Dipyridamole-Aspirin,D02.455.426.559.389.657.410.595.176.500\\r\\nExtended-Release Dipyridamole-Aspirin,D03.383.742.175.500\\r\\nExtended-Release Dipyridamole-Aspirin,D26.310.125\\r\\nAsasantin,D02.455.426.559.389.657.410.595.176.500\\r\\nAsasantin,D03.383.742.175.500\\r\\nAsasantin,D26.310.125\\r\\nAsasantin Retard,D02.455.426.559.389.657.410.595.176.500\\r\\nAsasantin Retard,D03.383.742.175.500\\r\\nAsasantin Retard,D26.310.125\\r\\nAggrenox,D02.455.426.559.389.657.410.595.176.500\\r\\nAggrenox,D03.383.742.175.500\\r\\nAggrenox,D26.310.125\\r\\nSelf-Control,F01.145.813.595\\r\\nSaline Waters,G16.500.275.725\\r\\nBrackish Water,G16.500.275.725\\r\\nCompassion Fatigue,C23.888.369.500.500\\r\\nCompassion Fatigue,F01.145.126.937.500\\r\\nCompassion Fatigue,F01.145.126.990.734.500\\r\\nCompassion Fatigue,F02.830.900.666.750\\r\\nPlantaginaceae,B01.650.940.800.575.912.250.583.700\\r\\nStemodia,B01.650.940.800.575.912.250.583.700\\r\\nGlobularia,B01.650.940.800.575.912.250.583.700\\r\\nLamiales,B01.650.940.800.575.912.250.583\\r\\nProboscidea Plant,B01.650.940.800.575.912.250.583\\r\\nClinical Study,V03.175\\r\\nSurgical Clearance,E01.370.505\\r\\nPemetrexed,D03.633.100.759.758.399.454.650\\r\\nPemetrexed,D12.125.067.625.525\\r\\nPemetrexed,D12.125.119.409.525\\r\\nPemetrexed Disodium,D03.633.100.759.758.399.454.650\\r\\nPemetrexed Disodium,D12.125.067.625.525\\r\\nPemetrexed Disodium,D12.125.119.409.525\\r\\nLY 231514,D03.633.100.759.758.399.454.650\\r\\nLY 231514,D12.125.067.625.525\\r\\nLY 231514,D12.125.119.409.525\\r\\nAlimta,D03.633.100.759.758.399.454.650\\r\\nAlimta,D12.125.067.625.525\\r\\nAlimta,D12.125.119.409.525\\r\\nBrimonidine Tartrate,D03.633.100.857.070\\r\\n\"Brimonidine Tartrate (1:1), (S-(R*,R*))-Isomer\",D03.633.100.857.070\\r\\nBrimonidine Purite,D03.633.100.857.070\\r\\nAGN 190342,D03.633.100.857.070\\r\\nSanrosa,D03.633.100.857.070\\r\\nAlphagan,D03.633.100.857.070\\r\\nBrimonidine,D03.633.100.857.070\\r\\nAlphagan P,D03.633.100.857.070\\r\\n\"UK 14,304\",D03.633.100.857.070\\r\\nRatio-Brimonidine,D03.633.100.857.070\\r\\n\"UK 14,304-18\",D03.633.100.857.070\\r\\nUK 14308,D03.633.100.857.070\\r\\n\"Brimonidine Tartrate, (R-(R*,R*))-Isomer\",D03.633.100.857.070\\r\\nBrimonidine Tartrate (1:1),D03.633.100.857.070\\r\\nMirvaso,D03.633.100.857.070\\r\\nClinical Studies as Topic,E05.318.372.250\\r\\nClinical Studies as Topic,N05.715.360.330.250\\r\\nClinical Studies as Topic,N06.850.520.450.250\\r\\nBeijing,Z01.252.474.164.225\\r\\nBeijing,Z01.433.114\\r\\nAfrican Union,I01.615.500.125\\r\\nAfrican Union,N03.540.089\\r\\nFirmicutes,B03.353\\r\\nDutasteride,D04.210.500.925.100.125\\r\\nAvodart,D04.210.500.925.100.125\\r\\nGG 745,D04.210.500.925.100.125\\r\\nGI198745,D04.210.500.925.100.125\\r\\nCalceolariaceae,B01.650.940.800.575.912.250.583.190\\r\\nJovellana,B01.650.940.800.575.912.250.583.190\\r\\nCalceolaria,B01.650.940.800.575.912.250.583.190\\r\\nPorodittia,B01.650.940.800.575.912.250.583.190\\r\\nInterferon beta-1a,D12.644.276.374.440.890.275.500\\r\\nInterferon beta-1a,D12.776.467.374.440.890.275.500\\r\\nInterferon beta-1a,D23.529.374.440.890.275.500\\r\\nAvonex Pen,D12.644.276.374.440.890.275.500\\r\\nAvonex Pen,D12.776.467.374.440.890.275.500\\r\\nAvonex Pen,D23.529.374.440.890.275.500\\r\\nRebif,D12.644.276.374.440.890.275.500\\r\\nRebif,D12.776.467.374.440.890.275.500\\r\\nRebif,D23.529.374.440.890.275.500\\r\\nAvonex,D12.644.276.374.440.890.275.500\\r\\nAvonex,D12.776.467.374.440.890.275.500\\r\\nAvonex,D23.529.374.440.890.275.500\\r\\nOlmesartan Medoxomil,D03.383.129.308.674\\r\\nOlmesartan Medoxomil,D03.383.129.617.584\\r\\nBenicar,D03.383.129.308.674\\r\\nBenicar,D03.383.129.617.584\\r\\nOlmetec,D03.383.129.308.674\\r\\nOlmetec,D03.383.129.617.584\\r\\nCS 866,D03.383.129.308.674\\r\\nCS 866,D03.383.129.617.584\\r\\nVotum,D03.383.129.308.674\\r\\nVotum,D03.383.129.617.584\\r\\n\"Amlodipine Besylate, Olmesartan Medoxomil Drug Combination\",D03.383.129.308.674.500\\r\\n\"Amlodipine Besylate, Olmesartan Medoxomil Drug Combination\",D03.383.129.617.584.500\\r\\n\"Amlodipine Besylate, Olmesartan Medoxomil Drug Combination\",D03.383.725.203.065.500\\r\\n\"Amlodipine Besylate, Olmesartan Medoxomil Drug Combination\",D26.310.063\\r\\nAzor,D03.383.129.308.674.500\\r\\nAzor,D03.383.129.617.584.500\\r\\nAzor,D03.383.725.203.065.500\\r\\nAzor,D26.310.063\\r\\nInterferon beta-1b,D12.644.276.374.440.890.275.750\\r\\nInterferon beta-1b,D12.776.467.374.440.890.275.750\\r\\nInterferon beta-1b,D23.529.374.440.890.275.750\\r\\nBetaseron,D12.644.276.374.440.890.275.750\\r\\nBetaseron,D12.776.467.374.440.890.275.750\\r\\nBetaseron,D23.529.374.440.890.275.750\\r\\nExtavia,D12.644.276.374.440.890.275.750\\r\\nExtavia,D12.776.467.374.440.890.275.750\\r\\nExtavia,D23.529.374.440.890.275.750\\r\\nBetaferon,D12.644.276.374.440.890.275.750\\r\\nBetaferon,D12.776.467.374.440.890.275.750\\r\\nBetaferon,D23.529.374.440.890.275.750\\r\\nNebivolol,D02.033.100.291.491\\r\\nNebivolol,D02.092.063.291.503\\r\\nNebivolol,D03.383.663.283.755\\r\\nNebivolol,D03.633.100.150.755\\r\\nBystolic,D02.033.100.291.491\\r\\nBystolic,D02.092.063.291.503\\r\\nBystolic,D03.383.663.283.755\\r\\nBystolic,D03.633.100.150.755\\r\\nNebilet,D02.033.100.291.491\\r\\nNebilet,D02.092.063.291.503\\r\\nNebilet,D03.383.663.283.755\\r\\nNebilet,D03.633.100.150.755\\r\\nSilostar,D02.033.100.291.491\\r\\nSilostar,D02.092.063.291.503\\r\\nSilostar,D03.383.663.283.755\\r\\nSilostar,D03.633.100.150.755\\r\\nNebivolol Hydrochloride,D02.033.100.291.491\\r\\nNebivolol Hydrochloride,D02.092.063.291.503\\r\\nNebivolol Hydrochloride,D03.383.663.283.755\\r\\nNebivolol Hydrochloride,D03.633.100.150.755\\r\\nR 67555,D02.033.100.291.491\\r\\nR 67555,D02.092.063.291.503\\r\\nR 67555,D03.383.663.283.755\\r\\nR 67555,D03.633.100.150.755\\r\\nLobivon,D02.033.100.291.491\\r\\nLobivon,D02.092.063.291.503\\r\\nLobivon,D03.383.663.283.755\\r\\nLobivon,D03.633.100.150.755\\r\\nCelecoxib,D02.065.884.247\\r\\nCelecoxib,D02.886.590.700.247\\r\\nCelecoxib,D03.383.129.539.160\\r\\nCelebrex,D02.065.884.247\\r\\nCelebrex,D02.886.590.700.247\\r\\nCelebrex,D03.383.129.539.160\\r\\nSC 58635,D02.065.884.247\\r\\nSC 58635,D02.886.590.700.247\\r\\nSC 58635,D03.383.129.539.160\\r\\nVarenicline,D03.633.100.079.900\\r\\nVarenicline,D03.633.100.857.942\\r\\nChantix,D03.633.100.079.900\\r\\nChantix,D03.633.100.857.942\\r\\nVarenicline Tartrate,D03.633.100.079.900\\r\\nVarenicline Tartrate,D03.633.100.857.942\\r\\nChampix,D03.633.100.079.900\\r\\nChampix,D03.633.100.857.942\\r\\nTadalafil,D03.383.725.150.500\\r\\nTadalafil,D03.633.100.473.155.500\\r\\nTadalafil,D03.633.300.154.672\\r\\nIC351,D03.383.725.150.500\\r\\nIC351,D03.633.100.473.155.500\\r\\nIC351,D03.633.300.154.672\\r\\nCialis,D03.383.725.150.500\\r\\nCialis,D03.633.100.473.155.500\\r\\nCialis,D03.633.300.154.672\\r\\nCertolizumab Pegol,D05.750.741.125\\r\\nCertolizumab Pegol,D12.644.541.500.650.250\\r\\nCertolizumab Pegol,D12.776.124.486.485.114.224.060.500\\r\\nCertolizumab Pegol,D12.776.124.486.485.680.650.250\\r\\nCertolizumab Pegol,D12.776.124.790.651.114.224.060.500\\r\\nCertolizumab Pegol,D12.776.124.790.651.680.650.250\\r\\nCertolizumab Pegol,D12.776.377.715.548.114.224.200.500\\r\\nCertolizumab Pegol,D12.776.377.715.548.680.650.250\\r\\nCimzia,D05.750.741.125\\r\\nCimzia,D12.644.541.500.650.250\\r\\nCimzia,D12.776.124.486.485.114.224.060.500\\r\\nCimzia,D12.776.124.486.485.680.650.250\\r\\nCimzia,D12.776.124.790.651.114.224.060.500\\r\\nCimzia,D12.776.124.790.651.680.650.250\\r\\nCimzia,D12.776.377.715.548.114.224.200.500\\r\\nCimzia,D12.776.377.715.548.680.650.250\\r\\nCDP870,D05.750.741.125\\r\\nCDP870,D12.644.541.500.650.250\\r\\nCDP870,D12.776.124.486.485.114.224.060.500\\r\\nCDP870,D12.776.124.486.485.680.650.250\\r\\nCDP870,D12.776.124.790.651.114.224.060.500\\r\\nCDP870,D12.776.124.790.651.680.650.250\\r\\nCDP870,D12.776.377.715.548.114.224.200.500\\r\\nCDP870,D12.776.377.715.548.680.650.250\\r\\n\"Censorship, Research\",I01.880.604.238\\r\\n\"Censorship, Research\",K01.752.566.479.173.200\\r\\n\"Censorship, Research\",N05.350.670.250\\r\\nData Accuracy,E05.318.308.028\\r\\nData Accuracy,E05.318.370.725.250\\r\\nData Accuracy,L01.399.250.202\\r\\nData Accuracy,N05.715.360.300.202\\r\\nData Accuracy,N05.715.360.325.685.250\\r\\nData Quality,E05.318.308.028\\r\\nData Quality,E05.318.370.725.250\\r\\nData Quality,L01.399.250.202\\r\\nData Quality,N05.715.360.300.202\\r\\nData Quality,N05.715.360.325.685.250\\r\\n\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.033.100.624.915.500\\r\\n\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.033.755.624.915.500\\r\\n\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.092.063.624.915.500\\r\\n\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.886.675.867.768.500\\r\\n\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D03.383.129.708.867.768.500\\r\\n\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D03.633.100.857.070.500\\r\\n\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D26.310.312\\r\\nCombigan,D02.033.100.624.915.500\\r\\nCombigan,D02.033.755.624.915.500\\r\\nCombigan,D02.092.063.624.915.500\\r\\nCombigan,D02.886.675.867.768.500\\r\\nCombigan,D03.383.129.708.867.768.500\\r\\nCombigan,D03.633.100.857.070.500\\r\\nCombigan,D26.310.312\\r\\n\"Albuterol, Ipratropium Drug Combination\",D02.033.100.291.057.125\\r\\n\"Albuterol, Ipratropium Drug Combination\",D02.092.063.291.057.125\\r\\n\"Albuterol, Ipratropium Drug Combination\",D02.092.471.683.061.125\\r\\n\"Albuterol, Ipratropium Drug Combination\",D02.145.074.722.229.400.500\\r\\n\"Albuterol, Ipratropium Drug Combination\",D03.132.760.180.572.400.500\\r\\n\"Albuterol, Ipratropium Drug Combination\",D03.132.889.180.648.400.500\\r\\n\"Albuterol, Ipratropium Drug Combination\",D03.605.084.500.722.229.400.500\\r\\n\"Albuterol, Ipratropium Drug Combination\",D03.605.869.229.400.500\\r\\n\"Albuterol, Ipratropium Drug Combination\",D26.310.344\\r\\nCombivent Respimat,D02.033.100.291.057.125\\r\\nCombivent Respimat,D02.092.063.291.057.125\\r\\nCombivent Respimat,D02.092.471.683.061.125\\r\\nCombivent Respimat,D02.145.074.722.229.400.500\\r\\nCombivent Respimat,D03.132.760.180.572.400.500\\r\\nCombivent Respimat,D03.132.889.180.648.400.500\\r\\nCombivent Respimat,D03.605.084.500.722.229.400.500\\r\\nCombivent Respimat,D03.605.869.229.400.500\\r\\nCombivent Respimat,D26.310.344\\r\\nDey Combination,D02.033.100.291.057.125\\r\\nDey Combination,D02.092.063.291.057.125\\r\\nDey Combination,D02.092.471.683.061.125\\r\\nDey Combination,D02.145.074.722.229.400.500\\r\\nDey Combination,D03.132.760.180.572.400.500\\r\\nDey Combination,D03.132.889.180.648.400.500\\r\\nDey Combination,D03.605.084.500.722.229.400.500\\r\\nDey Combination,D03.605.869.229.400.500\\r\\nDey Combination,D26.310.344\\r\\nCombivent,D02.033.100.291.057.125\\r\\nCombivent,D02.092.063.291.057.125\\r\\nCombivent,D02.092.471.683.061.125\\r\\nCombivent,D02.145.074.722.229.400.500\\r\\nCombivent,D03.132.760.180.572.400.500\\r\\nCombivent,D03.132.889.180.648.400.500\\r\\nCombivent,D03.605.084.500.722.229.400.500\\r\\nCombivent,D03.605.869.229.400.500\\r\\nCombivent,D26.310.344\\r\\nDual Use Research,H01.770.644.217\\r\\nProfessionalism,K01.752.566.479.171.566\\r\\nProfessionalism,N05.350.340.581\\r\\nMedical Professionalism,K01.752.566.479.171.566\\r\\nMedical Professionalism,N05.350.340.581\\r\\nProfessionalism Education,K01.752.566.479.171.566\\r\\nProfessionalism Education,N05.350.340.581\\r\\nSurgical Professionalism,K01.752.566.479.171.566\\r\\nSurgical Professionalism,N05.350.340.581\\r\\nGenetic Background,G05.346\\r\\nSelective Breeding,E05.820.150.760\\r\\nSelective Breeding,G05.090.701\\r\\nLegendary Creatures,I01.076.201.450.515.500\\r\\nWerewolves,I01.076.201.450.515.500\\r\\nUnicorns,I01.076.201.450.515.500\\r\\n\"Yeti, Himalayan\",I01.076.201.450.515.500\\r\\nVampires,I01.076.201.450.515.500\\r\\nMermaids,I01.076.201.450.515.500\\r\\nMometasone Furoate,D04.210.500.745.432.719.526\\r\\nNasonex,D04.210.500.745.432.719.526\\r\\nMometasone Furoate Monohydrate,D04.210.500.745.432.719.526\\r\\nAsmanex Twisthaler,D04.210.500.745.432.719.526\\r\\nAsmanex,D04.210.500.745.432.719.526\\r\\nRinelon,D04.210.500.745.432.719.526\\r\\nElocon,D04.210.500.745.432.719.526\\r\\nSch 32088,D04.210.500.745.432.719.526\\r\\nMometasone,D04.210.500.745.432.719.526\\r\\nFallopia multiflora,B01.650.940.800.575.912.250.825.359.590\\r\\nSildenafil Citrate,D02.065.884.675\\r\\nSildenafil Citrate,D02.886.590.700.675\\r\\nSildenafil Citrate,D03.383.606.854\\r\\nSildenafil Citrate,D03.633.100.759.824\\r\\nNCX-911,D02.065.884.675\\r\\nNCX-911,D02.886.590.700.675\\r\\nNCX-911,D03.383.606.854\\r\\nNCX-911,D03.633.100.759.824\\r\\nRevatio,D02.065.884.675\\r\\nRevatio,D02.886.590.700.675\\r\\nRevatio,D03.383.606.854\\r\\nRevatio,D03.633.100.759.824\\r\\nSildenafil,D02.065.884.675\\r\\nSildenafil,D02.886.590.700.675\\r\\nSildenafil,D03.383.606.854\\r\\nSildenafil,D03.633.100.759.824\\r\\nUK 92480-10,D02.065.884.675\\r\\nUK 92480-10,D02.886.590.700.675\\r\\nUK 92480-10,D03.383.606.854\\r\\nUK 92480-10,D03.633.100.759.824\\r\\nHomosildenafil,D02.065.884.675\\r\\nHomosildenafil,D02.886.590.700.675\\r\\nHomosildenafil,D03.383.606.854\\r\\nHomosildenafil,D03.633.100.759.824\\r\\nHydroxyhomosildenafil,D02.065.884.675\\r\\nHydroxyhomosildenafil,D02.886.590.700.675\\r\\nHydroxyhomosildenafil,D03.383.606.854\\r\\nHydroxyhomosildenafil,D03.633.100.759.824\\r\\nViagra,D02.065.884.675\\r\\nViagra,D02.886.590.700.675\\r\\nViagra,D03.383.606.854\\r\\nViagra,D03.633.100.759.824\\r\\nAcetildenafil,D02.065.884.675\\r\\nAcetildenafil,D02.886.590.700.675\\r\\nAcetildenafil,D03.383.606.854\\r\\nAcetildenafil,D03.633.100.759.824\\r\\nSildenafil Lactate,D02.065.884.675\\r\\nSildenafil Lactate,D02.886.590.700.675\\r\\nSildenafil Lactate,D03.383.606.854\\r\\nSildenafil Lactate,D03.633.100.759.824\\r\\nSildenafil Nitrate,D02.065.884.675\\r\\nSildenafil Nitrate,D02.886.590.700.675\\r\\nSildenafil Nitrate,D03.383.606.854\\r\\nSildenafil Nitrate,D03.633.100.759.824\\r\\nDesmethyl Sildenafil,D02.065.884.675\\r\\nDesmethyl Sildenafil,D02.886.590.700.675\\r\\nDesmethyl Sildenafil,D03.383.606.854\\r\\nDesmethyl Sildenafil,D03.633.100.759.824\\r\\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D02.626.809.500\\r\\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D02.705.429.906.500\\r\\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D03.383.742.680.245.500.600.500\\r\\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D03.383.742.755.500\\r\\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D03.633.100.759.138.881.500\\r\\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D26.310.407\\r\\nComplera,D02.626.809.500\\r\\nComplera,D02.705.429.906.500\\r\\nComplera,D03.383.742.680.245.500.600.500\\r\\nComplera,D03.383.742.755.500\\r\\nComplera,D03.633.100.759.138.881.500\\r\\nComplera,D26.310.407\\r\\nEmtricitabine,D03.383.742.680.245.500.600\\r\\nEmtricitabine,D13.570.230.329.525\\r\\nEmtricitabine,D13.570.685.245.500.600\\r\\nCoviracil,D03.383.742.680.245.500.600\\r\\nCoviracil,D13.570.230.329.525\\r\\nCoviracil,D13.570.685.245.500.600\\r\\nEmtriva,D03.383.742.680.245.500.600\\r\\nEmtriva,D13.570.230.329.525\\r\\nEmtriva,D13.570.685.245.500.600\\r\\nRilpivirine,D02.626.809\\r\\nRilpivirine,D03.383.742.755\\r\\nRilpivirine Hydrochloride,D02.626.809\\r\\nRilpivirine Hydrochloride,D03.383.742.755\\r\\nR278474,D02.626.809\\r\\nR278474,D03.383.742.755\\r\\nTMC 278,D02.626.809\\r\\nTMC 278,D03.383.742.755\\r\\nTenofovir,D02.705.429.906\\r\\nTenofovir,D03.633.100.759.138.881\\r\\n\"9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer\",D02.705.429.906\\r\\n\"9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer\",D03.633.100.759.138.881\\r\\n\"9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer\",D02.705.429.906\\r\\n\"9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer\",D03.633.100.759.138.881\\r\\nTenofovir Disoproxil Fumarate,D02.705.429.906\\r\\nTenofovir Disoproxil Fumarate,D03.633.100.759.138.881\\r\\nTenofovir Disoproxil,D02.705.429.906\\r\\nTenofovir Disoproxil,D03.633.100.759.138.881\\r\\n\"9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098\",D02.705.429.906\\r\\n\"9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098\",D03.633.100.759.138.881\\r\\nViread,D02.705.429.906\\r\\nViread,D03.633.100.759.138.881\\r\\nGlatiramer Acetate,D12.644.219\\r\\nCopaxone,D12.644.219\\r\\nGlatiramer,D12.644.219\\r\\nTV 5010,D12.644.219\\r\\nRosuvastatin Calcium,D02.065.884.650\\r\\nRosuvastatin Calcium,D02.455.526.510.432.500\\r\\nRosuvastatin Calcium,D02.886.590.700.650\\r\\nRosuvastatin Calcium,D03.383.742.775\\r\\nCrestor,D02.065.884.650\\r\\nCrestor,D02.455.526.510.432.500\\r\\nCrestor,D02.886.590.700.650\\r\\nCrestor,D03.383.742.775\\r\\nRosuvastatin,D02.065.884.650\\r\\nRosuvastatin,D02.455.526.510.432.500\\r\\nRosuvastatin,D02.886.590.700.650\\r\\nRosuvastatin,D03.383.742.775\\r\\nZD4522,D02.065.884.650\\r\\nZD4522,D02.455.526.510.432.500\\r\\nZD4522,D02.886.590.700.650\\r\\nZD4522,D03.383.742.775\\r\\nDuloxetine Hydrochloride,D02.886.778.260\\r\\nDuloxetine Hydrochloride,D03.383.903.260\\r\\nLY 248686,D02.886.778.260\\r\\nLY 248686,D03.383.903.260\\r\\n\"Duloxetine Ethanedioate (1:1), (+-)-isomer - T353987\",D02.886.778.260\\r\\n\"Duloxetine Ethanedioate (1:1), (+-)-isomer - T353987\",D03.383.903.260\\r\\nLY 227942,D02.886.778.260\\r\\nLY 227942,D03.383.903.260\\r\\nDuloxetine,D02.886.778.260\\r\\nDuloxetine,D03.383.903.260\\r\\n\"Duloxetine, (+)-isomer\",D02.886.778.260\\r\\n\"Duloxetine, (+)-isomer\",D03.383.903.260\\r\\nCymbalta,D02.886.778.260\\r\\nCymbalta,D03.383.903.260\\r\\nTolterodine Tartrate,D02.033.100.624.706.750\\r\\nTolterodine Tartrate,D02.033.755.624.706.750\\r\\nTolterodine Tartrate,D02.092.063.624.706.800\\r\\nTolterodine Tartrate,D02.455.426.559.389.115.900\\r\\nTolterodine Tartrate,D02.455.426.559.389.657.239.756\\r\\nTolterodine,D02.033.100.624.706.750\\r\\nTolterodine,D02.033.755.624.706.750\\r\\nTolterodine,D02.092.063.624.706.800\\r\\nTolterodine,D02.455.426.559.389.115.900\\r\\nTolterodine,D02.455.426.559.389.657.239.756\\r\\nDetrol,D02.033.100.624.706.750\\r\\nDetrol,D02.033.755.624.706.750\\r\\nDetrol,D02.092.063.624.706.800\\r\\nDetrol,D02.455.426.559.389.115.900\\r\\nDetrol,D02.455.426.559.389.657.239.756\\r\\nDetrol LA,D02.033.100.624.706.750\\r\\nDetrol LA,D02.033.755.624.706.750\\r\\nDetrol LA,D02.092.063.624.706.800\\r\\nDetrol LA,D02.455.426.559.389.115.900\\r\\nDetrol LA,D02.455.426.559.389.657.239.756\\r\\nUrotrol,D02.033.100.624.706.750\\r\\nUrotrol,D02.033.755.624.706.750\\r\\nUrotrol,D02.092.063.624.706.800\\r\\nUrotrol,D02.455.426.559.389.115.900\\r\\nUrotrol,D02.455.426.559.389.657.239.756\\r\\nPHA-686464B,D02.033.100.624.706.750\\r\\nPHA-686464B,D02.033.755.624.706.750\\r\\nPHA-686464B,D02.092.063.624.706.800\\r\\nPHA-686464B,D02.455.426.559.389.115.900\\r\\nPHA-686464B,D02.455.426.559.389.657.239.756\\r\\nDetrusitol,D02.033.100.624.706.750\\r\\nDetrusitol,D02.033.755.624.706.750\\r\\nDetrusitol,D02.092.063.624.706.800\\r\\nDetrusitol,D02.455.426.559.389.115.900\\r\\nDetrusitol,D02.455.426.559.389.657.239.756\\r\\nUnidet,D02.033.100.624.706.750\\r\\nUnidet,D02.033.755.624.706.750\\r\\nUnidet,D02.092.063.624.706.800\\r\\nUnidet,D02.455.426.559.389.115.900\\r\\nUnidet,D02.455.426.559.389.657.239.756\\r\\nValsartan,D03.383.129.617.850\\r\\nValsartan,D12.125.070.950.550\\r\\nValsartan,D12.125.142.930.500\\r\\nDiovan,D03.383.129.617.850\\r\\nDiovan,D12.125.070.950.550\\r\\nDiovan,D12.125.142.930.500\\r\\nKalpress,D03.383.129.617.850\\r\\nKalpress,D12.125.070.950.550\\r\\nKalpress,D12.125.142.930.500\\r\\nTareg,D03.383.129.617.850\\r\\nTareg,D12.125.070.950.550\\r\\nTareg,D12.125.142.930.500\\r\\nNisis,D03.383.129.617.850\\r\\nNisis,D12.125.070.950.550\\r\\nNisis,D12.125.142.930.500\\r\\nProvas,D03.383.129.617.850\\r\\nProvas,D12.125.070.950.550\\r\\nProvas,D12.125.142.930.500\\r\\nVals,D03.383.129.617.850\\r\\nVals,D12.125.070.950.550\\r\\nVals,D12.125.142.930.500\\r\\nCGP 48933,D03.383.129.617.850\\r\\nCGP 48933,D12.125.070.950.550\\r\\nCGP 48933,D12.125.142.930.500\\r\\nMiten,D03.383.129.617.850\\r\\nMiten,D12.125.070.950.550\\r\\nMiten,D12.125.142.930.500\\r\\nOnonis,B01.650.940.800.575.912.250.401.604\\r\\n\"Mometasone Furoate, Formoterol Fumarate Drug Combination\",D02.033.100.291.425.500\\r\\n\"Mometasone Furoate, Formoterol Fumarate Drug Combination\",D02.092.063.291.425.500\\r\\n\"Mometasone Furoate, Formoterol Fumarate Drug Combination\",D04.210.500.745.432.719.526.500\\r\\n\"Mometasone Furoate, Formoterol Fumarate Drug Combination\",D26.310.469\\r\\nDulera,D02.033.100.291.425.500\\r\\nDulera,D02.092.063.291.425.500\\r\\nDulera,D04.210.500.745.432.719.526.500\\r\\nDulera,D26.310.469\\r\\nZenhale,D02.033.100.291.425.500\\r\\nZenhale,D02.092.063.291.425.500\\r\\nZenhale,D04.210.500.745.432.719.526.500\\r\\nZenhale,D26.310.469\\r\\nFormoterol Fumarate,D02.033.100.291.425\\r\\nFormoterol Fumarate,D02.092.063.291.425\\r\\nBD 40A,D02.033.100.291.425\\r\\nBD 40A,D02.092.063.291.425\\r\\nFormoterol,D02.033.100.291.425\\r\\nFormoterol,D02.092.063.291.425\\r\\nOxis,D02.033.100.291.425\\r\\nOxis,D02.092.063.291.425\\r\\nArformoterol,D02.033.100.291.425\\r\\nArformoterol,D02.092.063.291.425\\r\\nForadil,D02.033.100.291.425\\r\\nForadil,D02.092.063.291.425\\r\\nSerotonin and Noradrenaline Reuptake Inhibitors,D27.505.519.562.437.693\\r\\nSerotonin and Noradrenaline Reuptake Inhibitors,D27.505.519.625.600.693\\r\\nSerotonin and Noradrenaline Reuptake Inhibitors,D27.505.696.577.600.693\\r\\n\"Sleep Aids, Pharmaceutical\",D27.505.696.277.350.500\\r\\n\"Sleep Aids, Pharmaceutical\",D27.505.954.427.210.350.500\\r\\nSleeping Pills,D27.505.696.277.350.500\\r\\nSleeping Pills,D27.505.954.427.210.350.500\\r\\nOrexin Receptor Antagonists,D27.505.519.625.663\\r\\nOrexin Receptor Antagonists,D27.505.696.277.350.500.500\\r\\nOrexin Receptor Antagonists,D27.505.696.577.663\\r\\nOrexin Receptor Antagonists,D27.505.954.427.210.350.500.500\\r\\nDual Orexin Receptor Antagonists,D27.505.519.625.663\\r\\nDual Orexin Receptor Antagonists,D27.505.696.277.350.500.500\\r\\nDual Orexin Receptor Antagonists,D27.505.696.577.663\\r\\nDual Orexin Receptor Antagonists,D27.505.954.427.210.350.500.500\\r\\nOrexins,D12.644.400.360\\r\\nOrexins,D12.776.631.650.363\\r\\nOrexin-B,D12.644.400.360\\r\\nOrexin-B,D12.776.631.650.363\\r\\nOrexin-A,D12.644.400.360\\r\\nOrexin-A,D12.776.631.650.363\\r\\nHoodia,B01.650.940.800.575.912.250.456.500.389\\r\\nHoodia gordonii,B01.650.940.800.575.912.250.456.500.389\\r\\nPrasugrel Hydrochloride,D02.886.778.600\\r\\nPrasugrel Hydrochloride,D03.383.606.800\\r\\nPrasugrel Hydrochloride,D03.383.903.600\\r\\nCS 747,D02.886.778.600\\r\\nCS 747,D03.383.606.800\\r\\nCS 747,D03.383.903.600\\r\\nPrasugrel,D02.886.778.600\\r\\nPrasugrel,D03.383.606.800\\r\\nPrasugrel,D03.383.903.600\\r\\nEfient,D02.886.778.600\\r\\nEfient,D03.383.606.800\\r\\nEfient,D03.383.903.600\\r\\nEffient,D02.886.778.600\\r\\nEffient,D03.383.606.800\\r\\nEffient,D03.383.903.600\\r\\nLY 640315,D02.886.778.600\\r\\nLY 640315,D03.383.606.800\\r\\nLY 640315,D03.383.903.600\\r\\nEtanercept,D12.644.541.500.697.624\\r\\nEtanercept,D12.776.124.486.485.538.500.624\\r\\nEtanercept,D12.776.124.486.485.680.697.624\\r\\nEtanercept,D12.776.124.790.651.538.500.624\\r\\nEtanercept,D12.776.124.790.651.680.660.624\\r\\nEtanercept,D12.776.377.715.548.538.500.624\\r\\nEtanercept,D12.776.377.715.548.680.660.624\\r\\nEtanercept,D12.776.543.750.705.852.760.232\\r\\nTNFR-Fc Fusion Protein,D12.644.541.500.697.624\\r\\nTNFR-Fc Fusion Protein,D12.776.124.486.485.538.500.624\\r\\nTNFR-Fc Fusion Protein,D12.776.124.486.485.680.697.624\\r\\nTNFR-Fc Fusion Protein,D12.776.124.790.651.538.500.624\\r\\nTNFR-Fc Fusion Protein,D12.776.124.790.651.680.660.624\\r\\nTNFR-Fc Fusion Protein,D12.776.377.715.548.538.500.624\\r\\nTNFR-Fc Fusion Protein,D12.776.377.715.548.680.660.624\\r\\nTNFR-Fc Fusion Protein,D12.776.543.750.705.852.760.232\\r\\nEtanercept-szzs,D12.644.541.500.697.624\\r\\nEtanercept-szzs,D12.776.124.486.485.538.500.624\\r\\nEtanercept-szzs,D12.776.124.486.485.680.697.624\\r\\nEtanercept-szzs,D12.776.124.790.651.538.500.624\\r\\nEtanercept-szzs,D12.776.124.790.651.680.660.624\\r\\nEtanercept-szzs,D12.776.377.715.548.538.500.624\\r\\nEtanercept-szzs,D12.776.377.715.548.680.660.624\\r\\nEtanercept-szzs,D12.776.543.750.705.852.760.232\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.644.541.500.697.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.124.486.485.538.500.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.124.486.485.680.697.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.124.790.651.538.500.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.124.790.651.680.660.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.377.715.548.538.500.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.377.715.548.680.660.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.543.750.705.852.760.232\\r\\nErelzi,D12.644.541.500.697.624\\r\\nErelzi,D12.776.124.486.485.538.500.624\\r\\nErelzi,D12.776.124.486.485.680.697.624\\r\\nErelzi,D12.776.124.790.651.538.500.624\\r\\nErelzi,D12.776.124.790.651.680.660.624\\r\\nErelzi,D12.776.377.715.548.538.500.624\\r\\nErelzi,D12.776.377.715.548.680.660.624\\r\\nErelzi,D12.776.543.750.705.852.760.232\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.644.541.500.697.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.124.486.485.538.500.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.124.486.485.680.697.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.124.790.651.538.500.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.124.790.651.680.660.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.377.715.548.538.500.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.377.715.548.680.660.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.543.750.705.852.760.232\\r\\nEnbrel,D12.644.541.500.697.624\\r\\nEnbrel,D12.776.124.486.485.538.500.624\\r\\nEnbrel,D12.776.124.486.485.680.697.624\\r\\nEnbrel,D12.776.124.790.651.538.500.624\\r\\nEnbrel,D12.776.124.790.651.680.660.624\\r\\nEnbrel,D12.776.377.715.548.538.500.624\\r\\nEnbrel,D12.776.377.715.548.680.660.624\\r\\nEnbrel,D12.776.543.750.705.852.760.232\\r\\n\"Adapalene, Benzoyl Peroxide Drug Combination\",D02.241.223.100.133.500\\r\\n\"Adapalene, Benzoyl Peroxide Drug Combination\",D02.455.426.559.389.127.133.500\\r\\n\"Adapalene, Benzoyl Peroxide Drug Combination\",D02.455.426.559.847.638.090.500\\r\\n\"Adapalene, Benzoyl Peroxide Drug Combination\",D04.615.638.090.500\\r\\n\"Adapalene, Benzoyl Peroxide Drug Combination\",D26.310.032\\r\\nEpiduo,D02.241.223.100.133.500\\r\\nEpiduo,D02.455.426.559.389.127.133.500\\r\\nEpiduo,D02.455.426.559.847.638.090.500\\r\\nEpiduo,D04.615.638.090.500\\r\\nEpiduo,D26.310.032\\r\\nAdapalene,D02.455.426.559.847.638.090\\r\\nAdapalene,D04.615.638.090\\r\\nCD 271,D02.455.426.559.847.638.090\\r\\nCD 271,D04.615.638.090\\r\\nAdaferin,D02.455.426.559.847.638.090\\r\\nAdaferin,D04.615.638.090\\r\\nDifferin,D02.455.426.559.847.638.090\\r\\nDifferin,D04.615.638.090\\r\\nEpoetin Alfa,D12.644.276.374.410.240.150.500\\r\\nEpoetin Alfa,D12.776.395.240.150.750\\r\\nEpoetin Alfa,D12.776.467.374.410.240.150.500\\r\\nEpoetin Alfa,D23.529.374.410.240.150.750\\r\\nEpoetin Alfa Hexal,D12.644.276.374.410.240.150.500\\r\\nEpoetin Alfa Hexal,D12.776.395.240.150.750\\r\\nEpoetin Alfa Hexal,D12.776.467.374.410.240.150.500\\r\\nEpoetin Alfa Hexal,D23.529.374.410.240.150.750\\r\\nEprex,D12.644.276.374.410.240.150.500\\r\\nEprex,D12.776.395.240.150.750\\r\\nEprex,D12.776.467.374.410.240.150.500\\r\\nEprex,D23.529.374.410.240.150.750\\r\\nHeberitro,D12.644.276.374.410.240.150.500\\r\\nHeberitro,D12.776.395.240.150.750\\r\\nHeberitro,D12.776.467.374.410.240.150.500\\r\\nHeberitro,D23.529.374.410.240.150.750\\r\\nProcrit,D12.644.276.374.410.240.150.500\\r\\nProcrit,D12.776.395.240.150.750\\r\\nProcrit,D12.776.467.374.410.240.150.500\\r\\nProcrit,D23.529.374.410.240.150.750\\r\\nBinocrit,D12.644.276.374.410.240.150.500\\r\\nBinocrit,D12.776.395.240.150.750\\r\\nBinocrit,D12.776.467.374.410.240.150.500\\r\\nBinocrit,D23.529.374.410.240.150.750\\r\\nHX575 Compound,D12.644.276.374.410.240.150.500\\r\\nHX575 Compound,D12.776.395.240.150.750\\r\\nHX575 Compound,D12.776.467.374.410.240.150.500\\r\\nHX575 Compound,D23.529.374.410.240.150.750\\r\\nEpogen,D12.644.276.374.410.240.150.500\\r\\nEpogen,D12.776.395.240.150.750\\r\\nEpogen,D12.776.467.374.410.240.150.500\\r\\nEpogen,D23.529.374.410.240.150.750\\r\\nHX575,D12.644.276.374.410.240.150.500\\r\\nHX575,D12.776.395.240.150.750\\r\\nHX575,D12.776.467.374.410.240.150.500\\r\\nHX575,D23.529.374.410.240.150.750\\r\\nCetuximab,D12.776.124.486.485.114.224.060.750\\r\\nCetuximab,D12.776.124.790.651.114.224.060.750\\r\\nCetuximab,D12.776.377.715.548.114.224.200.750\\r\\nErbitux,D12.776.124.486.485.114.224.060.750\\r\\nErbitux,D12.776.124.790.651.114.224.060.750\\r\\nErbitux,D12.776.377.715.548.114.224.200.750\\r\\nIMC C225,D12.776.124.486.485.114.224.060.750\\r\\nIMC C225,D12.776.124.790.651.114.224.060.750\\r\\nIMC C225,D12.776.377.715.548.114.224.200.750\\r\\nHyssopus Plant,B01.650.940.800.575.912.250.583.520.330\\r\\nHyssopus officinalis,B01.650.940.800.575.912.250.583.520.330\\r\\nRivastigmine,D02.241.081.251.583.899\\r\\nRivastigmineTartrate,D02.241.081.251.583.899\\r\\nExelon,D02.241.081.251.583.899\\r\\nENA 713,D02.241.081.251.583.899\\r\\nParmeliaceae,B01.300.107.685\\r\\nParmeliaceae,B01.300.340.458\\r\\nCetraria,B01.300.107.685\\r\\nCetraria,B01.300.340.458\\r\\nCetraria islandica,B01.300.107.685\\r\\nCetraria islandica,B01.300.340.458\\r\\n\"Amlodipine, Valsartan Drug Combination\",D03.383.129.617.850.500\\r\\n\"Amlodipine, Valsartan Drug Combination\",D03.383.725.203.065.750\\r\\n\"Amlodipine, Valsartan Drug Combination\",D12.125.070.950.550.500\\r\\n\"Amlodipine, Valsartan Drug Combination\",D12.125.142.930.500.500\\r\\n\"Amlodipine, Valsartan Drug Combination\",D26.310.094\\r\\nExforge,D03.383.129.617.850.500\\r\\nExforge,D03.383.725.203.065.750\\r\\nExforge,D12.125.070.950.550.500\\r\\nExforge,D12.125.142.930.500.500\\r\\nExforge,D26.310.094\\r\\nEugenia,B01.650.940.800.575.912.250.773.374\\r\\nEuginia uniflora,B01.650.940.800.575.912.250.773.374\\r\\n\"Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18\",D20.215.894.815.455\\r\\n\"Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18\",D20.215.894.899.498.500\\r\\nGardasil,D20.215.894.815.455\\r\\nGardasil,D20.215.894.899.498.500\\r\\n\"Human Papillomavirus Vaccine L1, Type 6,11,16,18\",D20.215.894.815.455\\r\\n\"Human Papillomavirus Vaccine L1, Type 6,11,16,18\",D20.215.894.899.498.500\\r\\nKombucha Tea,D20.215.784.844.500\\r\\nKombucha Tea,G07.203.100.831.500\\r\\nKombucha Tea,G07.203.200.625\\r\\nKombucha Tea,J02.200.831.500\\r\\nKombucha Tea,J02.350.625\\r\\nFingolimod Hydrochloride,D02.033.100.700.350\\r\\nFingolimod Hydrochloride,D02.033.455.706.431\\r\\nFingolimod Hydrochloride,D02.092.063.700.350\\r\\nFTY-720,D02.033.100.700.350\\r\\nFTY-720,D02.033.455.706.431\\r\\nFTY-720,D02.092.063.700.350\\r\\nGilenya,D02.033.100.700.350\\r\\nGilenya,D02.033.455.706.431\\r\\nGilenya,D02.092.063.700.350\\r\\nFingolimod,D02.033.100.700.350\\r\\nFingolimod,D02.033.455.706.431\\r\\nFingolimod,D02.092.063.700.350\\r\\nImatinib Mesylate,D02.065.277.456\\r\\nImatinib Mesylate,D02.241.223.100.100.435\\r\\nImatinib Mesylate,D02.455.426.559.389.127.085.465\\r\\nImatinib Mesylate,D03.383.606.405\\r\\nImatinib Mesylate,D03.383.742.349\\r\\nSTI571,D02.065.277.456\\r\\nSTI571,D02.241.223.100.100.435\\r\\nSTI571,D02.455.426.559.389.127.085.465\\r\\nSTI571,D03.383.606.405\\r\\nSTI571,D03.383.742.349\\r\\nGleevec,D02.065.277.456\\r\\nGleevec,D02.241.223.100.100.435\\r\\nGleevec,D02.455.426.559.389.127.085.465\\r\\nGleevec,D03.383.606.405\\r\\nGleevec,D03.383.742.349\\r\\nST 1571,D02.065.277.456\\r\\nST 1571,D02.241.223.100.100.435\\r\\nST 1571,D02.455.426.559.389.127.085.465\\r\\nST 1571,D03.383.606.405\\r\\nST 1571,D03.383.742.349\\r\\nCGP 57148,D02.065.277.456\\r\\nCGP 57148,D02.241.223.100.100.435\\r\\nCGP 57148,D02.455.426.559.389.127.085.465\\r\\nCGP 57148,D03.383.606.405\\r\\nCGP 57148,D03.383.742.349\\r\\nImatinib,D02.065.277.456\\r\\nImatinib,D02.241.223.100.100.435\\r\\nImatinib,D02.455.426.559.389.127.085.465\\r\\nImatinib,D03.383.606.405\\r\\nImatinib,D03.383.742.349\\r\\nTrastuzumab,D12.776.124.486.485.114.224.060.875\\r\\nTrastuzumab,D12.776.124.790.651.114.224.060.875\\r\\nTrastuzumab,D12.776.377.715.548.114.224.200.875\\r\\nHerceptin,D12.776.124.486.485.114.224.060.875\\r\\nHerceptin,D12.776.124.790.651.114.224.060.875\\r\\nHerceptin,D12.776.377.715.548.114.224.200.875\\r\\nTrazimera,D12.776.124.486.485.114.224.060.875\\r\\nTrazimera,D12.776.124.790.651.114.224.060.875\\r\\nTrazimera,D12.776.377.715.548.114.224.200.875\\r\\nAdalimumab,D12.776.124.486.485.114.224.060.250\\r\\nAdalimumab,D12.776.124.790.651.114.224.060.250\\r\\nAdalimumab,D12.776.377.715.548.114.224.200.250\\r\\nHumira,D12.776.124.486.485.114.224.060.250\\r\\nHumira,D12.776.124.790.651.114.224.060.250\\r\\nHumira,D12.776.377.715.548.114.224.200.250\\r\\nAdalimumab-adbm,D12.776.124.486.485.114.224.060.250\\r\\nAdalimumab-adbm,D12.776.124.790.651.114.224.060.250\\r\\nAdalimumab-adbm,D12.776.377.715.548.114.224.200.250\\r\\nAmjevita,D12.776.124.486.485.114.224.060.250\\r\\nAmjevita,D12.776.124.790.651.114.224.060.250\\r\\nAmjevita,D12.776.377.715.548.114.224.200.250\\r\\nAdalimumab-atto,D12.776.124.486.485.114.224.060.250\\r\\nAdalimumab-atto,D12.776.124.790.651.114.224.060.250\\r\\nAdalimumab-atto,D12.776.377.715.548.114.224.200.250\\r\\nCyltezo,D12.776.124.486.485.114.224.060.250\\r\\nCyltezo,D12.776.124.790.651.114.224.060.250\\r\\nCyltezo,D12.776.377.715.548.114.224.200.250\\r\\nD2E7 Antibody,D12.776.124.486.485.114.224.060.250\\r\\nD2E7 Antibody,D12.776.124.790.651.114.224.060.250\\r\\nD2E7 Antibody,D12.776.377.715.548.114.224.200.250\\r\\n\"Isophane Insulin, Human\",D06.472.699.587.200.300.200.500\\r\\n\"Isophane Insulin, Human\",D06.472.699.587.200.500.625.500.500\\r\\n\"Isophane Insulin, Human\",D12.644.548.586.200.300.200.500\\r\\n\"Isophane Insulin, Human\",D12.644.548.586.200.500.625.500.500\\r\\nHumulin N,D06.472.699.587.200.300.200.500\\r\\nHumulin N,D06.472.699.587.200.500.625.500.500\\r\\nHumulin N,D12.644.548.586.200.300.200.500\\r\\nHumulin N,D12.644.548.586.200.500.625.500.500\\r\\nNovolin N,D06.472.699.587.200.300.200.500\\r\\nNovolin N,D06.472.699.587.200.500.625.500.500\\r\\nNovolin N,D12.644.548.586.200.300.200.500\\r\\nNovolin N,D12.644.548.586.200.500.625.500.500\\r\\n\"Animals, Exotic\",B01.050.050.126\\r\\nExotic Pets,B01.050.050.126\\r\\nPaliperidone Palmitate,D03.383.129.385.650\\r\\nPaliperidone Palmitate,D03.383.742.592\\r\\nPaliperidone,D03.383.129.385.650\\r\\nPaliperidone,D03.383.742.592\\r\\nInvega,D03.383.129.385.650\\r\\nInvega,D03.383.742.592\\r\\nInvega Sustenna,D03.383.129.385.650\\r\\nInvega Sustenna,D03.383.742.592\\r\\nR 76477,D03.383.129.385.650\\r\\nR 76477,D03.383.742.592\\r\\nImmunosenescence,G07.345.124.390\\r\\nImmunosenescence,G12.460.500\\r\\nCanagliflozin,D02.886.778.075\\r\\nCanagliflozin,D03.383.903.075\\r\\nCanagliflozin,D09.408.348.113\\r\\nInvokana,D02.886.778.075\\r\\nInvokana,D03.383.903.075\\r\\nInvokana,D09.408.348.113\\r\\nCanagliflozin Hemihydrate,D02.886.778.075\\r\\nCanagliflozin Hemihydrate,D03.383.903.075\\r\\nCanagliflozin Hemihydrate,D09.408.348.113\\r\\n\"Canagliflozin, Anhydrous\",D02.886.778.075\\r\\n\"Canagliflozin, Anhydrous\",D03.383.903.075\\r\\n\"Canagliflozin, Anhydrous\",D09.408.348.113\\r\\nIridescence,G01.590.310\\r\\nOpalescence,G01.590.310\\r\\nRaltegravir Potassium,D03.383.773.812.752\\r\\nRaltegravir,D03.383.773.812.752\\r\\nMK 0518,D03.383.773.812.752\\r\\nIsentress'","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["[Truncated to first 65536 bytes]\n'term,tree\\r\\nCalcimycin,D03.633.100.221.173\\r\\nA-23187,D03.633.100.221.173\\r\\nTemefos,D02.705.400.625.800\\r\\nTemefos,D02.705.539.345.800\\r\\nTemefos,D02.886.300.692.800\\r\\nAbate,D02.705.400.625.800\\r\\nAbate,D02.705.539.345.800\\r\\nAbate,D02.886.300.692.800\\r\\nDifos,D02.705.400.625.800\\r\\nDifos,D02.705.539.345.800\\r\\nDifos,D02.886.300.692.800\\r\\nAbattoirs,J01.576.423.200.700.100\\r\\nAbattoirs,J03.540.020\\r\\nAbbreviations as Topic,L01.559.598.400.556.131\\r\\nAcronyms as Topic,L01.559.598.400.556.131\\r\\nAbdomen,A01.923.047\\r\\n\"Abdomen, Acute\",C23.888.592.612.054.200\\r\\n\"Abdomen, Acute\",C23.888.821.030.249\\r\\nAbdominal Injuries,C26.017\\r\\nAbdominal Neoplasms,C04.588.033\\r\\nAbdominal Muscles,A02.633.567.050\\r\\nCremaster Muscle,A02.633.567.050\\r\\nPyramidalis Muscle,A02.633.567.050\\r\\nQuadratus Abdominis,A02.633.567.050\\r\\nTransversus Abdominis,A02.633.567.050\\r\\nAbducens Nerve,A08.800.800.120.030\\r\\nAbelson murine leukemia virus,B04.613.807.375.525.020\\r\\nAbelson murine leukemia virus,B04.820.650.375.525.020\\r\\nAbetalipoproteinemia,C16.320.565.398.500.440.500\\r\\nAbetalipoproteinemia,C18.452.584.500.875.440.500\\r\\nAbetalipoproteinemia,C18.452.648.398.500.440.500\\r\\nCongenital Abnormalities,C16.131\\r\\nFetal Malformations,C16.131\\r\\nFetal Anomalies,C16.131\\r\\n\"Abnormalities, Drug-Induced\",C16.131.042\\r\\n\"Abnormalities, Multiple\",C16.131.077\\r\\n\"Abnormalities, Radiation-Induced\",C16.131.080\\r\\n\"Abnormalities, Radiation-Induced\",C26.733.031\\r\\n\"Abnormalities, Radiation-Induced\",G01.750.748.500.031\\r\\n\"Abnormalities, Radiation-Induced\",N06.850.460.350.850.500.031\\r\\n\"Abnormalities, Radiation-Induced\",N06.850.810.300.360.031\\r\\nABO Blood-Group System,D23.050.301.290.031\\r\\nABO Blood-Group System,D23.050.705.230.031\\r\\nBlood Group H Type 1 Antigen,D23.050.301.290.031\\r\\nBlood Group H Type 1 Antigen,D23.050.705.230.031\\r\\nABO Factors,D23.050.301.290.031\\r\\nABO Factors,D23.050.705.230.031\\r\\nAbomasum,A13.869.106\\r\\nAbortifacient Agents,D27.505.696.875.131\\r\\nAbortifacient Agents,D27.505.954.705.131\\r\\nAbortifacient Effect,D27.505.696.875.131\\r\\nAbortifacient Effect,D27.505.954.705.131\\r\\n\"Abortifacient Agents, Nonsteroidal\",D27.505.696.875.131.100\\r\\n\"Abortifacient Agents, Nonsteroidal\",D27.505.954.705.131.100\\r\\n\"Abortifacient Agents, Steroidal\",D27.505.696.875.131.200\\r\\n\"Abortifacient Agents, Steroidal\",D27.505.954.705.131.200\\r\\n\"Abortion, Spontaneous\",C13.703.039\\r\\n\"Abortion, Spontaneous\",G08.686.784.769.496.125\\r\\nEarly Pregnancy Loss,C13.703.039\\r\\nEarly Pregnancy Loss,G08.686.784.769.496.125\\r\\nMiscarriage,C13.703.039\\r\\nMiscarriage,G08.686.784.769.496.125\\r\\n\"Abortion, Tubal\",C13.703.039\\r\\n\"Abortion, Tubal\",G08.686.784.769.496.125\\r\\nAbortion Applicants,M01.050\\r\\n\"Abortion Seekers, Repeated\",M01.050\\r\\n\"Abortion Seekers, Refused\",M01.050\\r\\n\"Abortion, Criminal\",I01.198.240.089\\r\\n\"Abortion, Eugenic\",E04.520.050.050\\r\\n\"Abortion, Selective\",E04.520.050.050\\r\\n\"Abortion, Habitual\",C13.703.039.089\\r\\n\"Abortion, Incomplete\",C13.703.039.093\\r\\n\"Abortion, Induced\",E04.520.050\\r\\nAbortion Rate,E04.520.050\\r\\nAbortion Techniques,E04.520.050\\r\\n\"Abortion, Drug-Induced\",E04.520.050\\r\\nPrevious Abortion,E04.520.050\\r\\n\"Abortion, Saline-Solution\",E04.520.050\\r\\n\"Abortion, Soap-Solution\",E04.520.050\\r\\nAnti-Abortion Groups,E04.520.050\\r\\nEmbryotomy,E04.520.050\\r\\n\"Fertility Control, Postconception\",E04.520.050\\r\\nAbortion Failure,E04.520.050\\r\\n\"Abortion, Rivanol\",E04.520.050\\r\\n\"Abortion, Legal\",E04.520.050.055\\r\\nAbortion on Demand,E04.520.050.055\\r\\n\"Abortion, Missed\",C13.703.039.173\\r\\n\"Abortion, Septic\",C01.674.173\\r\\n\"Abortion, Septic\",C13.703.039.256\\r\\n\"Abortion, Septic\",C13.703.700.173\\r\\n\"Abortion, Therapeutic\",E04.520.050.060\\r\\n\"Abortion, Threatened\",C13.703.090\\r\\n\"Abortion, Veterinary\",C13.703.039.422\\r\\n\"Abortion, Veterinary\",C22.021\\r\\nAbreaction,F04.754.720.107\\r\\nAbrin,D08.811.277.450.430.700.750.111\\r\\nAbrin,D12.776.503.499.249\\r\\nAbrin,D12.776.765.678.906.111\\r\\nAbrin C,D08.811.277.450.430.700.750.111\\r\\nAbrin C,D12.776.503.499.249\\r\\nAbrin C,D12.776.765.678.906.111\\r\\nAbrin A,D08.811.277.450.430.700.750.111\\r\\nAbrin A,D12.776.503.499.249\\r\\nAbrin A,D12.776.765.678.906.111\\r\\nAbruptio Placentae,C13.703.420.078\\r\\nAbruptio Placentae,C13.703.590.132\\r\\nAbscess,C01.830.025\\r\\nAbscess,C23.550.470.756.100\\r\\nPeritonsillar Abscess,C01.748.561.750.500\\r\\nPeritonsillar Abscess,C01.830.025.675\\r\\nPeritonsillar Abscess,C07.550.781.750.500\\r\\nPeritonsillar Abscess,C08.730.561.750.500\\r\\nPeritonsillar Abscess,C09.775.649.750.500\\r\\nAbscisic Acid,D02.241.223.268.034\\r\\nAbscisic Acid,D02.455.326.271.665.202.061\\r\\nAbscisic Acid,D02.455.426.392.368.367.379.249.024\\r\\nAbscisic Acid,D02.455.849.131.061\\r\\nAbscisic Acid,D02.455.849.765.521.500\\r\\n\"Abscisic Acid, (+,-)-Isomer\",D02.241.223.268.034\\r\\n\"Abscisic Acid, (+,-)-Isomer\",D02.455.326.271.665.202.061\\r\\n\"Abscisic Acid, (+,-)-Isomer\",D02.455.426.392.368.367.379.249.024\\r\\n\"Abscisic Acid, (+,-)-Isomer\",D02.455.849.131.061\\r\\n\"Abscisic Acid, (+,-)-Isomer\",D02.455.849.765.521.500\\r\\n\"Abscisic Acid, (Z,E)-Isomer\",D02.241.223.268.034\\r\\n\"Abscisic Acid, (Z,E)-Isomer\",D02.455.326.271.665.202.061\\r\\n\"Abscisic Acid, (Z,E)-Isomer\",D02.455.426.392.368.367.379.249.024\\r\\n\"Abscisic Acid, (Z,E)-Isomer\",D02.455.849.131.061\\r\\n\"Abscisic Acid, (Z,E)-Isomer\",D02.455.849.765.521.500\\r\\n\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.241.223.268.034\\r\\n\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.326.271.665.202.061\\r\\n\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.426.392.368.367.379.249.024\\r\\n\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.849.131.061\\r\\n\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.849.765.521.500\\r\\n\"Abscisic Acid, (R)-Isomer\",D02.241.223.268.034\\r\\n\"Abscisic Acid, (R)-Isomer\",D02.455.326.271.665.202.061\\r\\n\"Abscisic Acid, (R)-Isomer\",D02.455.426.392.368.367.379.249.024\\r\\n\"Abscisic Acid, (R)-Isomer\",D02.455.849.131.061\\r\\n\"Abscisic Acid, (R)-Isomer\",D02.455.849.765.521.500\\r\\n\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.241.223.268.034\\r\\n\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.326.271.665.202.061\\r\\n\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.426.392.368.367.379.249.024\\r\\n\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.849.131.061\\r\\n\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.849.765.521.500\\r\\n\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.241.223.268.034\\r\\n\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.326.271.665.202.061\\r\\n\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.426.392.368.367.379.249.024\\r\\n\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.849.131.061\\r\\n\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.849.765.521.500\\r\\nAbsenteeism,F02.784.692.107\\r\\nAbsorption,G01.015\\r\\nAbsorption,G02.010\\r\\nAbsorption,G03.015\\r\\nAbsorption,G03.787.024\\r\\nAbsorption,G07.690.725.015\\r\\nAbstracting and Indexing,L01.453.245.100\\r\\nIndexing,L01.453.245.100\\r\\nIndexes as Topic,L01.453.245.100\\r\\nAbstracting,L01.453.245.100\\r\\nDental Abutments,E06.780.346.500\\r\\nDental Abutments,E07.695.190.175\\r\\nAcacia,B01.650.940.800.575.912.250.401.025\\r\\nAcacia catechu,B01.650.940.800.575.912.250.401.025\\r\\nAcademic Medical Centers,N02.278.020\\r\\nAcademies and Institutes,N03.540.052\\r\\nInstitutes,N03.540.052\\r\\nResearch Institutes,N03.540.052\\r\\nAcademies,N03.540.052\\r\\nAcanthamoeba,B01.046.500.100.075.080\\r\\nAcanthocephala,B01.050.500.500.132\\r\\nAcanthocytes,A11.118.290.330.100\\r\\nAcanthocytes,A11.443.240.330.100\\r\\nAcanthocytes,A15.145.229.334.330.100\\r\\nAcantholysis,C17.800.865.070\\r\\nAcantholysis,C23.550.035\\r\\nAcanthosis Nigricans,C17.800.621.430.530.100\\r\\nAcari,B01.050.500.131.166.132\\r\\nAcceleration,G01.482.107\\r\\nAccessory Nerve,A08.800.800.120.060\\r\\nAccident Prevention,N06.850.135.060\\r\\nAccident Proneness,F01.145.015\\r\\nAccidental Falls,N06.850.135.122\\r\\nSlip and Fall,N06.850.135.122\\r\\nAccidents,N06.850.135\\r\\n\"Accidents, Aviation\",N06.850.135.185\\r\\n\"Accidents, Home\",N06.850.135.217\\r\\n\"Accidents, Occupational\",N06.850.135.240\\r\\n\"Accidents, Industrial\",N06.850.135.240\\r\\n\"Accidents, Traffic\",N06.850.135.392\\r\\nTraffic Collisions,N06.850.135.392\\r\\nTraffic Crashes,N06.850.135.392\\r\\nAcclimatization,G07.025.133\\r\\nAcclimatization,G16.012.500.133\\r\\n\"Accommodation, Ocular\",G14.010\\r\\n\"Accommodation, Lens\",G14.010\\r\\nAccounting,N03.219.463.030\\r\\nOil and Gas Industry,J01.576.655.875.750\\r\\nPetroleum Industry,J01.576.655.875.750\\r\\nOil Refinery,J01.576.655.875.750\\r\\nNatural Gas Industry,J01.576.655.875.750\\r\\nCoal Industry,J01.576.655.875.200\\r\\nDriving Under the Influence,F01.145.250.250\\r\\nDriving Under the Influence,F01.145.263.500\\r\\nDriving Under the Influence,I01.880.735.223.250\\r\\nDriving Under the Influence,I03.125.649\\r\\nDrinking and Driving,F01.145.250.250\\r\\nDrinking and Driving,F01.145.263.500\\r\\nDrinking and Driving,I01.880.735.223.250\\r\\nDrinking and Driving,I03.125.649\\r\\nHuman Embryonic Stem Cells,A11.872.700.250.750\\r\\nMouse Embryonic Stem Cells,A11.872.700.250.875\\r\\nEmbryonic Germ Cells,A11.497.124\\r\\nEmbryonic Germ Cells,A11.872.700.250.625\\r\\nWork Performance,I03.946.675\\r\\nJob Performance,I03.946.675\\r\\nCriminal Behavior,F01.145.250\\r\\nClinical Decision-Making,E01.055\\r\\nCognitive Aging,G07.345.124.260\\r\\nCognitive Neuroscience,F04.096.628.255.500\\r\\nCognitive Neuroscience,H01.158.610.030\\r\\nSocial Neuroscience,F04.096.628.255.500\\r\\nSocial Neuroscience,H01.158.610.030\\r\\nEmotional Adjustment,F01.058.144\\r\\nEmotional Adjustment,F01.752.543.500.250\\r\\nFacial Recognition,F02.463.593.524.250.500\\r\\nFacial Recognition,F02.463.593.524.500.500\\r\\nFacial Recognition,F02.463.593.932.622.500\\r\\nFacial Emotion Recognition,F02.463.593.524.250.500\\r\\nFacial Emotion Recognition,F02.463.593.524.500.500\\r\\nFacial Emotion Recognition,F02.463.593.932.622.500\\r\\nGrandparents,F01.829.263.403\\r\\nGrandparents,I01.880.853.150.452\\r\\nGrandparents,M01.264\\r\\nGrandmother,F01.829.263.403\\r\\nGrandmother,I01.880.853.150.452\\r\\nGrandmother,M01.264\\r\\nGrandfather,F01.829.263.403\\r\\nGrandfather,I01.880.853.150.452\\r\\nGrandfather,M01.264\\r\\nHelp-Seeking Behavior,F01.145.813.217\\r\\nHeuristics,F02.463.425.725.500\\r\\nHeuristics,F02.463.785.810.500\\r\\nIntimate Partner Violence,I01.198.240.856.575\\r\\nIntimate Partner Violence,I01.880.735.900.688\\r\\nDating Violence,I01.198.240.856.575\\r\\nDating Violence,I01.880.735.900.688\\r\\nNeurological Rehabilitation,E02.760.169.063.500.477\\r\\nNeurological Rehabilitation,E02.831.477\\r\\nNeurological Rehabilitation,H02.403.680.600.750\\r\\nNeurological Rehabilitation,N02.421.784.511\\r\\nPhysical Abuse,I01.198.240.856.688\\r\\nPhysical Abuse,I01.880.735.900.744\\r\\nProblem Behavior,F01.145.126.972\\r\\nProblem Behavior,F01.145.179.750\\r\\n\"Dysfunctional Behavior, Psychology\",F01.145.126.972\\r\\n\"Dysfunctional Behavior, Psychology\",F01.145.179.750\\r\\nDisruptive Behavior,F01.145.126.972\\r\\nDisruptive Behavior,F01.145.179.750\\r\\nUnderage Drinking,F01.145.022.750\\r\\nUnderage Drinking,F01.145.317.269.875\\r\\nUnderage Drinking,I01.880.735.878\\r\\nLegal Drinking Age,F01.145.022.750\\r\\nLegal Drinking Age,F01.145.317.269.875\\r\\nLegal Drinking Age,I01.880.735.878\\r\\nEctopic Gene Expression,G05.308.202\\r\\nCell Plasticity,G04.356.250\\r\\nCell Self Renewal,G04.144.220.235\\r\\nCell Self Renewal,G04.161.750.500.375\\r\\nCell Self Renewal,G05.113.415\\r\\nCell Self Renewal,G07.345.249.410.750.500.625\\r\\nStem Cell Self-Renewal,G04.144.220.235\\r\\nStem Cell Self-Renewal,G04.161.750.500.375\\r\\nStem Cell Self-Renewal,G05.113.415\\r\\nStem Cell Self-Renewal,G07.345.249.410.750.500.625\\r\\nRehabilitation Research,H01.770.644.145.472\\r\\nOrthodontists,M01.526.485.330.655\\r\\nOrthodontists,N02.360.330.655\\r\\nDentofacial Orthopedists,M01.526.485.330.655\\r\\nDentofacial Orthopedists,N02.360.330.655\\r\\nOral and Maxillofacial Surgeons,M01.526.485.330.483\\r\\nOral and Maxillofacial Surgeons,N02.360.330.483\\r\\nExodontists,M01.526.485.330.483\\r\\nExodontists,N02.360.330.483\\r\\nNeuroprotection,G11.561.645\\r\\n\"Diet, Food, and Nutrition\",G07.203\\r\\nTriticale,B01.650.940.800.575.912.250.822.906\\r\\nCritical Care Outcomes,N04.761.559.590.399.250\\r\\nCritical Care Outcomes,N05.715.360.575.575.399.250\\r\\nSimulation Training,I02.903.847\\r\\nInteractive Learning,I02.903.847\\r\\nMillets,B01.650.940.800.575.912.250.822.587\\r\\nBiobehavioral Sciences,H01.770.644.108.687\\r\\nProtein Corona,D12.776.642\\r\\nVegetarians,M01.928\\r\\nLacto-Ovo Vegetarians,M01.928\\r\\nVegans,M01.928.500\\r\\nAccounts Payable and Receivable,N03.219.463.030.080\\r\\nAccounts Payable,N03.219.463.030.080\\r\\nYouth Sports,I03.450.642.845.987\\r\\nOrganized Youth Sports,I03.450.642.845.987\\r\\nLiteracy,F01.145.209.429\\r\\nLiteracy,N01.824.196.500\\r\\nIlliteracy,F01.145.209.429\\r\\nIlliteracy,N01.824.196.500\\r\\nSevere Acute Malnutrition,C18.654.521.719\\r\\n\"Banking, Personal\",N03.219.463.030.100\\r\\nSavings Accounts,N03.219.463.030.100\\r\\nChecking Accounts,N03.219.463.030.100\\r\\nEvidence-Based Facility Design,N02.278.200.252\\r\\n\"Physical Appearance, Body\",E01.370.600.115.450\\r\\n\"Physical Appearance, Body\",G07.100.175\\r\\nFruit and Vegetable Juices,G07.203.100.606\\r\\nFruit and Vegetable Juices,J02.200.606\\r\\nVegetable Juices,G07.203.100.606\\r\\nVegetable Juices,J02.200.606\\r\\nFruit Juices,G07.203.100.606\\r\\nFruit Juices,J02.200.606\\r\\nGhee,D10.212.302.199.500\\r\\nGhee,G07.203.300.350.100.500\\r\\nGhee,G07.203.300.375.200.500\\r\\nGhee,J02.500.350.100.500\\r\\nGhee,J02.500.375.200.500\\r\\nHydraulic Fracking,J01.576.655.875.750.500\\r\\nPsychological Trauma,F03.950.750.375\\r\\nPeer Influence,F01.829.316.483.750\\r\\nPeer Pressure,F01.829.316.483.750\\r\\nVegetable Products,G07.203.300.850.450\\r\\nVegetable Products,J02.500.850.800\\r\\nDirect-to-Consumer Advertising,J01.219.687.274.500\\r\\nDirect-To-Consumer Screening and Testing,E01.370.398\\r\\nDirect-To-Consumer Screening and Testing,N02.421.726.233.166\\r\\nExtracellular Vesicles,A11.284.295.588\\r\\nExovesicles,A11.284.295.588\\r\\nApoptotic Bodies,A11.284.295.588\\r\\nFungal Viruses,B04.352\\r\\nTelocytes,A11.329.830.750\\r\\nExoskeleton Device,E07.341\\r\\nRobotic Exoskeleton,E07.341\\r\\nShellfish Hypersensitivity,C20.543.480.370.763\\r\\n\"Failure to Rescue, Health Care\",E01.789.800.760.500\\r\\n\"Failure to Rescue, Health Care\",H01.770.644.145.431.500\\r\\n\"Failure to Rescue, Health Care\",N04.761.559.590.800.760.500\\r\\n\"Failure to Rescue, Health Care\",N05.715.360.575.575.800.760.500\\r\\nPsychiatric Rehabilitation,H02.403.680.600.875\\r\\nPsychiatric Rehabilitation,N02.421.784.578\\r\\nPsychosocial Care,H02.403.680.600.875\\r\\nPsychosocial Care,N02.421.784.578\\r\\nSymptom Flare Up,C23.550.291.937.500\\r\\nSymptom Exacerbation,C23.550.291.937.500\\r\\nIsolated Heart Preparation,E05.519\\r\\nIsolated Heart Preparation,E05.598.750\\r\\nLangendorff Perfused Heart,E05.519\\r\\nLangendorff Perfused Heart,E05.598.750\\r\\nWorking Heart Preparation Technique,E05.519\\r\\nWorking Heart Preparation Technique,E05.598.750\\r\\nWorking Heart Preparation,E05.519\\r\\nWorking Heart Preparation,E05.598.750\\r\\nIsolated Heart Preparation Technique,E05.519\\r\\nIsolated Heart Preparation Technique,E05.598.750\\r\\n\"Diet, Vegan\",E02.642.249.300.750\\r\\n\"Diet, Vegan\",G07.203.650.240.300.750\\r\\nVeganism,E02.642.249.300.750\\r\\nVeganism,G07.203.650.240.300.750\\r\\nBehavior Observation Techniques,E05.796.112\\r\\nBehavior Observation Techniques,F04.669.112\\r\\nBehavior Rating Scale,F04.711.271\\r\\nBehavior Test,F04.711.271\\r\\nAlcohol Drinking in College,F01.145.317.269.625\\r\\n\"Obesity, Metabolically Benign\",C18.654.726.500.650\\r\\n\"Obesity, Metabolically Benign\",C23.888.144.699.500.250\\r\\n\"Obesity, Metabolically Benign\",E01.370.600.115.100.160.120.699.500.375\\r\\n\"Obesity, Metabolically Benign\",G07.100.100.160.120.699.500.375\\r\\nWhole Grains,G07.203.300.300.550.500\\r\\nWhole Grains,G07.203.300.775.500.500\\r\\nWhole Grains,J02.500.300.550.500\\r\\nWhole Grains,J02.500.775.500.500\\r\\nWhole Grain Cereals,G07.203.300.300.550.500\\r\\nWhole Grain Cereals,G07.203.300.775.500.500\\r\\nWhole Grain Cereals,J02.500.300.550.500\\r\\nWhole Grain Cereals,J02.500.775.500.500\\r\\nTransanal Endoscopic Surgery,E01.370.388.250.630.500\\r\\nTransanal Endoscopic Surgery,E04.210.240.250.680.500\\r\\nTransanal Endoscopic Surgery,E04.502.250.250.250.680.500\\r\\nTransanal Endoscopic Surgery,E04.502.250.630.500\\r\\nTransanal Minimally Invasive Surgery,E01.370.388.250.630.500\\r\\nTransanal Minimally Invasive Surgery,E04.210.240.250.680.500\\r\\nTransanal Minimally Invasive Surgery,E04.502.250.250.250.680.500\\r\\nTransanal Minimally Invasive Surgery,E04.502.250.630.500\\r\\nTransanal Endoscopic Microsurgery,E01.370.388.250.630.500.500\\r\\nTransanal Endoscopic Microsurgery,E04.210.240.250.680.500.500\\r\\nTransanal Endoscopic Microsurgery,E04.494.787\\r\\nTransanal Endoscopic Microsurgery,E04.502.250.250.250.680.500.500\\r\\nTransanal Endoscopic Microsurgery,E04.502.250.630.500.500\\r\\nCold Injury,C26.212\\r\\nPersonal Protective Equipment,E07.700.560\\r\\nPersonal Protective Equipment,J01.637.708.560\\r\\nNerve Agents,D27.720.599\\r\\nNerve Agents,D27.720.777.300.500\\r\\nNerve Gas,D27.720.599\\r\\nNerve Gas,D27.720.777.300.500\\r\\nWar-Related Injuries,C26.946\\r\\nWar-Related Injuries,I01.880.735.950.500.951.500\\r\\nWar-Related Injuries,N06.850.460.350.600.903.500\\r\\nWar-Related Trauma,C26.946\\r\\nWar-Related Trauma,I01.880.735.950.500.951.500\\r\\nWar-Related Trauma,N06.850.460.350.600.903.500\\r\\nAbnormal Involuntary Movement Scale,E01.370.600.550.162\\r\\nBlood Alcohol Content,D02.033.375.135\\r\\nSocial Communication Disorder,F03.625.374.250\\r\\nLegal Services,I01.880.604.583.482\\r\\nDefamation,I01.198.240.240\\r\\nDefamation,I01.880.735.191.051\\r\\nSlander,I01.198.240.240\\r\\nSlander,I01.880.735.191.051\\r\\nLibel,I01.198.240.240\\r\\nLibel,I01.880.735.191.051\\r\\nAnger Management Therapy,F04.754.137.087\\r\\n\"Psychology, Sports\",F04.096.628.914\\r\\nWar Exposure,I01.880.735.950.500.951\\r\\nWar Exposure,N06.850.460.350.600.903\\r\\nChildhood-Onset Fluency Disorder,F03.625.374.125\\r\\nNo-Show Patients,F01.100.150.750.500.600.750\\r\\nNo-Show Patients,F01.145.488.887.500.600.750\\r\\nNo-Show Patients,M01.643.550\\r\\nNo-Show Patients,N04.452.758.635.500\\r\\nNo-Show Patients,N05.300.150.800.500.600.750\\r\\nCellular Reprogramming Techniques,E05.200.500.380\\r\\nCellular Reprogramming Techniques,E05.242.378\\r\\nCellular Reprogramming Techniques,E05.393.085\\r\\nDirected Differentiation Techniques,E05.200.500.380\\r\\nDirected Differentiation Techniques,E05.242.378\\r\\nDirected Differentiation Techniques,E05.393.085\\r\\nDirect Cell Reprogramming Techniques,E05.200.500.380\\r\\nDirect Cell Reprogramming Techniques,E05.242.378\\r\\nDirect Cell Reprogramming Techniques,E05.393.085\\r\\nMetacognition,F02.463.188.756\\r\\nMetacognitive Awareness,F02.463.188.756\\r\\nMetacognitive Monitoring,F02.463.188.756\\r\\nMetacognitive Control,F02.463.188.756\\r\\nMetaemotion,F02.463.188.756\\r\\nMetamemory,F02.463.188.756\\r\\nPrescription Drug Overuse,E02.319.306.500.750\\r\\n\"Near Miss, Healthcare\",E02.319.529.750\\r\\n\"Near Miss, Healthcare\",N02.421.450.500.750\\r\\n\"Near Miss, Healthcare\",N02.421.450.550\\r\\n\"Near Miss, Healthcare\",N04.761.700.594\\r\\n\"Near Miss, Healthcare\",N05.700.513\\r\\nRNAi Therapeutics,E02.095.301.250\\r\\nDynamic Light Scattering,E05.196.822.325\\r\\nQuasi-Elastic Light Scattering (QELS),E05.196.822.325\\r\\n\"Time Out, Healthcare\",N04.761.700.635\\r\\n\"Time Out, Healthcare\",N05.700.739\\r\\nSurgical Time Out,N04.761.700.635\\r\\nSurgical Time Out,N05.700.739\\r\\nHealthcare Failure Mode and Effect Analysis,E05.318.740.600.800.715.500\\r\\nHealthcare Failure Mode and Effect Analysis,N04.452.871.715.400\\r\\nHealthcare Failure Mode and Effect Analysis,N05.715.360.750.625.700.690.400\\r\\nHealthcare Failure Mode and Effect Analysis,N06.850.505.715.500\\r\\nHealthcare Failure Mode and Effect Analysis,N06.850.520.830.600.800.715.500\\r\\nFailure Mode and Effect Analysis,E05.318.740.600.800.715.500\\r\\nFailure Mode and Effect Analysis,N04.452.871.715.400\\r\\nFailure Mode and Effect Analysis,N05.715.360.750.625.700.690.400\\r\\nFailure Mode and Effect Analysis,N06.850.505.715.500\\r\\nFailure Mode and Effect Analysis,N06.850.520.830.600.800.715.500\\r\\nSpirit Possession,K01.844.619.500\\r\\n\"Crew Resource Management, Healthcare\",N04.590.254\\r\\nComputer Heuristics,L01.224.050.375.095\\r\\nAtaxins,D12.776.631.069\\r\\nAtaxins,D12.776.660.075\\r\\nAlarmins,D23.035\\r\\nDermal Fillers,D27.720.102.461\\r\\nAction Spectrum,E05.196.867.826.150\\r\\nDiplomacy,F01.829.316.171\\r\\nDiplomacy,F02.463.785.373.520.500\\r\\nDiplomacy,I01.738.305\\r\\nMutation Accumulation,G05.365.590.594\\r\\nSpontaneous Mutation Accumulation,G05.365.590.594\\r\\nInternal Ribosome Entry Sites,D13.444.735.790.878.942.250\\r\\nInternal Ribosome Entry Sites,G02.111.570.080.689.687.093\\r\\nInternal Ribosome Entry Sites,G05.360.080.689.687.093\\r\\nBiological Mimicry,G16.012.750\\r\\nBiological Camouflage,G16.012.750\\r\\nSpecific Learning Disorder,F03.625.562.700\\r\\nPotentially Inappropriate Medication List,N04.761.700.615\\r\\nPotentially Inappropriate Medication List,N05.700.594\\r\\nBeers Criteria,N04.761.700.615\\r\\nBeers Criteria,N05.700.594\\r\\nSTOPP (Screening Tool of Older Persons Potentially Inappropriate Prescriptions),N04.761.700.615\\r\\nSTOPP (Screening Tool of Older Persons Potentially Inappropriate Prescriptions),N05.700.594\\r\\nMedication Appropriateness Index,N04.761.700.615\\r\\nMedication Appropriateness Index,N05.700.594\\r\\nLate Onset Disorders,C23.550.291.883\\r\\nPhakopsora pachyrhizi,B01.300.179.113\\r\\nFarmers,M01.526.390\\r\\nRanchers,M01.526.390\\r\\nCulturally Appropriate Technology,J01.897.052\\r\\nIntermediate Technology,J01.897.052\\r\\nSoft Technology,J01.897.052\\r\\nSocial Learning,F02.784.629.529.663\\r\\nFinancial Statements,N03.219.463.030.140\\r\\n\"Assets, Financial\",N03.219.463.030.140\\r\\nCash Flow Statement,N03.219.463.030.140\\r\\nBalance Sheet,N03.219.463.030.140\\r\\nExpense Statement,N03.219.463.030.140\\r\\nIncome Statement,N03.219.463.030.140\\r\\n\"Equity, Financial\",N03.219.463.030.140\\r\\n\"Liabilities, Financial\",N03.219.463.030.140\\r\\nMiners,M01.526.693\\r\\nChronopharmacokinetics,G07.690.725.249\\r\\n\"Administrative Claims, Healthcare\",N04.452.859.564.137\\r\\nChild Health,N01.400.225\\r\\nChild Well Being,N01.400.225\\r\\nInterleukin-33,D12.644.276.374.465.850\\r\\nInterleukin-33,D12.776.467.374.465.850\\r\\nInterleukin-33,D23.529.374.465.850\\r\\nS100A12 Protein,D12.776.157.125.750.875\\r\\nTelopodes,A11.284.180.900\\r\\nTelopodes,A11.329.830.750.500\\r\\nPodomers,A11.284.180.900\\r\\nPodomers,A11.329.830.750.500\\r\\nPodoms,A11.284.180.900\\r\\nPodoms,A11.329.830.750.500\\r\\nDrosophila simulans,B01.050.500.131.617.720.500.500.750.310.250.750\\r\\nOptimism,F01.100.787\\r\\nPositive Attitude,F01.100.787\\r\\nPositive Thinking,F01.100.787\\r\\nPessimism,F01.100.893\\r\\nAtaxin-1,D12.776.631.069.500\\r\\nAtaxin-1,D12.776.660.075.500\\r\\nAdolescent Health,N01.400.075\\r\\nAdolescent Well Being,N01.400.075\\r\\nAtaxin-2,D12.776.157.725.452.125\\r\\nAtaxin-2,D12.776.631.069.750\\r\\nAtaxin-2,D12.776.660.075.750\\r\\nAtaxin-2,D12.776.664.962.452.125\\r\\nAtaxin-3,D08.811.037.250\\r\\nAtaxin-3,D12.776.631.069.875\\r\\nAtaxin-3,D12.776.660.075.875\\r\\nPoint-of-Care Testing,N04.590.874.500\\r\\nBedside Testing,N04.590.874.500\\r\\nAtaxin-7,D12.776.631.069.901\\r\\nAtaxin-7,D12.776.660.075.900\\r\\nAtaxin-10,D12.776.631.069.950\\r\\nGlucagon-Like Peptide Receptors,D12.776.543.750.695.021\\r\\nGlucagon-Like Peptide Receptors,D12.776.543.750.750.360.100\\r\\nGlucagon-Like Peptide-1 Receptor,D12.776.543.750.695.021.500\\r\\nGlucagon-Like Peptide-1 Receptor,D12.776.543.750.750.360.100.500\\r\\nGlucagon-Like Peptide-2 Receptor,D12.776.543.750.695.021.600\\r\\nGlucagon-Like Peptide-2 Receptor,D12.776.543.750.750.360.100.600\\r\\nReceptor for Advanced Glycation End Products,D12.776.543.750.615\\r\\nRNA Recognition Motif Proteins,D12.776.157.725.813\\r\\nRNA Recognition Motif Proteins,D12.776.664.962.813\\r\\nELAV-Like Protein 2,D12.776.157.725.813.500.500\\r\\nELAV-Like Protein 2,D12.776.631.520.500\\r\\nELAV-Like Protein 2,D12.776.664.962.813.500.500\\r\\nELAV-Like Protein 3,D12.776.157.725.813.500.750\\r\\nELAV-Like Protein 3,D12.776.631.520.750\\r\\nELAV-Like Protein 3,D12.776.664.962.813.500.750\\r\\nELAV-Like Protein 4,D12.776.157.725.813.500.875\\r\\nELAV-Like Protein 4,D12.776.631.520.875\\r\\nELAV-Like Protein 4,D12.776.664.962.813.500.875\\r\\nELAV-Like Protein 1,D12.776.157.725.813.500.250\\r\\nELAV-Like Protein 1,D12.776.664.962.813.500.250\\r\\nWhey,A12.790.760\\r\\nWhey,G07.203.100.700.750\\r\\nWhey,G07.203.300.350.525.760\\r\\nWhey,J02.200.700.750\\r\\nWhey,J02.500.350.525.760\\r\\nWhey Proteins,A12.790.520.500\\r\\nWhey Proteins,A12.790.760.500\\r\\nWhey Proteins,D12.776.256.159.750.816\\r\\nWhey Proteins,G07.203.300.350.525.760.500\\r\\nWhey Proteins,G07.203.300.428.159.812.500\\r\\nWhey Proteins,J02.500.350.525.520.500\\r\\nWhey Proteins,J02.500.350.525.760.500\\r\\nWhey Proteins,J02.500.428.159.750.500\\r\\nHoarding Disorder,F03.080.600.250\\r\\nObsessive Hoarding,F03.080.600.250\\r\\nPoly(ADP-ribose) Polymerase Inhibitors,D27.505.519.389.739\\r\\nPoly(ADP-ribose) Polymerase Inhibitors,D27.505.954.248.692\\r\\nAutism Spectrum Disorder,F03.625.164.113\\r\\nCELF Proteins,D12.776.157.725.813.250\\r\\nCELF Proteins,D12.776.664.962.813.250\\r\\nCELF1 Protein,D12.776.157.725.813.250.500\\r\\nCELF1 Protein,D12.776.664.962.813.250.500\\r\\nIndustrial Development,I01.261.262.500\\r\\nIndustrial Development,J01.576.519\\r\\nTechnology Development,I01.261.262.500\\r\\nTechnology Development,J01.576.519\\r\\nIndustrialization,I01.261.262.500\\r\\nIndustrialization,J01.576.519\\r\\nCloud Computing,L01.224.097\\r\\nNatural Resources,G16.500.275.553\\r\\nNatural Resources,J01.728\\r\\nNatural Resources,N06.230.350\\r\\nLand Supply,G16.500.275.553\\r\\nLand Supply,J01.728\\r\\nLand Supply,N06.230.350\\r\\nGlycemic Load,G07.203.650.660.750\\r\\nGlycemic Load,J01.576.423.850.730.750.750\\r\\nGlycemic Load,N06.850.601.750.750\\r\\nAdenylyl Cyclase Inhibitors,D27.505.519.389.108\\r\\nRAW 264.7 Cells,A11.251.210.172.875\\r\\nRAW 264.7 Cells,A11.733.397.815\\r\\nAccreditation,N03.706.110.070\\r\\nAccreditation,N05.700.200.100\\r\\nClostridiales,B03.353.625\\r\\nGraphic Novel,V02.700.415\\r\\nComic Book,V02.700.415\\r\\nSouth Sudan,Z01.058.290.120.745\\r\\nMotor Disorders,F03.608\\r\\nMaternal Health,N01.400.900.500\\r\\nSeed Bank,N02.278.065.650\\r\\nGermplasm Bank,N02.278.065.650\\r\\nTrauma and Stressor Related Disorders,F03.950\\r\\nMaternal-Child Health Services,N02.421.143.130.660\\r\\nMaternal-Child Health Services,N02.421.143.620.275\\r\\nSerine-Arginine Splicing Factors,D12.776.157.725.829.500\\r\\nSerine-Arginine Splicing Factors,D12.776.664.962.829.500\\r\\nInfant Health,N01.400.388\\r\\nNewborn Health,N01.400.388\\r\\nBipolar and Related Disorders,F03.084\\r\\nGender Dysphoria,F03.835.550\\r\\nFormative Feedback,F02.784.629.529.223\\r\\nAripiprazole,D03.383.606.170\\r\\nAripiprazole,D03.633.100.810.835.122\\r\\nAbilify,D03.383.606.170\\r\\nAbilify,D03.633.100.810.835.122\\r\\nOPC 14597,D03.383.606.170\\r\\nOPC 14597,D03.633.100.810.835.122\\r\\nPrunus dulcis,B01.650.940.800.575.912.250.859.937.500.625.500\\r\\nAlmonds,B01.650.940.800.575.912.250.859.937.500.625.500\\r\\nAlbumin-Bound Paclitaxel,D02.455.426.392.368.242.888.777.500\\r\\nAlbumin-Bound Paclitaxel,D02.455.849.291.850.777.500\\r\\nAlbumin-Bound Paclitaxel,D12.776.034.073\\r\\nAbraxane,D02.455.426.392.368.242.888.777.500\\r\\nAbraxane,D02.455.849.291.850.777.500\\r\\nAbraxane,D12.776.034.073\\r\\nABI007,D02.455.426.392.368.242.888.777.500\\r\\nABI007,D02.455.849.291.850.777.500\\r\\nABI007,D12.776.034.073\\r\\nChild Protective Services,I01.409.418.500\\r\\nChild Protective Services,N03.540.400.500\\r\\nSocial Workers,M01.526.919\\r\\nPrunus africana,B01.650.940.800.575.912.250.859.937.500.625.250\\r\\nPrunus armeniaca,B01.650.940.800.575.912.250.859.937.500.625.375\\r\\nApricot,B01.650.940.800.575.912.250.859.937.500.625.375\\r\\nPrunus avium,B01.650.940.800.575.912.250.859.937.500.625.400\\r\\nPrunus serotina,B01.650.940.800.575.912.250.859.937.500.625.400\\r\\nSweet Cherries,B01.650.940.800.575.912.250.859.937.500.625.400\\r\\nPrunus cerasus,B01.650.940.800.575.912.250.859.937.500.625.400\\r\\nRefugium,G16.500.275.683\\r\\nRefugium,G16.500.819\\r\\nDistance Counseling,F02.784.176.350\\r\\nDistance Counseling,F04.408.413.437\\r\\nDistance Counseling,N02.421.143.303.175\\r\\nDistance Counseling,N02.421.461.363.437\\r\\nDistance Counseling,N04.452.758.849.550.500\\r\\nLubiprostone,D10.251.355.325.050.500\\r\\nRU 0211,D10.251.355.325.050.500\\r\\nAmitiza,D10.251.355.325.050.500\\r\\nSPI 0211,D10.251.355.325.050.500\\r\\nPrunus persica,B01.650.940.800.575.912.250.859.937.500.625.750\\r\\nPeach,B01.650.940.800.575.912.250.859.937.500.625.750\\r\\nData Anonymization,H01.770.644.205\\r\\nData Anonymization,L01.224.134.500\\r\\nData Anonymization,N03.706.437.650.124.160\\r\\nData Anonymization,N04.452.910.200.500\\r\\nDe-Identification,H01.770.644.205\\r\\nDe-Identification,L01.224.134.500\\r\\nDe-Identification,N03.706.437.650.124.160\\r\\nDe-Identification,N04.452.910.200.500\\r\\nData Masking,H01.770.644.205\\r\\nData Masking,L01.224.134.500\\r\\nData Masking,N03.706.437.650.124.160\\r\\nData Masking,N04.452.910.200.500\\r\\nPersonally Identifiable Information,I01.880.604.583.080.660\\r\\nPrunus domestica,B01.650.940.800.575.912.250.859.937.500.625.450\\r\\nPlum,B01.650.940.800.575.912.250.859.937.500.625.450\\r\\nPrunus cerasifera,B01.650.940.800.575.912.250.859.937.500.625.450\\r\\nPrunus salicina,B01.650.940.800.575.912.250.859.937.500.625.450\\r\\nDarbepoetin alfa,D12.776.395.240.150.500\\r\\nAranesp,D12.776.395.240.150.500\\r\\nKRN 321,D12.776.395.240.150.500\\r\\n\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D02.705.429.906.125\\r\\n\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D03.383.533.375\\r\\n\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D03.383.742.680.245.500.600.125\\r\\n\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D03.633.100.759.138.881.125\\r\\n\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D26.310.375\\r\\nAtripla,D02.705.429.906.125\\r\\nAtripla,D03.383.533.375\\r\\nAtripla,D03.383.742.680.245.500.600.125\\r\\nAtripla,D03.633.100.759.138.881.125\\r\\nAtripla,D26.310.375\\r\\nBevacizumab,D12.776.124.486.485.114.224.060.375\\r\\nBevacizumab,D12.776.124.790.651.114.224.060.438\\r\\nBevacizumab,D12.776.377.715.548.114.224.200.438\\r\\nMvasi,D12.776.124.486.485.114.224.060.375\\r\\nMvasi,D12.776.124.790.651.114.224.060.438\\r\\nMvasi,D12.776.377.715.548.114.224.200.438\\r\\nBevacizumab-awwb,D12.776.124.486.485.114.224.060.375\\r\\nBevacizumab-awwb,D12.776.124.790.651.114.224.060.438\\r\\nBevacizumab-awwb,D12.776.377.715.548.114.224.200.438\\r\\nAvastin,D12.776.124.486.485.114.224.060.375\\r\\nAvastin,D12.776.124.790.651.114.224.060.438\\r\\nAvastin,D12.776.377.715.548.114.224.200.438\\r\\nGiraffes,B01.050.150.900.649.313.500.380.443\\r\\nOkapis,B01.050.150.900.649.313.500.380.443\\r\\nRisedronic Acid,D02.705.429.500.872\\r\\nRisedronic Acid,D03.383.725.836\\r\\n1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate,D02.705.429.500.872\\r\\n1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate,D03.383.725.836\\r\\nAtelvia,D02.705.429.500.872\\r\\nAtelvia,D03.383.725.836\\r\\nRisedronate Sodium,D02.705.429.500.872\\r\\nRisedronate Sodium,D03.383.725.836\\r\\n2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonate,D02.705.429.500.872\\r\\n2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonate,D03.383.725.836\\r\\n\"Risedronic Acid, Monosodium Salt\",D02.705.429.500.872\\r\\n\"Risedronic Acid, Monosodium Salt\",D03.383.725.836\\r\\nActonel,D02.705.429.500.872\\r\\nActonel,D03.383.725.836\\r\\nRisedronate,D02.705.429.500.872\\r\\nRisedronate,D03.383.725.836\\r\\nBisphosphonate Risedronate Sodium,D02.705.429.500.872\\r\\nBisphosphonate Risedronate Sodium,D03.383.725.836\\r\\nFluticasone-Salmeterol Drug Combination,D02.033.100.291.057.750.500\\r\\nFluticasone-Salmeterol Drug Combination,D02.092.063.291.057.750.500\\r\\nFluticasone-Salmeterol Drug Combination,D02.092.471.683.061.750.500\\r\\nFluticasone-Salmeterol Drug Combination,D04.210.500.054.079.129.114.500\\r\\nFluticasone-Salmeterol Drug Combination,D26.310.438\\r\\n\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D02.033.100.291.057.750.500\\r\\n\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D02.092.063.291.057.750.500\\r\\n\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D02.092.471.683.061.750.500\\r\\n\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D04.210.500.054.079.129.114.500\\r\\n\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D26.310.438\\r\\nAdvair Diskus,D02.033.100.291.057.750.500\\r\\nAdvair Diskus,D02.092.063.291.057.750.500\\r\\nAdvair Diskus,D02.092.471.683.061.750.500\\r\\nAdvair Diskus,D04.210.500.054.079.129.114.500\\r\\nAdvair Diskus,D26.310.438\\r\\nSeretide,D02.033.100.291.057.750.500\\r\\nSeretide,D02.092.063.291.057.750.500\\r\\nSeretide,D02.092.471.683.061.750.500\\r\\nSeretide,D04.210.500.054.079.129.114.500\\r\\nSeretide,D26.310.438\\r\\nAdvair HFA,D02.033.100.291.057.750.500\\r\\nAdvair HFA,D02.092.063.291.057.750.500\\r\\nAdvair HFA,D02.092.471.683.061.750.500\\r\\nAdvair HFA,D04.210.500.054.079.129.114.500\\r\\nAdvair HFA,D26.310.438\\r\\nAdvair,D02.033.100.291.057.750.500\\r\\nAdvair,D02.092.063.291.057.750.500\\r\\nAdvair,D02.092.471.683.061.750.500\\r\\nAdvair,D04.210.500.054.079.129.114.500\\r\\nAdvair,D26.310.438\\r\\nFluticasone,D04.210.500.054.079.129.114\\r\\nFlonase,D04.210.500.054.079.129.114\\r\\nFlovent HFA,D04.210.500.054.079.129.114\\r\\nCutivate,D04.210.500.054.079.129.114\\r\\nFluticasone Propionate,D04.210.500.054.079.129.114\\r\\nFlixonase,D04.210.500.054.079.129.114\\r\\nFlixotide,D04.210.500.054.079.129.114\\r\\nFlovent,D04.210.500.054.079.129.114\\r\\nSalmeterol Xinafoate,D02.033.100.291.057.750\\r\\nSalmeterol Xinafoate,D02.092.063.291.057.750\\r\\nSalmeterol Xinafoate,D02.092.471.683.061.750\\r\\nSalmeterol,D02.033.100.291.057.750\\r\\nSalmeterol,D02.092.063.291.057.750\\r\\nSalmeterol,D02.092.471.683.061.750\\r\\nSerevent,D02.033.100.291.057.750\\r\\nSerevent,D02.092.063.291.057.750\\r\\nSerevent,D02.092.471.683.061.750\\r\\n\"Parks, Recreational\",J03.925.680\\r\\nNational Parks,J03.925.680\\r\\nCommunity Parks,J03.925.680\\r\\nGreen Space,J03.925.680\\r\\nUrban Parks,J03.925.680\\r\\nWarfare and Armed Conflicts,I01.880.735.950\\r\\nArmed Conflicts,I01.880.735.950.250\\r\\nWars,I01.880.735.950.250\\r\\nEverolimus,D02.540.505.760.500\\r\\nRAD 001,D02.540.505.760.500\\r\\nAfinitor,D02.540.505.760.500\\r\\nCertican,D02.540.505.760.500\\r\\n\"Aspirin, Dipyridamole Drug Combination\",D02.455.426.559.389.657.410.595.176.500\\r\\n\"Aspirin, Dipyridamole Drug Combination\",D03.383.742.175.500\\r\\n\"Aspirin, Dipyridamole Drug Combination\",D26.310.125\\r\\nTX 3301,D02.455.426.559.389.657.410.595.176.500\\r\\nTX 3301,D03.383.742.175.500\\r\\nTX 3301,D26.310.125\\r\\nExtended-Release Dipyridamole-Aspirin,D02.455.426.559.389.657.410.595.176.500\\r\\nExtended-Release Dipyridamole-Aspirin,D03.383.742.175.500\\r\\nExtended-Release Dipyridamole-Aspirin,D26.310.125\\r\\nAsasantin,D02.455.426.559.389.657.410.595.176.500\\r\\nAsasantin,D03.383.742.175.500\\r\\nAsasantin,D26.310.125\\r\\nAsasantin Retard,D02.455.426.559.389.657.410.595.176.500\\r\\nAsasantin Retard,D03.383.742.175.500\\r\\nAsasantin Retard,D26.310.125\\r\\nAggrenox,D02.455.426.559.389.657.410.595.176.500\\r\\nAggrenox,D03.383.742.175.500\\r\\nAggrenox,D26.310.125\\r\\nSelf-Control,F01.145.813.595\\r\\nSaline Waters,G16.500.275.725\\r\\nBrackish Water,G16.500.275.725\\r\\nCompassion Fatigue,C23.888.369.500.500\\r\\nCompassion Fatigue,F01.145.126.937.500\\r\\nCompassion Fatigue,F01.145.126.990.734.500\\r\\nCompassion Fatigue,F02.830.900.666.750\\r\\nPlantaginaceae,B01.650.940.800.575.912.250.583.700\\r\\nStemodia,B01.650.940.800.575.912.250.583.700\\r\\nGlobularia,B01.650.940.800.575.912.250.583.700\\r\\nLamiales,B01.650.940.800.575.912.250.583\\r\\nProboscidea Plant,B01.650.940.800.575.912.250.583\\r\\nClinical Study,V03.175\\r\\nSurgical Clearance,E01.370.505\\r\\nPemetrexed,D03.633.100.759.758.399.454.650\\r\\nPemetrexed,D12.125.067.625.525\\r\\nPemetrexed,D12.125.119.409.525\\r\\nPemetrexed Disodium,D03.633.100.759.758.399.454.650\\r\\nPemetrexed Disodium,D12.125.067.625.525\\r\\nPemetrexed Disodium,D12.125.119.409.525\\r\\nLY 231514,D03.633.100.759.758.399.454.650\\r\\nLY 231514,D12.125.067.625.525\\r\\nLY 231514,D12.125.119.409.525\\r\\nAlimta,D03.633.100.759.758.399.454.650\\r\\nAlimta,D12.125.067.625.525\\r\\nAlimta,D12.125.119.409.525\\r\\nBrimonidine Tartrate,D03.633.100.857.070\\r\\n\"Brimonidine Tartrate (1:1), (S-(R*,R*))-Isomer\",D03.633.100.857.070\\r\\nBrimonidine Purite,D03.633.100.857.070\\r\\nAGN 190342,D03.633.100.857.070\\r\\nSanrosa,D03.633.100.857.070\\r\\nAlphagan,D03.633.100.857.070\\r\\nBrimonidine,D03.633.100.857.070\\r\\nAlphagan P,D03.633.100.857.070\\r\\n\"UK 14,304\",D03.633.100.857.070\\r\\nRatio-Brimonidine,D03.633.100.857.070\\r\\n\"UK 14,304-18\",D03.633.100.857.070\\r\\nUK 14308,D03.633.100.857.070\\r\\n\"Brimonidine Tartrate, (R-(R*,R*))-Isomer\",D03.633.100.857.070\\r\\nBrimonidine Tartrate (1:1),D03.633.100.857.070\\r\\nMirvaso,D03.633.100.857.070\\r\\nClinical Studies as Topic,E05.318.372.250\\r\\nClinical Studies as Topic,N05.715.360.330.250\\r\\nClinical Studies as Topic,N06.850.520.450.250\\r\\nBeijing,Z01.252.474.164.225\\r\\nBeijing,Z01.433.114\\r\\nAfrican Union,I01.615.500.125\\r\\nAfrican Union,N03.540.089\\r\\nFirmicutes,B03.353\\r\\nDutasteride,D04.210.500.925.100.125\\r\\nAvodart,D04.210.500.925.100.125\\r\\nGG 745,D04.210.500.925.100.125\\r\\nGI198745,D04.210.500.925.100.125\\r\\nCalceolariaceae,B01.650.940.800.575.912.250.583.190\\r\\nJovellana,B01.650.940.800.575.912.250.583.190\\r\\nCalceolaria,B01.650.940.800.575.912.250.583.190\\r\\nPorodittia,B01.650.940.800.575.912.250.583.190\\r\\nInterferon beta-1a,D12.644.276.374.440.890.275.500\\r\\nInterferon beta-1a,D12.776.467.374.440.890.275.500\\r\\nInterferon beta-1a,D23.529.374.440.890.275.500\\r\\nAvonex Pen,D12.644.276.374.440.890.275.500\\r\\nAvonex Pen,D12.776.467.374.440.890.275.500\\r\\nAvonex Pen,D23.529.374.440.890.275.500\\r\\nRebif,D12.644.276.374.440.890.275.500\\r\\nRebif,D12.776.467.374.440.890.275.500\\r\\nRebif,D23.529.374.440.890.275.500\\r\\nAvonex,D12.644.276.374.440.890.275.500\\r\\nAvonex,D12.776.467.374.440.890.275.500\\r\\nAvonex,D23.529.374.440.890.275.500\\r\\nOlmesartan Medoxomil,D03.383.129.308.674\\r\\nOlmesartan Medoxomil,D03.383.129.617.584\\r\\nBenicar,D03.383.129.308.674\\r\\nBenicar,D03.383.129.617.584\\r\\nOlmetec,D03.383.129.308.674\\r\\nOlmetec,D03.383.129.617.584\\r\\nCS 866,D03.383.129.308.674\\r\\nCS 866,D03.383.129.617.584\\r\\nVotum,D03.383.129.308.674\\r\\nVotum,D03.383.129.617.584\\r\\n\"Amlodipine Besylate, Olmesartan Medoxomil Drug Combination\",D03.383.129.308.674.500\\r\\n\"Amlodipine Besylate, Olmesartan Medoxomil Drug Combination\",D03.383.129.617.584.500\\r\\n\"Amlodipine Besylate, Olmesartan Medoxomil Drug Combination\",D03.383.725.203.065.500\\r\\n\"Amlodipine Besylate, Olmesartan Medoxomil Drug Combination\",D26.310.063\\r\\nAzor,D03.383.129.308.674.500\\r\\nAzor,D03.383.129.617.584.500\\r\\nAzor,D03.383.725.203.065.500\\r\\nAzor,D26.310.063\\r\\nInterferon beta-1b,D12.644.276.374.440.890.275.750\\r\\nInterferon beta-1b,D12.776.467.374.440.890.275.750\\r\\nInterferon beta-1b,D23.529.374.440.890.275.750\\r\\nBetaseron,D12.644.276.374.440.890.275.750\\r\\nBetaseron,D12.776.467.374.440.890.275.750\\r\\nBetaseron,D23.529.374.440.890.275.750\\r\\nExtavia,D12.644.276.374.440.890.275.750\\r\\nExtavia,D12.776.467.374.440.890.275.750\\r\\nExtavia,D23.529.374.440.890.275.750\\r\\nBetaferon,D12.644.276.374.440.890.275.750\\r\\nBetaferon,D12.776.467.374.440.890.275.750\\r\\nBetaferon,D23.529.374.440.890.275.750\\r\\nNebivolol,D02.033.100.291.491\\r\\nNebivolol,D02.092.063.291.503\\r\\nNebivolol,D03.383.663.283.755\\r\\nNebivolol,D03.633.100.150.755\\r\\nBystolic,D02.033.100.291.491\\r\\nBystolic,D02.092.063.291.503\\r\\nBystolic,D03.383.663.283.755\\r\\nBystolic,D03.633.100.150.755\\r\\nNebilet,D02.033.100.291.491\\r\\nNebilet,D02.092.063.291.503\\r\\nNebilet,D03.383.663.283.755\\r\\nNebilet,D03.633.100.150.755\\r\\nSilostar,D02.033.100.291.491\\r\\nSilostar,D02.092.063.291.503\\r\\nSilostar,D03.383.663.283.755\\r\\nSilostar,D03.633.100.150.755\\r\\nNebivolol Hydrochloride,D02.033.100.291.491\\r\\nNebivolol Hydrochloride,D02.092.063.291.503\\r\\nNebivolol Hydrochloride,D03.383.663.283.755\\r\\nNebivolol Hydrochloride,D03.633.100.150.755\\r\\nR 67555,D02.033.100.291.491\\r\\nR 67555,D02.092.063.291.503\\r\\nR 67555,D03.383.663.283.755\\r\\nR 67555,D03.633.100.150.755\\r\\nLobivon,D02.033.100.291.491\\r\\nLobivon,D02.092.063.291.503\\r\\nLobivon,D03.383.663.283.755\\r\\nLobivon,D03.633.100.150.755\\r\\nCelecoxib,D02.065.884.247\\r\\nCelecoxib,D02.886.590.700.247\\r\\nCelecoxib,D03.383.129.539.160\\r\\nCelebrex,D02.065.884.247\\r\\nCelebrex,D02.886.590.700.247\\r\\nCelebrex,D03.383.129.539.160\\r\\nSC 58635,D02.065.884.247\\r\\nSC 58635,D02.886.590.700.247\\r\\nSC 58635,D03.383.129.539.160\\r\\nVarenicline,D03.633.100.079.900\\r\\nVarenicline,D03.633.100.857.942\\r\\nChantix,D03.633.100.079.900\\r\\nChantix,D03.633.100.857.942\\r\\nVarenicline Tartrate,D03.633.100.079.900\\r\\nVarenicline Tartrate,D03.633.100.857.942\\r\\nChampix,D03.633.100.079.900\\r\\nChampix,D03.633.100.857.942\\r\\nTadalafil,D03.383.725.150.500\\r\\nTadalafil,D03.633.100.473.155.500\\r\\nTadalafil,D03.633.300.154.672\\r\\nIC351,D03.383.725.150.500\\r\\nIC351,D03.633.100.473.155.500\\r\\nIC351,D03.633.300.154.672\\r\\nCialis,D03.383.725.150.500\\r\\nCialis,D03.633.100.473.155.500\\r\\nCialis,D03.633.300.154.672\\r\\nCertolizumab Pegol,D05.750.741.125\\r\\nCertolizumab Pegol,D12.644.541.500.650.250\\r\\nCertolizumab Pegol,D12.776.124.486.485.114.224.060.500\\r\\nCertolizumab Pegol,D12.776.124.486.485.680.650.250\\r\\nCertolizumab Pegol,D12.776.124.790.651.114.224.060.500\\r\\nCertolizumab Pegol,D12.776.124.790.651.680.650.250\\r\\nCertolizumab Pegol,D12.776.377.715.548.114.224.200.500\\r\\nCertolizumab Pegol,D12.776.377.715.548.680.650.250\\r\\nCimzia,D05.750.741.125\\r\\nCimzia,D12.644.541.500.650.250\\r\\nCimzia,D12.776.124.486.485.114.224.060.500\\r\\nCimzia,D12.776.124.486.485.680.650.250\\r\\nCimzia,D12.776.124.790.651.114.224.060.500\\r\\nCimzia,D12.776.124.790.651.680.650.250\\r\\nCimzia,D12.776.377.715.548.114.224.200.500\\r\\nCimzia,D12.776.377.715.548.680.650.250\\r\\nCDP870,D05.750.741.125\\r\\nCDP870,D12.644.541.500.650.250\\r\\nCDP870,D12.776.124.486.485.114.224.060.500\\r\\nCDP870,D12.776.124.486.485.680.650.250\\r\\nCDP870,D12.776.124.790.651.114.224.060.500\\r\\nCDP870,D12.776.124.790.651.680.650.250\\r\\nCDP870,D12.776.377.715.548.114.224.200.500\\r\\nCDP870,D12.776.377.715.548.680.650.250\\r\\n\"Censorship, Research\",I01.880.604.238\\r\\n\"Censorship, Research\",K01.752.566.479.173.200\\r\\n\"Censorship, Research\",N05.350.670.250\\r\\nData Accuracy,E05.318.308.028\\r\\nData Accuracy,E05.318.370.725.250\\r\\nData Accuracy,L01.399.250.202\\r\\nData Accuracy,N05.715.360.300.202\\r\\nData Accuracy,N05.715.360.325.685.250\\r\\nData Quality,E05.318.308.028\\r\\nData Quality,E05.318.370.725.250\\r\\nData Quality,L01.399.250.202\\r\\nData Quality,N05.715.360.300.202\\r\\nData Quality,N05.715.360.325.685.250\\r\\n\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.033.100.624.915.500\\r\\n\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.033.755.624.915.500\\r\\n\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.092.063.624.915.500\\r\\n\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.886.675.867.768.500\\r\\n\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D03.383.129.708.867.768.500\\r\\n\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D03.633.100.857.070.500\\r\\n\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D26.310.312\\r\\nCombigan,D02.033.100.624.915.500\\r\\nCombigan,D02.033.755.624.915.500\\r\\nCombigan,D02.092.063.624.915.500\\r\\nCombigan,D02.886.675.867.768.500\\r\\nCombigan,D03.383.129.708.867.768.500\\r\\nCombigan,D03.633.100.857.070.500\\r\\nCombigan,D26.310.312\\r\\n\"Albuterol, Ipratropium Drug Combination\",D02.033.100.291.057.125\\r\\n\"Albuterol, Ipratropium Drug Combination\",D02.092.063.291.057.125\\r\\n\"Albuterol, Ipratropium Drug Combination\",D02.092.471.683.061.125\\r\\n\"Albuterol, Ipratropium Drug Combination\",D02.145.074.722.229.400.500\\r\\n\"Albuterol, Ipratropium Drug Combination\",D03.132.760.180.572.400.500\\r\\n\"Albuterol, Ipratropium Drug Combination\",D03.132.889.180.648.400.500\\r\\n\"Albuterol, Ipratropium Drug Combination\",D03.605.084.500.722.229.400.500\\r\\n\"Albuterol, Ipratropium Drug Combination\",D03.605.869.229.400.500\\r\\n\"Albuterol, Ipratropium Drug Combination\",D26.310.344\\r\\nCombivent Respimat,D02.033.100.291.057.125\\r\\nCombivent Respimat,D02.092.063.291.057.125\\r\\nCombivent Respimat,D02.092.471.683.061.125\\r\\nCombivent Respimat,D02.145.074.722.229.400.500\\r\\nCombivent Respimat,D03.132.760.180.572.400.500\\r\\nCombivent Respimat,D03.132.889.180.648.400.500\\r\\nCombivent Respimat,D03.605.084.500.722.229.400.500\\r\\nCombivent Respimat,D03.605.869.229.400.500\\r\\nCombivent Respimat,D26.310.344\\r\\nDey Combination,D02.033.100.291.057.125\\r\\nDey Combination,D02.092.063.291.057.125\\r\\nDey Combination,D02.092.471.683.061.125\\r\\nDey Combination,D02.145.074.722.229.400.500\\r\\nDey Combination,D03.132.760.180.572.400.500\\r\\nDey Combination,D03.132.889.180.648.400.500\\r\\nDey Combination,D03.605.084.500.722.229.400.500\\r\\nDey Combination,D03.605.869.229.400.500\\r\\nDey Combination,D26.310.344\\r\\nCombivent,D02.033.100.291.057.125\\r\\nCombivent,D02.092.063.291.057.125\\r\\nCombivent,D02.092.471.683.061.125\\r\\nCombivent,D02.145.074.722.229.400.500\\r\\nCombivent,D03.132.760.180.572.400.500\\r\\nCombivent,D03.132.889.180.648.400.500\\r\\nCombivent,D03.605.084.500.722.229.400.500\\r\\nCombivent,D03.605.869.229.400.500\\r\\nCombivent,D26.310.344\\r\\nDual Use Research,H01.770.644.217\\r\\nProfessionalism,K01.752.566.479.171.566\\r\\nProfessionalism,N05.350.340.581\\r\\nMedical Professionalism,K01.752.566.479.171.566\\r\\nMedical Professionalism,N05.350.340.581\\r\\nProfessionalism Education,K01.752.566.479.171.566\\r\\nProfessionalism Education,N05.350.340.581\\r\\nSurgical Professionalism,K01.752.566.479.171.566\\r\\nSurgical Professionalism,N05.350.340.581\\r\\nGenetic Background,G05.346\\r\\nSelective Breeding,E05.820.150.760\\r\\nSelective Breeding,G05.090.701\\r\\nLegendary Creatures,I01.076.201.450.515.500\\r\\nWerewolves,I01.076.201.450.515.500\\r\\nUnicorns,I01.076.201.450.515.500\\r\\n\"Yeti, Himalayan\",I01.076.201.450.515.500\\r\\nVampires,I01.076.201.450.515.500\\r\\nMermaids,I01.076.201.450.515.500\\r\\nMometasone Furoate,D04.210.500.745.432.719.526\\r\\nNasonex,D04.210.500.745.432.719.526\\r\\nMometasone Furoate Monohydrate,D04.210.500.745.432.719.526\\r\\nAsmanex Twisthaler,D04.210.500.745.432.719.526\\r\\nAsmanex,D04.210.500.745.432.719.526\\r\\nRinelon,D04.210.500.745.432.719.526\\r\\nElocon,D04.210.500.745.432.719.526\\r\\nSch 32088,D04.210.500.745.432.719.526\\r\\nMometasone,D04.210.500.745.432.719.526\\r\\nFallopia multiflora,B01.650.940.800.575.912.250.825.359.590\\r\\nSildenafil Citrate,D02.065.884.675\\r\\nSildenafil Citrate,D02.886.590.700.675\\r\\nSildenafil Citrate,D03.383.606.854\\r\\nSildenafil Citrate,D03.633.100.759.824\\r\\nNCX-911,D02.065.884.675\\r\\nNCX-911,D02.886.590.700.675\\r\\nNCX-911,D03.383.606.854\\r\\nNCX-911,D03.633.100.759.824\\r\\nRevatio,D02.065.884.675\\r\\nRevatio,D02.886.590.700.675\\r\\nRevatio,D03.383.606.854\\r\\nRevatio,D03.633.100.759.824\\r\\nSildenafil,D02.065.884.675\\r\\nSildenafil,D02.886.590.700.675\\r\\nSildenafil,D03.383.606.854\\r\\nSildenafil,D03.633.100.759.824\\r\\nUK 92480-10,D02.065.884.675\\r\\nUK 92480-10,D02.886.590.700.675\\r\\nUK 92480-10,D03.383.606.854\\r\\nUK 92480-10,D03.633.100.759.824\\r\\nHomosildenafil,D02.065.884.675\\r\\nHomosildenafil,D02.886.590.700.675\\r\\nHomosildenafil,D03.383.606.854\\r\\nHomosildenafil,D03.633.100.759.824\\r\\nHydroxyhomosildenafil,D02.065.884.675\\r\\nHydroxyhomosildenafil,D02.886.590.700.675\\r\\nHydroxyhomosildenafil,D03.383.606.854\\r\\nHydroxyhomosildenafil,D03.633.100.759.824\\r\\nViagra,D02.065.884.675\\r\\nViagra,D02.886.590.700.675\\r\\nViagra,D03.383.606.854\\r\\nViagra,D03.633.100.759.824\\r\\nAcetildenafil,D02.065.884.675\\r\\nAcetildenafil,D02.886.590.700.675\\r\\nAcetildenafil,D03.383.606.854\\r\\nAcetildenafil,D03.633.100.759.824\\r\\nSildenafil Lactate,D02.065.884.675\\r\\nSildenafil Lactate,D02.886.590.700.675\\r\\nSildenafil Lactate,D03.383.606.854\\r\\nSildenafil Lactate,D03.633.100.759.824\\r\\nSildenafil Nitrate,D02.065.884.675\\r\\nSildenafil Nitrate,D02.886.590.700.675\\r\\nSildenafil Nitrate,D03.383.606.854\\r\\nSildenafil Nitrate,D03.633.100.759.824\\r\\nDesmethyl Sildenafil,D02.065.884.675\\r\\nDesmethyl Sildenafil,D02.886.590.700.675\\r\\nDesmethyl Sildenafil,D03.383.606.854\\r\\nDesmethyl Sildenafil,D03.633.100.759.824\\r\\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D02.626.809.500\\r\\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D02.705.429.906.500\\r\\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D03.383.742.680.245.500.600.500\\r\\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D03.383.742.755.500\\r\\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D03.633.100.759.138.881.500\\r\\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D26.310.407\\r\\nComplera,D02.626.809.500\\r\\nComplera,D02.705.429.906.500\\r\\nComplera,D03.383.742.680.245.500.600.500\\r\\nComplera,D03.383.742.755.500\\r\\nComplera,D03.633.100.759.138.881.500\\r\\nComplera,D26.310.407\\r\\nEmtricitabine,D03.383.742.680.245.500.600\\r\\nEmtricitabine,D13.570.230.329.525\\r\\nEmtricitabine,D13.570.685.245.500.600\\r\\nCoviracil,D03.383.742.680.245.500.600\\r\\nCoviracil,D13.570.230.329.525\\r\\nCoviracil,D13.570.685.245.500.600\\r\\nEmtriva,D03.383.742.680.245.500.600\\r\\nEmtriva,D13.570.230.329.525\\r\\nEmtriva,D13.570.685.245.500.600\\r\\nRilpivirine,D02.626.809\\r\\nRilpivirine,D03.383.742.755\\r\\nRilpivirine Hydrochloride,D02.626.809\\r\\nRilpivirine Hydrochloride,D03.383.742.755\\r\\nR278474,D02.626.809\\r\\nR278474,D03.383.742.755\\r\\nTMC 278,D02.626.809\\r\\nTMC 278,D03.383.742.755\\r\\nTenofovir,D02.705.429.906\\r\\nTenofovir,D03.633.100.759.138.881\\r\\n\"9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer\",D02.705.429.906\\r\\n\"9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer\",D03.633.100.759.138.881\\r\\n\"9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer\",D02.705.429.906\\r\\n\"9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer\",D03.633.100.759.138.881\\r\\nTenofovir Disoproxil Fumarate,D02.705.429.906\\r\\nTenofovir Disoproxil Fumarate,D03.633.100.759.138.881\\r\\nTenofovir Disoproxil,D02.705.429.906\\r\\nTenofovir Disoproxil,D03.633.100.759.138.881\\r\\n\"9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098\",D02.705.429.906\\r\\n\"9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098\",D03.633.100.759.138.881\\r\\nViread,D02.705.429.906\\r\\nViread,D03.633.100.759.138.881\\r\\nGlatiramer Acetate,D12.644.219\\r\\nCopaxone,D12.644.219\\r\\nGlatiramer,D12.644.219\\r\\nTV 5010,D12.644.219\\r\\nRosuvastatin Calcium,D02.065.884.650\\r\\nRosuvastatin Calcium,D02.455.526.510.432.500\\r\\nRosuvastatin Calcium,D02.886.590.700.650\\r\\nRosuvastatin Calcium,D03.383.742.775\\r\\nCrestor,D02.065.884.650\\r\\nCrestor,D02.455.526.510.432.500\\r\\nCrestor,D02.886.590.700.650\\r\\nCrestor,D03.383.742.775\\r\\nRosuvastatin,D02.065.884.650\\r\\nRosuvastatin,D02.455.526.510.432.500\\r\\nRosuvastatin,D02.886.590.700.650\\r\\nRosuvastatin,D03.383.742.775\\r\\nZD4522,D02.065.884.650\\r\\nZD4522,D02.455.526.510.432.500\\r\\nZD4522,D02.886.590.700.650\\r\\nZD4522,D03.383.742.775\\r\\nDuloxetine Hydrochloride,D02.886.778.260\\r\\nDuloxetine Hydrochloride,D03.383.903.260\\r\\nLY 248686,D02.886.778.260\\r\\nLY 248686,D03.383.903.260\\r\\n\"Duloxetine Ethanedioate (1:1), (+-)-isomer - T353987\",D02.886.778.260\\r\\n\"Duloxetine Ethanedioate (1:1), (+-)-isomer - T353987\",D03.383.903.260\\r\\nLY 227942,D02.886.778.260\\r\\nLY 227942,D03.383.903.260\\r\\nDuloxetine,D02.886.778.260\\r\\nDuloxetine,D03.383.903.260\\r\\n\"Duloxetine, (+)-isomer\",D02.886.778.260\\r\\n\"Duloxetine, (+)-isomer\",D03.383.903.260\\r\\nCymbalta,D02.886.778.260\\r\\nCymbalta,D03.383.903.260\\r\\nTolterodine Tartrate,D02.033.100.624.706.750\\r\\nTolterodine Tartrate,D02.033.755.624.706.750\\r\\nTolterodine Tartrate,D02.092.063.624.706.800\\r\\nTolterodine Tartrate,D02.455.426.559.389.115.900\\r\\nTolterodine Tartrate,D02.455.426.559.389.657.239.756\\r\\nTolterodine,D02.033.100.624.706.750\\r\\nTolterodine,D02.033.755.624.706.750\\r\\nTolterodine,D02.092.063.624.706.800\\r\\nTolterodine,D02.455.426.559.389.115.900\\r\\nTolterodine,D02.455.426.559.389.657.239.756\\r\\nDetrol,D02.033.100.624.706.750\\r\\nDetrol,D02.033.755.624.706.750\\r\\nDetrol,D02.092.063.624.706.800\\r\\nDetrol,D02.455.426.559.389.115.900\\r\\nDetrol,D02.455.426.559.389.657.239.756\\r\\nDetrol LA,D02.033.100.624.706.750\\r\\nDetrol LA,D02.033.755.624.706.750\\r\\nDetrol LA,D02.092.063.624.706.800\\r\\nDetrol LA,D02.455.426.559.389.115.900\\r\\nDetrol LA,D02.455.426.559.389.657.239.756\\r\\nUrotrol,D02.033.100.624.706.750\\r\\nUrotrol,D02.033.755.624.706.750\\r\\nUrotrol,D02.092.063.624.706.800\\r\\nUrotrol,D02.455.426.559.389.115.900\\r\\nUrotrol,D02.455.426.559.389.657.239.756\\r\\nPHA-686464B,D02.033.100.624.706.750\\r\\nPHA-686464B,D02.033.755.624.706.750\\r\\nPHA-686464B,D02.092.063.624.706.800\\r\\nPHA-686464B,D02.455.426.559.389.115.900\\r\\nPHA-686464B,D02.455.426.559.389.657.239.756\\r\\nDetrusitol,D02.033.100.624.706.750\\r\\nDetrusitol,D02.033.755.624.706.750\\r\\nDetrusitol,D02.092.063.624.706.800\\r\\nDetrusitol,D02.455.426.559.389.115.900\\r\\nDetrusitol,D02.455.426.559.389.657.239.756\\r\\nUnidet,D02.033.100.624.706.750\\r\\nUnidet,D02.033.755.624.706.750\\r\\nUnidet,D02.092.063.624.706.800\\r\\nUnidet,D02.455.426.559.389.115.900\\r\\nUnidet,D02.455.426.559.389.657.239.756\\r\\nValsartan,D03.383.129.617.850\\r\\nValsartan,D12.125.070.950.550\\r\\nValsartan,D12.125.142.930.500\\r\\nDiovan,D03.383.129.617.850\\r\\nDiovan,D12.125.070.950.550\\r\\nDiovan,D12.125.142.930.500\\r\\nKalpress,D03.383.129.617.850\\r\\nKalpress,D12.125.070.950.550\\r\\nKalpress,D12.125.142.930.500\\r\\nTareg,D03.383.129.617.850\\r\\nTareg,D12.125.070.950.550\\r\\nTareg,D12.125.142.930.500\\r\\nNisis,D03.383.129.617.850\\r\\nNisis,D12.125.070.950.550\\r\\nNisis,D12.125.142.930.500\\r\\nProvas,D03.383.129.617.850\\r\\nProvas,D12.125.070.950.550\\r\\nProvas,D12.125.142.930.500\\r\\nVals,D03.383.129.617.850\\r\\nVals,D12.125.070.950.550\\r\\nVals,D12.125.142.930.500\\r\\nCGP 48933,D03.383.129.617.850\\r\\nCGP 48933,D12.125.070.950.550\\r\\nCGP 48933,D12.125.142.930.500\\r\\nMiten,D03.383.129.617.850\\r\\nMiten,D12.125.070.950.550\\r\\nMiten,D12.125.142.930.500\\r\\nOnonis,B01.650.940.800.575.912.250.401.604\\r\\n\"Mometasone Furoate, Formoterol Fumarate Drug Combination\",D02.033.100.291.425.500\\r\\n\"Mometasone Furoate, Formoterol Fumarate Drug Combination\",D02.092.063.291.425.500\\r\\n\"Mometasone Furoate, Formoterol Fumarate Drug Combination\",D04.210.500.745.432.719.526.500\\r\\n\"Mometasone Furoate, Formoterol Fumarate Drug Combination\",D26.310.469\\r\\nDulera,D02.033.100.291.425.500\\r\\nDulera,D02.092.063.291.425.500\\r\\nDulera,D04.210.500.745.432.719.526.500\\r\\nDulera,D26.310.469\\r\\nZenhale,D02.033.100.291.425.500\\r\\nZenhale,D02.092.063.291.425.500\\r\\nZenhale,D04.210.500.745.432.719.526.500\\r\\nZenhale,D26.310.469\\r\\nFormoterol Fumarate,D02.033.100.291.425\\r\\nFormoterol Fumarate,D02.092.063.291.425\\r\\nBD 40A,D02.033.100.291.425\\r\\nBD 40A,D02.092.063.291.425\\r\\nFormoterol,D02.033.100.291.425\\r\\nFormoterol,D02.092.063.291.425\\r\\nOxis,D02.033.100.291.425\\r\\nOxis,D02.092.063.291.425\\r\\nArformoterol,D02.033.100.291.425\\r\\nArformoterol,D02.092.063.291.425\\r\\nForadil,D02.033.100.291.425\\r\\nForadil,D02.092.063.291.425\\r\\nSerotonin and Noradrenaline Reuptake Inhibitors,D27.505.519.562.437.693\\r\\nSerotonin and Noradrenaline Reuptake Inhibitors,D27.505.519.625.600.693\\r\\nSerotonin and Noradrenaline Reuptake Inhibitors,D27.505.696.577.600.693\\r\\n\"Sleep Aids, Pharmaceutical\",D27.505.696.277.350.500\\r\\n\"Sleep Aids, Pharmaceutical\",D27.505.954.427.210.350.500\\r\\nSleeping Pills,D27.505.696.277.350.500\\r\\nSleeping Pills,D27.505.954.427.210.350.500\\r\\nOrexin Receptor Antagonists,D27.505.519.625.663\\r\\nOrexin Receptor Antagonists,D27.505.696.277.350.500.500\\r\\nOrexin Receptor Antagonists,D27.505.696.577.663\\r\\nOrexin Receptor Antagonists,D27.505.954.427.210.350.500.500\\r\\nDual Orexin Receptor Antagonists,D27.505.519.625.663\\r\\nDual Orexin Receptor Antagonists,D27.505.696.277.350.500.500\\r\\nDual Orexin Receptor Antagonists,D27.505.696.577.663\\r\\nDual Orexin Receptor Antagonists,D27.505.954.427.210.350.500.500\\r\\nOrexins,D12.644.400.360\\r\\nOrexins,D12.776.631.650.363\\r\\nOrexin-B,D12.644.400.360\\r\\nOrexin-B,D12.776.631.650.363\\r\\nOrexin-A,D12.644.400.360\\r\\nOrexin-A,D12.776.631.650.363\\r\\nHoodia,B01.650.940.800.575.912.250.456.500.389\\r\\nHoodia gordonii,B01.650.940.800.575.912.250.456.500.389\\r\\nPrasugrel Hydrochloride,D02.886.778.600\\r\\nPrasugrel Hydrochloride,D03.383.606.800\\r\\nPrasugrel Hydrochloride,D03.383.903.600\\r\\nCS 747,D02.886.778.600\\r\\nCS 747,D03.383.606.800\\r\\nCS 747,D03.383.903.600\\r\\nPrasugrel,D02.886.778.600\\r\\nPrasugrel,D03.383.606.800\\r\\nPrasugrel,D03.383.903.600\\r\\nEfient,D02.886.778.600\\r\\nEfient,D03.383.606.800\\r\\nEfient,D03.383.903.600\\r\\nEffient,D02.886.778.600\\r\\nEffient,D03.383.606.800\\r\\nEffient,D03.383.903.600\\r\\nLY 640315,D02.886.778.600\\r\\nLY 640315,D03.383.606.800\\r\\nLY 640315,D03.383.903.600\\r\\nEtanercept,D12.644.541.500.697.624\\r\\nEtanercept,D12.776.124.486.485.538.500.624\\r\\nEtanercept,D12.776.124.486.485.680.697.624\\r\\nEtanercept,D12.776.124.790.651.538.500.624\\r\\nEtanercept,D12.776.124.790.651.680.660.624\\r\\nEtanercept,D12.776.377.715.548.538.500.624\\r\\nEtanercept,D12.776.377.715.548.680.660.624\\r\\nEtanercept,D12.776.543.750.705.852.760.232\\r\\nTNFR-Fc Fusion Protein,D12.644.541.500.697.624\\r\\nTNFR-Fc Fusion Protein,D12.776.124.486.485.538.500.624\\r\\nTNFR-Fc Fusion Protein,D12.776.124.486.485.680.697.624\\r\\nTNFR-Fc Fusion Protein,D12.776.124.790.651.538.500.624\\r\\nTNFR-Fc Fusion Protein,D12.776.124.790.651.680.660.624\\r\\nTNFR-Fc Fusion Protein,D12.776.377.715.548.538.500.624\\r\\nTNFR-Fc Fusion Protein,D12.776.377.715.548.680.660.624\\r\\nTNFR-Fc Fusion Protein,D12.776.543.750.705.852.760.232\\r\\nEtanercept-szzs,D12.644.541.500.697.624\\r\\nEtanercept-szzs,D12.776.124.486.485.538.500.624\\r\\nEtanercept-szzs,D12.776.124.486.485.680.697.624\\r\\nEtanercept-szzs,D12.776.124.790.651.538.500.624\\r\\nEtanercept-szzs,D12.776.124.790.651.680.660.624\\r\\nEtanercept-szzs,D12.776.377.715.548.538.500.624\\r\\nEtanercept-szzs,D12.776.377.715.548.680.660.624\\r\\nEtanercept-szzs,D12.776.543.750.705.852.760.232\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.644.541.500.697.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.124.486.485.538.500.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.124.486.485.680.697.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.124.790.651.538.500.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.124.790.651.680.660.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.377.715.548.538.500.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.377.715.548.680.660.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.543.750.705.852.760.232\\r\\nErelzi,D12.644.541.500.697.624\\r\\nErelzi,D12.776.124.486.485.538.500.624\\r\\nErelzi,D12.776.124.486.485.680.697.624\\r\\nErelzi,D12.776.124.790.651.538.500.624\\r\\nErelzi,D12.776.124.790.651.680.660.624\\r\\nErelzi,D12.776.377.715.548.538.500.624\\r\\nErelzi,D12.776.377.715.548.680.660.624\\r\\nErelzi,D12.776.543.750.705.852.760.232\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.644.541.500.697.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.124.486.485.538.500.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.124.486.485.680.697.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.124.790.651.538.500.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.124.790.651.680.660.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.377.715.548.538.500.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.377.715.548.680.660.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.543.750.705.852.760.232\\r\\nEnbrel,D12.644.541.500.697.624\\r\\nEnbrel,D12.776.124.486.485.538.500.624\\r\\nEnbrel,D12.776.124.486.485.680.697.624\\r\\nEnbrel,D12.776.124.790.651.538.500.624\\r\\nEnbrel,D12.776.124.790.651.680.660.624\\r\\nEnbrel,D12.776.377.715.548.538.500.624\\r\\nEnbrel,D12.776.377.715.548.680.660.624\\r\\nEnbrel,D12.776.543.750.705.852.760.232\\r\\n\"Adapalene, Benzoyl Peroxide Drug Combination\",D02.241.223.100.133.500\\r\\n\"Adapalene, Benzoyl Peroxide Drug Combination\",D02.455.426.559.389.127.133.500\\r\\n\"Adapalene, Benzoyl Peroxide Drug Combination\",D02.455.426.559.847.638.090.500\\r\\n\"Adapalene, Benzoyl Peroxide Drug Combination\",D04.615.638.090.500\\r\\n\"Adapalene, Benzoyl Peroxide Drug Combination\",D26.310.032\\r\\nEpiduo,D02.241.223.100.133.500\\r\\nEpiduo,D02.455.426.559.389.127.133.500\\r\\nEpiduo,D02.455.426.559.847.638.090.500\\r\\nEpiduo,D04.615.638.090.500\\r\\nEpiduo,D26.310.032\\r\\nAdapalene,D02.455.426.559.847.638.090\\r\\nAdapalene,D04.615.638.090\\r\\nCD 271,D02.455.426.559.847.638.090\\r\\nCD 271,D04.615.638.090\\r\\nAdaferin,D02.455.426.559.847.638.090\\r\\nAdaferin,D04.615.638.090\\r\\nDifferin,D02.455.426.559.847.638.090\\r\\nDifferin,D04.615.638.090\\r\\nEpoetin Alfa,D12.644.276.374.410.240.150.500\\r\\nEpoetin Alfa,D12.776.395.240.150.750\\r\\nEpoetin Alfa,D12.776.467.374.410.240.150.500\\r\\nEpoetin Alfa,D23.529.374.410.240.150.750\\r\\nEpoetin Alfa Hexal,D12.644.276.374.410.240.150.500\\r\\nEpoetin Alfa Hexal,D12.776.395.240.150.750\\r\\nEpoetin Alfa Hexal,D12.776.467.374.410.240.150.500\\r\\nEpoetin Alfa Hexal,D23.529.374.410.240.150.750\\r\\nEprex,D12.644.276.374.410.240.150.500\\r\\nEprex,D12.776.395.240.150.750\\r\\nEprex,D12.776.467.374.410.240.150.500\\r\\nEprex,D23.529.374.410.240.150.750\\r\\nHeberitro,D12.644.276.374.410.240.150.500\\r\\nHeberitro,D12.776.395.240.150.750\\r\\nHeberitro,D12.776.467.374.410.240.150.500\\r\\nHeberitro,D23.529.374.410.240.150.750\\r\\nProcrit,D12.644.276.374.410.240.150.500\\r\\nProcrit,D12.776.395.240.150.750\\r\\nProcrit,D12.776.467.374.410.240.150.500\\r\\nProcrit,D23.529.374.410.240.150.750\\r\\nBinocrit,D12.644.276.374.410.240.150.500\\r\\nBinocrit,D12.776.395.240.150.750\\r\\nBinocrit,D12.776.467.374.410.240.150.500\\r\\nBinocrit,D23.529.374.410.240.150.750\\r\\nHX575 Compound,D12.644.276.374.410.240.150.500\\r\\nHX575 Compound,D12.776.395.240.150.750\\r\\nHX575 Compound,D12.776.467.374.410.240.150.500\\r\\nHX575 Compound,D23.529.374.410.240.150.750\\r\\nEpogen,D12.644.276.374.410.240.150.500\\r\\nEpogen,D12.776.395.240.150.750\\r\\nEpogen,D12.776.467.374.410.240.150.500\\r\\nEpogen,D23.529.374.410.240.150.750\\r\\nHX575,D12.644.276.374.410.240.150.500\\r\\nHX575,D12.776.395.240.150.750\\r\\nHX575,D12.776.467.374.410.240.150.500\\r\\nHX575,D23.529.374.410.240.150.750\\r\\nCetuximab,D12.776.124.486.485.114.224.060.750\\r\\nCetuximab,D12.776.124.790.651.114.224.060.750\\r\\nCetuximab,D12.776.377.715.548.114.224.200.750\\r\\nErbitux,D12.776.124.486.485.114.224.060.750\\r\\nErbitux,D12.776.124.790.651.114.224.060.750\\r\\nErbitux,D12.776.377.715.548.114.224.200.750\\r\\nIMC C225,D12.776.124.486.485.114.224.060.750\\r\\nIMC C225,D12.776.124.790.651.114.224.060.750\\r\\nIMC C225,D12.776.377.715.548.114.224.200.750\\r\\nHyssopus Plant,B01.650.940.800.575.912.250.583.520.330\\r\\nHyssopus officinalis,B01.650.940.800.575.912.250.583.520.330\\r\\nRivastigmine,D02.241.081.251.583.899\\r\\nRivastigmineTartrate,D02.241.081.251.583.899\\r\\nExelon,D02.241.081.251.583.899\\r\\nENA 713,D02.241.081.251.583.899\\r\\nParmeliaceae,B01.300.107.685\\r\\nParmeliaceae,B01.300.340.458\\r\\nCetraria,B01.300.107.685\\r\\nCetraria,B01.300.340.458\\r\\nCetraria islandica,B01.300.107.685\\r\\nCetraria islandica,B01.300.340.458\\r\\n\"Amlodipine, Valsartan Drug Combination\",D03.383.129.617.850.500\\r\\n\"Amlodipine, Valsartan Drug Combination\",D03.383.725.203.065.750\\r\\n\"Amlodipine, Valsartan Drug Combination\",D12.125.070.950.550.500\\r\\n\"Amlodipine, Valsartan Drug Combination\",D12.125.142.930.500.500\\r\\n\"Amlodipine, Valsartan Drug Combination\",D26.310.094\\r\\nExforge,D03.383.129.617.850.500\\r\\nExforge,D03.383.725.203.065.750\\r\\nExforge,D12.125.070.950.550.500\\r\\nExforge,D12.125.142.930.500.500\\r\\nExforge,D26.310.094\\r\\nEugenia,B01.650.940.800.575.912.250.773.374\\r\\nEuginia uniflora,B01.650.940.800.575.912.250.773.374\\r\\n\"Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18\",D20.215.894.815.455\\r\\n\"Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18\",D20.215.894.899.498.500\\r\\nGardasil,D20.215.894.815.455\\r\\nGardasil,D20.215.894.899.498.500\\r\\n\"Human Papillomavirus Vaccine L1, Type 6,11,16,18\",D20.215.894.815.455\\r\\n\"Human Papillomavirus Vaccine L1, Type 6,11,16,18\",D20.215.894.899.498.500\\r\\nKombucha Tea,D20.215.784.844.500\\r\\nKombucha Tea,G07.203.100.831.500\\r\\nKombucha Tea,G07.203.200.625\\r\\nKombucha Tea,J02.200.831.500\\r\\nKombucha Tea,J02.350.625\\r\\nFingolimod Hydrochloride,D02.033.100.700.350\\r\\nFingolimod Hydrochloride,D02.033.455.706.431\\r\\nFingolimod Hydrochloride,D02.092.063.700.350\\r\\nFTY-720,D02.033.100.700.350\\r\\nFTY-720,D02.033.455.706.431\\r\\nFTY-720,D02.092.063.700.350\\r\\nGilenya,D02.033.100.700.350\\r\\nGilenya,D02.033.455.706.431\\r\\nGilenya,D02.092.063.700.350\\r\\nFingolimod,D02.033.100.700.350\\r\\nFingolimod,D02.033.455.706.431\\r\\nFingolimod,D02.092.063.700.350\\r\\nImatinib Mesylate,D02.065.277.456\\r\\nImatinib Mesylate,D02.241.223.100.100.435\\r\\nImatinib Mesylate,D02.455.426.559.389.127.085.465\\r\\nImatinib Mesylate,D03.383.606.405\\r\\nImatinib Mesylate,D03.383.742.349\\r\\nSTI571,D02.065.277.456\\r\\nSTI571,D02.241.223.100.100.435\\r\\nSTI571,D02.455.426.559.389.127.085.465\\r\\nSTI571,D03.383.606.405\\r\\nSTI571,D03.383.742.349\\r\\nGleevec,D02.065.277.456\\r\\nGleevec,D02.241.223.100.100.435\\r\\nGleevec,D02.455.426.559.389.127.085.465\\r\\nGleevec,D03.383.606.405\\r\\nGleevec,D03.383.742.349\\r\\nST 1571,D02.065.277.456\\r\\nST 1571,D02.241.223.100.100.435\\r\\nST 1571,D02.455.426.559.389.127.085.465\\r\\nST 1571,D03.383.606.405\\r\\nST 1571,D03.383.742.349\\r\\nCGP 57148,D02.065.277.456\\r\\nCGP 57148,D02.241.223.100.100.435\\r\\nCGP 57148,D02.455.426.559.389.127.085.465\\r\\nCGP 57148,D03.383.606.405\\r\\nCGP 57148,D03.383.742.349\\r\\nImatinib,D02.065.277.456\\r\\nImatinib,D02.241.223.100.100.435\\r\\nImatinib,D02.455.426.559.389.127.085.465\\r\\nImatinib,D03.383.606.405\\r\\nImatinib,D03.383.742.349\\r\\nTrastuzumab,D12.776.124.486.485.114.224.060.875\\r\\nTrastuzumab,D12.776.124.790.651.114.224.060.875\\r\\nTrastuzumab,D12.776.377.715.548.114.224.200.875\\r\\nHerceptin,D12.776.124.486.485.114.224.060.875\\r\\nHerceptin,D12.776.124.790.651.114.224.060.875\\r\\nHerceptin,D12.776.377.715.548.114.224.200.875\\r\\nTrazimera,D12.776.124.486.485.114.224.060.875\\r\\nTrazimera,D12.776.124.790.651.114.224.060.875\\r\\nTrazimera,D12.776.377.715.548.114.224.200.875\\r\\nAdalimumab,D12.776.124.486.485.114.224.060.250\\r\\nAdalimumab,D12.776.124.790.651.114.224.060.250\\r\\nAdalimumab,D12.776.377.715.548.114.224.200.250\\r\\nHumira,D12.776.124.486.485.114.224.060.250\\r\\nHumira,D12.776.124.790.651.114.224.060.250\\r\\nHumira,D12.776.377.715.548.114.224.200.250\\r\\nAdalimumab-adbm,D12.776.124.486.485.114.224.060.250\\r\\nAdalimumab-adbm,D12.776.124.790.651.114.224.060.250\\r\\nAdalimumab-adbm,D12.776.377.715.548.114.224.200.250\\r\\nAmjevita,D12.776.124.486.485.114.224.060.250\\r\\nAmjevita,D12.776.124.790.651.114.224.060.250\\r\\nAmjevita,D12.776.377.715.548.114.224.200.250\\r\\nAdalimumab-atto,D12.776.124.486.485.114.224.060.250\\r\\nAdalimumab-atto,D12.776.124.790.651.114.224.060.250\\r\\nAdalimumab-atto,D12.776.377.715.548.114.224.200.250\\r\\nCyltezo,D12.776.124.486.485.114.224.060.250\\r\\nCyltezo,D12.776.124.790.651.114.224.060.250\\r\\nCyltezo,D12.776.377.715.548.114.224.200.250\\r\\nD2E7 Antibody,D12.776.124.486.485.114.224.060.250\\r\\nD2E7 Antibody,D12.776.124.790.651.114.224.060.250\\r\\nD2E7 Antibody,D12.776.377.715.548.114.224.200.250\\r\\n\"Isophane Insulin, Human\",D06.472.699.587.200.300.200.500\\r\\n\"Isophane Insulin, Human\",D06.472.699.587.200.500.625.500.500\\r\\n\"Isophane Insulin, Human\",D12.644.548.586.200.300.200.500\\r\\n\"Isophane Insulin, Human\",D12.644.548.586.200.500.625.500.500\\r\\nHumulin N,D06.472.699.587.200.300.200.500\\r\\nHumulin N,D06.472.699.587.200.500.625.500.500\\r\\nHumulin N,D12.644.548.586.200.300.200.500\\r\\nHumulin N,D12.644.548.586.200.500.625.500.500\\r\\nNovolin N,D06.472.699.587.200.300.200.500\\r\\nNovolin N,D06.472.699.587.200.500.625.500.500\\r\\nNovolin N,D12.644.548.586.200.300.200.500\\r\\nNovolin N,D12.644.548.586.200.500.625.500.500\\r\\n\"Animals, Exotic\",B01.050.050.126\\r\\nExotic Pets,B01.050.050.126\\r\\nPaliperidone Palmitate,D03.383.129.385.650\\r\\nPaliperidone Palmitate,D03.383.742.592\\r\\nPaliperidone,D03.383.129.385.650\\r\\nPaliperidone,D03.383.742.592\\r\\nInvega,D03.383.129.385.650\\r\\nInvega,D03.383.742.592\\r\\nInvega Sustenna,D03.383.129.385.650\\r\\nInvega Sustenna,D03.383.742.592\\r\\nR 76477,D03.383.129.385.650\\r\\nR 76477,D03.383.742.592\\r\\nImmunosenescence,G07.345.124.390\\r\\nImmunosenescence,G12.460.500\\r\\nCanagliflozin,D02.886.778.075\\r\\nCanagliflozin,D03.383.903.075\\r\\nCanagliflozin,D09.408.348.113\\r\\nInvokana,D02.886.778.075\\r\\nInvokana,D03.383.903.075\\r\\nInvokana,D09.408.348.113\\r\\nCanagliflozin Hemihydrate,D02.886.778.075\\r\\nCanagliflozin Hemihydrate,D03.383.903.075\\r\\nCanagliflozin Hemihydrate,D09.408.348.113\\r\\n\"Canagliflozin, Anhydrous\",D02.886.778.075\\r\\n\"Canagliflozin, Anhydrous\",D03.383.903.075\\r\\n\"Canagliflozin, Anhydrous\",D09.408.348.113\\r\\nIridescence,G01.590.310\\r\\nOpalescence,G01.590.310\\r\\nRaltegravir Potassium,D03.383.773.812.752\\r\\nRaltegravir,D03.383.773.812.752\\r\\nMK 0518,D03.383.773.812.752\\r\\nIsentress'"]}}],"execution_count":0},{"cell_type":"code","source":["dbutils.fs.ls (\"dbfs:/user/hive/warehouse/df2019_clin_table\")\n"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"To see the datafiles in dbfs","showTitle":true,"inputWidgets":{},"nuid":"23b2df12-2c32-4dc3-9c73-4d04338e881c"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[37]: [FileInfo(path='dbfs:/user/hive/warehouse/df2019_clin_table/_delta_log/', name='_delta_log/', size=0),\n FileInfo(path='dbfs:/user/hive/warehouse/df2019_clin_table/part-00000-769d9cbf-b61a-4fb3-95c9-122b611401d6-c000.snappy.parquet', name='part-00000-769d9cbf-b61a-4fb3-95c9-122b611401d6-c000.snappy.parquet', size=1088131),\n FileInfo(path='dbfs:/user/hive/warehouse/df2019_clin_table/part-00001-15d3a971-2ed4-41e4-854b-1370ffbdab47-c000.snappy.parquet', name='part-00001-15d3a971-2ed4-41e4-854b-1370ffbdab47-c000.snappy.parquet', size=1088374),\n FileInfo(path='dbfs:/user/hive/warehouse/df2019_clin_table/part-00002-e84bda07-2107-4bd7-ae02-36f113faf7b7-c000.snappy.parquet', name='part-00002-e84bda07-2107-4bd7-ae02-36f113faf7b7-c000.snappy.parquet', size=1095364),\n FileInfo(path='dbfs:/user/hive/warehouse/df2019_clin_table/part-00003-1dfd4ac5-dad5-4729-a63d-1ced1e3e7773-c000.snappy.parquet', name='part-00003-1dfd4ac5-dad5-4729-a63d-1ced1e3e7773-c000.snappy.parquet', size=1087286),\n FileInfo(path='dbfs:/user/hive/warehouse/df2019_clin_table/part-00004-499191a5-c7fd-4f3a-a0c2-cecae0453be2-c000.snappy.parquet', name='part-00004-499191a5-c7fd-4f3a-a0c2-cecae0453be2-c000.snappy.parquet', size=1088414),\n FileInfo(path='dbfs:/user/hive/warehouse/df2019_clin_table/part-00005-3d26858e-2cb6-483c-beec-5dc351201d81-c000.snappy.parquet', name='part-00005-3d26858e-2cb6-483c-beec-5dc351201d81-c000.snappy.parquet', size=1091011),\n FileInfo(path='dbfs:/user/hive/warehouse/df2019_clin_table/part-00006-109df198-7dd8-420e-8f6c-e938553f974b-c000.snappy.parquet', name='part-00006-109df198-7dd8-420e-8f6c-e938553f974b-c000.snappy.parquet', size=1093522),\n FileInfo(path='dbfs:/user/hive/warehouse/df2019_clin_table/part-00007-51df4dfd-64be-416d-b097-664403f51249-c000.snappy.parquet', name='part-00007-51df4dfd-64be-416d-b097-664403f51249-c000.snappy.parquet', size=362445)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[37]: [FileInfo(path='dbfs:/user/hive/warehouse/df2019_clin_table/_delta_log/', name='_delta_log/', size=0),\n FileInfo(path='dbfs:/user/hive/warehouse/df2019_clin_table/part-00000-769d9cbf-b61a-4fb3-95c9-122b611401d6-c000.snappy.parquet', name='part-00000-769d9cbf-b61a-4fb3-95c9-122b611401d6-c000.snappy.parquet', size=1088131),\n FileInfo(path='dbfs:/user/hive/warehouse/df2019_clin_table/part-00001-15d3a971-2ed4-41e4-854b-1370ffbdab47-c000.snappy.parquet', name='part-00001-15d3a971-2ed4-41e4-854b-1370ffbdab47-c000.snappy.parquet', size=1088374),\n FileInfo(path='dbfs:/user/hive/warehouse/df2019_clin_table/part-00002-e84bda07-2107-4bd7-ae02-36f113faf7b7-c000.snappy.parquet', name='part-00002-e84bda07-2107-4bd7-ae02-36f113faf7b7-c000.snappy.parquet', size=1095364),\n FileInfo(path='dbfs:/user/hive/warehouse/df2019_clin_table/part-00003-1dfd4ac5-dad5-4729-a63d-1ced1e3e7773-c000.snappy.parquet', name='part-00003-1dfd4ac5-dad5-4729-a63d-1ced1e3e7773-c000.snappy.parquet', size=1087286),\n FileInfo(path='dbfs:/user/hive/warehouse/df2019_clin_table/part-00004-499191a5-c7fd-4f3a-a0c2-cecae0453be2-c000.snappy.parquet', name='part-00004-499191a5-c7fd-4f3a-a0c2-cecae0453be2-c000.snappy.parquet', size=1088414),\n FileInfo(path='dbfs:/user/hive/warehouse/df2019_clin_table/part-00005-3d26858e-2cb6-483c-beec-5dc351201d81-c000.snappy.parquet', name='part-00005-3d26858e-2cb6-483c-beec-5dc351201d81-c000.snappy.parquet', size=1091011),\n FileInfo(path='dbfs:/user/hive/warehouse/df2019_clin_table/part-00006-109df198-7dd8-420e-8f6c-e938553f974b-c000.snappy.parquet', name='part-00006-109df198-7dd8-420e-8f6c-e938553f974b-c000.snappy.parquet', size=1093522),\n FileInfo(path='dbfs:/user/hive/warehouse/df2019_clin_table/part-00007-51df4dfd-64be-416d-b097-664403f51249-c000.snappy.parquet', name='part-00007-51df4dfd-64be-416d-b097-664403f51249-c000.snappy.parquet', size=362445)]"]}}],"execution_count":0},{"cell_type":"code","source":["# creting hive tables from existing dataframes\n# Hive table Location : dbfs:/user/hive/warehouse/df_2019\n# Hive table Location : dbfs:/user/hive/warehouse/df_2020\n# Hive table Location : dbfs:/user/hive/warehouse/df_2021\ntableName_2019 = \"df2019_clin_table1\"\ntableName_2020 = \"df2020_clin_table1\"\ntableName_2021 = \"df2021_clin_table1\"\ndf_2019.write.saveAsTable(tableName_2019)\ndf_2020.write.saveAsTable(tableName_2020)\ndf_2021.write.saveAsTable(tableName_2021)\n\n\n\n\n\n\n\n\n"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"DEFINING HIVE TABLES FROM EXISTING DATAFRAMES","showTitle":true,"inputWidgets":{},"nuid":"8197c13e-3001-4630-a787-dab4930f7547"}},"outputs":[],"execution_count":0},{"cell_type":"markdown","source":["databricks fs rm /user/hive/warehouse/df2019_clin_table/*\n#dbutils.fs.rm -r(\"dbfs:/user/hive/warehouse/df2019_clin_table\")"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"301b7b3d-7374-4b9d-8f50-76514942bb80"}}}],"metadata":{"application/vnd.databricks.v1+notebook":{"notebookName":"Sravani_DF","dashboards":[],"notebookMetadata":{"pythonIndentUnit":4},"language":"python","widgets":{},"notebookOrigID":3753669792832736}},"nbformat":4,"nbformat_minor":0}
